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Abstract
A method of designing early clinical trials is developed for ﬁnding an optimum dose
level of a new drug to be recommended for use in later phases. During the trial,
the eﬃcacious doses are allocated to the patients more often and those with a high
probability of toxicity are less likely to be chosen. The method proposed is adaptive
in the sense that the statistical models are updated after the data from each cohort
of patients are collected and the dose level is adjusted at each stage based on the
current data.
Two classes of designs are presented. Although both are for eﬃcacy and toxicity
responses, one of them also considers pharmacokinetic information. The dose opti-
misation criteria are based on the probability of success and on the determinant of
the Fisher information matrix for estimation of the dose-response parameters. They
can be constrained by both acceptable levels of the probability of toxicity and desir-
able levels of the area under the concentration curve or the maximum concentration.
The method presented is general and can be applied to various dose-response and
pharmacokinetic models. To illustrate the methodology, it is applied to two diﬀerent
classes of models. In both cases, the pharmacokinetic model incorporates the popu-
lation variability by making appropriate assumptions about the model parameters,
while the dose responses are assumed to be either trinomial or bivariate binomial.
Various design properties of the method are examined by simulation studies. Eﬃ-
ciency measures and the sensitivity of the designs to the assumed prior parameter
values are presented. All of the computations are conducted in R, where the D-
v
optimal sampling time points are obtained by using the package PFIM. The results
show that the proposed adaptive method works well and could be appropriate as a
seamless phase IB/IIA trial design.
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Chapter 1
Introduction
1.1 Preliminary Concepts
Clinical trials, commonly classiﬁed into four phases, have become an integral part
of drug development. Phase I is the ﬁrst stage of testing in humans and designed
to assess safety, tolerability and the pharmacokinetics (PK) of a drug. Phase II is
designed to assess how well the drug works (pharmacodynamics, PD) and it also
monitors safety in a large group of patients. Another goal of the early phases is
to establish a dose level to recommend for further studies in later phases. Phase
III assesses the eﬀectiveness of the drug in comparison with the current standard
treatments. Phase IV, also known as post-marketing surveillance, aims to detect
any rare or long-term adverse eﬀects over a large population.
1.1.1 Pharmacokinetics and Pharmacodynamics
Pharmacokinetics is generally deﬁned as what the body does to the drug. It reﬂects
the movement of the drug in the body, that is, how the drug enters into the body,
how it is distributed throughout the body and how it leaves the body. It involves
the study of the processes that aﬀect the plasma concentration of drug in the body
at any time after the administration of a dose (Rosenbaum, 2011). PK modelling
helps in determining important PK parameters.
Pharmacodynamics is deﬁned as what the drug does to the body. PD eﬀects are usu-
ally classiﬁed as changes in biomarkers, surrogate endpoints and clinical endpoints.
A biomarker reﬂects any pharmacological eﬀect that has some link to the therapeu-
tic beneﬁt of the drug. A surrogate endpoint is a biomarker which is intended to
substitute for a clinical endpoint. A clinical endpoint is a response variable measur-
ing the direct beneﬁt to a patient, that is, how a patient feels, functions or survives
(Derendorf et al., 2000). For antihypertensive drugs, blood pressure is a biomarker
and stroke is the clinical endpoint. For anticancer agents, tumour shrinkage and
survival are the biomarker and clinical endpoint, respectively. PD modelling estab-
lishes the relationship between the dose and the resulting eﬀect.
After administration of a dose, the PK mechanism transforms it into plasma con-
centration and through the systematic circulation of blood, it reaches the site of
action and produces a response: see Figure 1.1. The extent of response depends on
the concentration at the site of action. We cannot measure concentration at the site
of action, but can measure the plasma, which reﬂects the concentration at the site.
Concentration needs to be kept high enough to produce a desirable response, but
low enough to avoid toxicity. Even if the same dose is given to a group of individ-
uals, concentration proﬁles are very likely to be diﬀerent since it depends on how a
body functions. Therefore, for the eﬃcient determination of the optimum dose, it
is essential to monitor concentration.
Figure 1.1: A schematic diagram showing how dose of a drug works.
Generally, concentration is modelled as a function of time for a given dose and the
PD eﬀect is often modelled as a function of dose. However, in the PK/PD approach,
the PD response is modelled as a function of concentration. Concentration is in-
herently more informative than dose because unlike dose, which is only a nominal
mass ﬁxed by the clinicians, it gives biological information (Riviere, 2011). Such
an approach establishes the dose-concentration-eﬀect relationship and is capable of
predicting the eﬀect at any time after administering a dose. It also helps in estimat-
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ing dose and dosing interval to achieve the eﬀect of a desired level.
The PK/PD approach has been described in Hooker and Vicini (2005) and Davidian
(2010). To illustrate the approach, we introduce an example that comprises a one-
compartment PK model with bolus input and ﬁrst-order elimination and the Emax
model for the PD eﬀect. The PK model for modelling the drug concentration is
y1 = f1(t1;θ1) + 1 =
x
V
exp
(
−Cl
V
t1
)
+ 1, (1.1)
where x is the dose received by an individual, θ1 = (V,Cl)
T is the vector of PK pa-
rameters with V and Cl as the volume of distribution and clearance, respectively, t1
denotes the sampling time for measuring concentration and 1 is the random error.
More detailed explanations on the volume of distribution and clearance are available
in Section 3.3.
The simple Emax model for modelling the PD eﬀect is given as
y2 = f2(x;θ2) + 2 = E0 +
Emax x
C50 + x
+ 2, (1.2)
where θ2 = (E0, Emax, C50)
T is the vector of PD parameters with E0, Emax and C50
as the eﬀect at baseline, the maximum eﬀect and the dose needed to observe half of
the maximum eﬀect, respectively, and 2 is the random error. The parameter Emax
measures the eﬃcacy for a drug and C50 reﬂects a drug's potency.
The PK/PD approach expresses the PD eﬀect as a function of the mean concentra-
tion. In our case, we can write
y2 = E0 +
Emax f1(t2;θ1)
C50 + f1(t2;θ1)
+ 2, (1.3)
where t2 represents the sampling time for measuring the PD response. It is also
assumed that 1 and 2 are independent.
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There are two approaches to ﬁt the above models: sequential ﬁtting and simultane-
ous ﬁtting. In sequential ﬁtting, the PK model is ﬁtted ﬁrst to obtain the parameter
estimates θˆ1. These parameters are then ﬁxed and assumed known in ﬁtting the
model (1.3) to obtain θˆ2. This approach is based on the simplifying assumption that
the two sets of parameters are independent. In the simultaneous ﬁtting approach,
the model (1.3) is ﬁtted directly. It allows the assumption that the two sets of pa-
rameters are correlated (Hooker and Vicini, 2005).
The PK/PD approach requires the PD response to be a continuous random variable.
However, the type of PD response we are interested in in this thesis is categorical.
We want to see how the rate of success of a drug changes in the population of
patients with the change of dose level. Therefore, the dose-response models that are
going to be used are diﬀerent from those in the PK/PD approach.
1.1.2 Dose-Response Relationship
The dose-response relationship describes the relation between a response and doses
of a drug. The graphical presentation of such a relationship is known as a dose-
response curve. More speciﬁcally, a dose-response curve considered in this thesis
is a two-dimensional graph, where the x-axis represents dose and the y-axis repre-
sents the percentage of the population that exhibits the response. Depending on the
response, which can be toxicity or desired eﬀect, there are two types of important
dose-response curves. A dose-eﬃcacy curve is the one that describes the relationship
between dose and some eﬃcacy endpoint. The other one is the dose-toxicity curve
that describes the relationship between dose and a toxicity endpoint (Chow and
Liu, 2004). Although dose-response curves can assume any shape, there are many
drugs for which the curves are S-shaped. Figure 1.2 shows such dose-response curves.
The dose-response relationship on toxicity is as equally important as that on eﬃcacy.
These relationships together help in identifying an appropriate dose. Development
of these relationships is a central part in clinical trial studies to make the safe and
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Figure 1.2: Typical dose-response curves.
eﬀective use of a drug. Regression methods for modelling the probabilities of re-
sponses are used in developing such models. The main interest is to assess the
eﬃcacy and toxicity levels of a drug in a population of patients.
Although dose-response relationships mainly depend on dose, covariates are often
considered to account for some known patient characteristics which may inﬂuence
the dose eﬀects. Generally, lower doses produce no desired eﬀect and higher doses
produce undesired side eﬀects. To reduce the time for drug development and also to
decrease the cost of the studies, accurate and early establishment of the relationships
is essential.
1.1.3 Incorporating PK Information
A drug's pharmacokinetics are determined by the processes of absorption, distribu-
tion, metabolism and excretion (ADME). Also, concentrations at the site of action
are determined by the ADME. It is the concentrations at the site of action which
produce the PD response. The objectives in a early phase clinical trial are to quan-
tify the ADME of the drug and also to identify an optimal dose for further studies.
Quantifying these PK parameters is often straightforward, as it does not require the
administration of an optimal dose (Piantadosi and Liu, 1998). However, obtaining
the optimal dose is a diﬃcult task. There are drugs for which the therapeutic range
is narrow and as such careful dose escalation is essential since a small increase in
dose may lead to a drastic change in outcomes.
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Since the PD response depends on the concentration at the site of action, it may not
be enough to consider only the administered dose in establishing the dose-response
relationship. Rather, the resulting concentration from that dose has a vital role in
it. One possible way to consider such pharmacokinetic data could be the formal
inclusion of measures like area under the concentration curve or the maximum con-
centration in the dose-response model. One such method that puts the area under
the concentration curve in the dose-response model is that of Piantadosi and Liu
(1998). But that method requires many blood samples to be collected for measuring
the concentration of a drug, as it uses the trapezoidal rule to obtain the area under
the concentration curve. A larger number of blood samples gives more trapeziums
to ﬁnd an accurate estimate of the area.
Other possible ways of considering PK data in dose-ﬁnding studies could be con-
straining the area under the concentration curve or the maximum concentration
during dose escalation. In this case, the measures are not incorporated in the dose-
response model directly, rather they help the dose-ﬁnding procedure to identify an
optimal dose. Such a PK-guided design will be more careful, so that patients do
not receive doses which are too toxic or have no therapeutic beneﬁt. This kind of
approach is diﬀerent from the standard PK/PD approach in the sense that unlike
the PK/PD approach, we have a categorical PD response, and instead of replacing
the dose by concentration, we take some PK parameters associated with the best
dose.
1.2 Motivation for the Work
As indicated at the beginning, a phase I trial is the ﬁrst step in applying a new drug
to humans. The designs for phase I trials, particularly those in cancer, focus on the
maximum tolerated dose (MTD). This MTD is based on the toxicity response and
it ignores the eﬃcacy response. Phase II designs aim to determine the eﬃcacy level
of an experimental drug assuming that a dose range has been established in phase
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I.
For cytotoxic agents that are used in treating cancer, it is believed that the higher
doses are more likely to be toxic, and also more likely to kill the cancer cells and
therefore will be eﬃcacious. As a consequence, cancer clinical trials assume that the
dose-toxicity and dose-eﬃcacy relationships are monotone non-decreasing functions
of dose. Therefore, the MTD determined from the phase I trial will provide a dose
with a desirable level of eﬃcacy.
In recent years, targeted therapies have drawn attention for treating cancer patients.
These are drugs or other substances that block the growth and spread of cancer by
interfering with speciﬁc molecules that are involved in the growth, progression and
spread of cancer. According to Cunningham et al. (2004), many clinical trials of
targeted therapies are underway and many such therapies are already in use for cur-
ing the patients. For these targeted agents, the dose-eﬃcacy curve may not increase
with dose and therefore eﬃcacy may occur at doses that lie in the middle of the
range of possible doses. Therefore, conducting the phase II trials based on the MTD
from phase I for those agents may not be an eﬃcient way of running the trial. In
such situations, it will be useful to consider the toxicity and eﬃcacy simultaneously
to come up with an optimum dose for further investigation in the next phase. Some
examples that illustrate combined phase I/II trials are available in Gooley et al.
(1994), O'Quigley et al. (2001), Braun (2002) and Zhang et al. (2006).
Zhang et al. (2006) consider an agent for targeted therapy which is theorised to
boost haemoglobin levels (HbL) in patients for whom the HbL is below the stan-
dard range (14-18 g/dL for men; 12-16 g/dL for women). The response that is
obtained following the administration of the agent can be categorised as follows: no
response, success and toxicity. These successive categories mean that patients are
under-stimulated and their HbL is still below the standard range; rightly stimulated
and their HbL raised to the standard level; and over-stimulated and their HbL raised
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above the standard level.
Also for drugs other than those for cancer, a dose will be acceptable only if it is eﬃ-
cacious and safe. Since it is quite diﬃcult to ﬁnd a dose which is both eﬃcacious and
non-toxic, eﬀorts are necessary to make a trade-oﬀ between the two. The speciﬁc
goal is to ﬁnd a dose which has a high probability of eﬃcacy and a low probability
of toxicity.
Regardless of the method, phase I trials are small and as a consequence the dose-
toxicity curves are not well estimated. They often determine the dose which is either
unacceptably toxic or ineﬀective. Phase I/II trials can be larger and so the methods
could potentially lead to more eﬃcient dose selection.
The designs that we are going to consider are for combined phase IB/IIA trials.
We also consider pharmacokinetic constraints during dose escalation in cases where
it is important to avoid doses likely to cause toxicity, considered as possibly life-
threatening. Since inter-patient variability in the plasma concentration is very likely,
random eﬀects PK models are being considered. The purpose of this thesis is to
develop an eﬃcient method for dose ﬁnding in early phase clinical trials.
1.3 Outline of Thesis
In Chapter 2, we review the literature on the commonly used designs in early phase
clinical trials. The discussed designs are mainly used in phase I and II trials.
Chapter 3 contains the general population PK model and its Fisher information
matrix. Some commonly used optimality criteria in designing experiments are also
discussed. The chapter then introduces one-compartment PK models and the asso-
ciated Fisher information matrices to be used in the simulation study. The general
expressions for measuring the inter-patient variability in the area under the con-
centration curve and the maximum concentration following the administration of a
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dose are presented. As special cases, analytical forms for these variances have been
obtained for the PK models introduced.
Chapter 4 gives the dose-response models that will be used in the simulation study.
The associated Fisher information matrices have been derived. Properties of the
models are also discussed and some plausible dose-response scenarios for each of
them are presented.
Chapters 5 and 6 are the ones with major contributions in dose-ﬁnding studies and
they present new results. Chapter 5 introduces the general algorithm for the pro-
posed dose-ﬁnding design. It also describes an up-and-down design to gather infor-
mation prior to any estimation of the model parameters. Possible dose-optimisation
criterion, constraints and stopping rules are also discussed in the chapter. To eval-
uate the quality of the designs, we introduce some performance measures.
Simulation studies using various dose-optimisation criteria and constraints are pre-
sented in Chapter 6. The numerical computations are implemented in R. The main
purpose is to understand the behaviour of the designs numerically. Three examples
are introduced with the dose-response and PK models introduced in the earlier chap-
ters. Sensitivity analyses of the designs to the assumed values for the parameters
are also presented. Finally, we discuss the major ﬁndings.
In Chapter 7, we draw conclusions of the work and discuss possible future research.
It has been found from the simulation studies that the proposed dose-optimisation
criteria and constraints can ﬁnd the optimal dose accurately. The methods can limit
toxic doses as the optimum dose by a considerable amount and assign most relevant
doses to the cohorts during the trial. We have also seen that the eﬃciency of the
design can be increased if it is possible to assume target values for the PK parame-
ters like the area under the concentration curve and the maximum concentration.
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Finally, we present the appendices. Appendix A gives a ﬂow chart indicating the
diﬀerent steps of the proposed design and some supplementary material. Appendix
B shows the R code that is used to simulate designs using various dose-optimisation
criteria and constraints.
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Chapter 2
Review of Early Clinical Trials
2.1 Introduction
This chapter gives a brief introduction to some commonly used designs in the early
phases of clinical trials. Clinical trial designs are broadly classiﬁed as adaptive and
non-adaptive. Here we present some adaptive early phase designs.
The goal of the early phases is to study the pharmacokinetics and pharmacodynam-
ics of new drugs, and also to explore eﬃcacy and toxicity proﬁles. For nontoxic
agents, phase I trials are often conducted with healthy volunteers. But for toxic
agents, such as those for cancer treatments, phase I trials are conducted among
cancer patients at the last stage for whom standard treatments have failed. Since
the beneﬁts from such agents are believed to increase with dose, the highest possible
dose is searched for during the development of an agent. However, toxicity also
increases with dose. Therefore, the main challenge for those trials is to ﬁnd a dose
with a low chance of toxicity among the patients. This dose is usually referred to
as the MTD.
Early phase clinical trials test drugs that were found promising in preclinical stud-
ies. For cytotoxic agents, usually the starting dose is one tenth of the LD10 in mice,
that is, the dose lethal to 10% of mice, or one-third of the toxic dose low (TDL) in
dogs or monkeys (Collins et al., 1986). The TDL is deﬁned as the lowest dose that
produces drug-induced pathological alterations in haematological, chemical, clini-
cal or morphological parameters and which, when doubled, produces no lethality
(Prieur et al., 1973). In areas other than oncology, the approaches that are used to
estimate the starting dose include: (1) the dose-by-factor approach; (2) the similar
drug approach; (3) the pharmacokinetically-guided approach; and (4) the compar-
ative approach. A detailed description of these methods is available in Reigner and
Blesch (2002).
The dose-by-factor approach is based on the highest dose of the compound found to
have no toxic eﬀect in the most sensitive species tested in the preclinical toxicology
studies. The maximum starting dose for a ﬁrst-in-human study is the smallest of
the following three doses: 1/10 of the highest no-eﬀect dose in rodents, 1/6 of the
highest no-eﬀect dose in dogs and 1/3 of the highest no-eﬀect dose in monkeys.
This classical approach is used widely. However, it is often criticised as it ignores
preclinical pharmacokinetic data.
The similar drug approach can be applied when human safety data are available
for a drug similar to the one under investigation. The similar drug is usually of
the same chemical class, with similar or related chemical structure. The method
assumes that the ratio of the starting dose to the dose at which no adverse eﬀect
is observed is the same for similar drug and investigational drug, and from that
relation it is possible to ﬁnd the starting dose for the investigational drug. The dose
thus obtained is again multiplied by a factor to accommodate the uncertainty about
the safety. One can proceed with the method only if it is found that the assumption
upon which it is based is valid.
The pharmacokinetically-guided approach uses systemic exposure rather than dose
for the extrapolation from animal to human. The area under the concentration
curve from the preclinical study for a dose at which no adverse eﬀect is observed is
multiplied by the predicted clearance for humans to obtain the starting dose. The
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uncertainty about the prediction of human clearance is a shortcoming of the method.
The practice of using this approach in pharmaceutical companies is increasing. The
comparative approach utilises two or more methods to estimate a starting dose and
then critically compares the results to arrive at the starting dose. This method
can be criticised for being time consuming. However, obtaining similar results from
several approaches is reassuring. This is not a very commonly used method.
Dose increment, dose assignment, cohort size and number of cohorts are the impor-
tant components of dose-escalation schemes. Once the starting dose is determined,
the subsequent dose levels need to be established. Sometimes they are determined
by the modiﬁed Fibonacci sequence. A Fibonacci sequence is a sequence where
each number is the sum of the previous two numbers in the sequence. For in-
stance, {1, 1, 2, 3, 5, 8, 13, 21, . . .} is a Fibonacci sequence. Dose increments follow
the percentages of increments in this sequence and are {100, 50, 67, 60, 63, 62, . . .}.
A slightly modiﬁed version of this sequence is used in practice where the increment
decreases. However, simple dose levels like 5 mg/kg, 10 mg/kg, 15 mg/kg, 20 mg/kg
are often used in many studies.
Dose assignment is the way in which new patients entering the trial are allocated to
doses. It depends on the design chosen, as diﬀerent designs have diﬀerent allocation
rules. A dose allocation design to be used in early phases should be such that it
does not expose too many patients either to subtherapeutic or to toxic doses. Often,
patients are treated in cohorts of size 3 or 6. Determining the number of cohorts
that will be appropriate for a trial is also an interesting research problem.
By early phase, we mean phases I and II. Ratain et al. (1993) discussed the statistical
and ethical issues that need to be addressed in the early phases of development of
anticancer agents. Many phase I trials deal with the estimation of the best dose
rather than testing a hypothesis about it. On the other hand, many standard phase
II trials test a hypothesis in order to select the best dose out of a set of candidate
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doses. It may seem contradictory that sometimes the patients in phase I trials
experience less toxicity than those in phase II trials. But this may happen because
many patients are often under-treated in phase I trials, whereas phase II trials treat
many patients at a dose that can result in moderate to severe toxicity. The statistical
issue in early phase trials is to locate the best dose in an eﬃcient way. However,
the ethical one concerns the minimisation of under- and over- treatment during a
trial. A dose-ﬁnding design will be ideal if it reaches the best dose in an eﬃcient
and ethically appropriate way. In the following sections, we present some commonly
used dose-allocation designs for early phases.
2.2 Phase I Designs
Although several improved statistical methods have been developed in recent years,
many current studies still use a traditional 3+3 design (Le Tourneau et al., 2009).
The 3+3 design, which we describe in more detail in the next subsection, is often
used as the speciﬁc issues to be achieved in phase I trials are not stated clearly.
According to O'Quigley et al. (1990), a phase I design should aim to: (1) minimise
the number of under-treated patients and the number of over-treated patients; (2)
minimise the number of patients needed to complete the study; and (3) rapidly
escalate the dose in the absence of toxicity or rapidly de-escalate the dose in the
presence of an unacceptable level of toxicity. It is possible in a 3+3 design to come
to a conclusion by using only a few patients, but Reiner et al. (1999) and Lévy et al.
(2001) showed that the probability of an incorrect recommendation for the MTD is
very high for this design.
Phase I designs can be classiﬁed into two types: rule-based and model-based. Many
rule-based designs only utilise information from the current cohort in allocating
a dose to the next cohort. O'Quigley and Zohar (2006) called these memoryless
designs, as the previous information is completely ignored. The opposite of these
are the designs which carry information through the trial. Designs with memory are
mostly model-based.
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2.2.1 Rule-Based Designs
The essence of the rule-based designs is that they do not assume any parametric
dose-response model, but they use instead pre-speciﬁed rules. Some of these designs
are based on the up-and-down rule (Dixon and Mood, 1948), where escalation or
de-escalation of dose depends on the occurrences of toxicity in the previous cohort.
Commonly used rule-based designs are the 3+3 design, Storer's up-and-down de-
signs, accelerated titration designs (Simon et al., 1997), pharmacologically-guided
dose-escalation design and designs using isotonic regression.
3+3 Design
The 3+3 design is the most widely used design in clinical practice. Starting with a
pre-speciﬁed number of doses {x(1), . . . , x(d)}, the design ﬁrst assigns the dose x(1) to
a cohort of three patients. Escalation to dose x(2) is carried out if none of the three
patients experiences toxicity. The trial stops if at least two of the three patients
have toxicities. The same dose x(1) is given to three additional patients if one of the
initial three patients has a toxic response. Then, if only one of the six patients has
toxicity, escalation to dose x(2) is made; otherwise, the trial stops. In such a design,
the MTD is usually deﬁned as the highest dose at which the observed toxicity rate
is no more than 0.33. Some researchers claim that the MTD should be the dose
at which 2 or fewer toxicities in six patients are observed. Therefore, it is recom-
mended to check exactly six patients at the MTD, which may sometimes require a
single de-escalation in the 3+3 design.
Simplicity of implementation and safety concerns made the 3+3 design very pop-
ular. However, the design is ineﬃcient when the starting dose is very low and the
dose increment is moderate. In such a case, the design requires an excessive number
of steps to reach the desirable dose, which in turn means that many patients are
treated at subtherapeutic doses and very few patients receive doses at or near the
MTD. Also, the maximum probability of toxicity that the MTD can have is ﬁxed
once the deﬁnition is set. For instance, if we deﬁne the MTD as the dose at which
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2 or fewer toxicities are observed in six patients, then the toxicity rate at that dose
is less than or equal to 0.33.
Some modiﬁed versions of the design, such as 2+4, 3+3+3 and 3+1+1, are also
available to accelerate the dose escalation (Storer, 2001). In the 2+4 design, an
additional cohort of size 4 is added if one of the two individuals in the ﬁrst cohort
shows toxicity. The same stopping rule as the traditional 3+3 design is followed.
In the 3+3+3 design, the same dose is applied to an additional cohort of size 3 if
two individuals in the ﬁrst two cohorts experience toxicity. The trial stops if three
or more individuals in three cohorts show toxicity. The 3+1+1 design is a more
aggressive design than 3+3 and is known as `best-of-ﬁve' design in the literature. If
one or even two of the individuals in the ﬁrst cohort experience toxicity, the same
dose is given to one more individual. If two individuals in the ﬁrst four experience
toxicity, the dose is administered to one more individual. The trial stops if three or
more toxicities are observed in ﬁve individuals. Although the modiﬁed versions are
aimed at accelerating the dose escalation, it is not clear in the literature whether
they are completely better than the conservative 3+3 approach or even which is best
out of all these modiﬁed versions.
Storer's Up-and-Down Designs
The 3+3 design and its modiﬁed versions that have been discussed only allow dose
to be escalated upward. Therefore, as a precaution, the starting dose level is the
lowest one and hence many patients are treated at the subtherapeutic doses. Another
problem with the design is that, since many patients are treated at the low doses, it
may take a long time to reach the MTD. To overcome these problems, Storer (1989)
recommended three designs which allow both dose escalation and de-escalation, and
do not require the lowest dose to be the starting dose. The proposed designs are as
follows:
1. Cohort size is one at each dose. Escalate to the next higher dose if a nontoxic
outcome is observed; otherwise, de-escalate to the next lower dose.
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2. Similar to the design in 1, except that escalation is done only if two consecutive
nontoxic responses are seen. De-escalate if a toxic response is seen.
3. Cohort size is three at each dose. Escalation is made if there is no toxic
response, stay at the same dose level if one toxic response is seen and de-
escalate if two or more toxic responses are seen.
Design 1 is not implemented as a single-stage design itself, but together with design
2 or 3 to make a two-stage design. All of these designs are implemented with a ﬁxed
sample size usually ranging from 12 to 36. At the end of a two-stage trial, a logistic
regression model is ﬁtted to the data and the MTD is determined from that model
for a particular choice of target toxicity rate.
Pharmacologically-Guided Dose Escalation
Collins et al. (1990) proposed pharmacologically-guided dose escalation (PGDE). It
needs the area under the concentration curve (AUC) in humans to be extrapolated
from preclinical data and the AUC value at the LD10 in mice is usually used as
the target. At the ﬁrst stage of the design, dose escalation proceeds with one pa-
tient per dose level as long as the target AUC is not reached and typically at 100%
dose increments between successive patients. When the target AUC is reached or
if dose-limiting toxicity occurs, the design turns into stage 2 where dose escalation
is carried out by following the traditional 3+3 design and the MTD is determined
accordingly. Successive doses are increased by around 40% in the second stage.
The method has been found to produce good results for some cytotoxic agents,
such as certain anthracyclines and platinum compounds. It has been found to be
inappropriate for other classes of agents, such as antifolates where high inter-patient
variability in pharmacokinetics exists (Berry et al., 2010). Some other practical
issues, such as logistical diﬃculties in obtaining real-time pharmacokinetic results
and problems in extrapolating preclinical pharmacokinetic data, impede the frequent
use of PGDE. The method also suﬀers from the risk of exposing the next patient
to a highly toxic dose if the AUC for the last patient was considerably lower due
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to inter-patient variability in drug metabolism. One possible way to overcome this
problem could be the consideration of inter-patient variability in the AUC.
Designs using Isotonic Regression
Leung and Wang (2001) introduced a design which uses the idea of isotonic regres-
sion to estimate the risk at each dose, so that toxicity is non-decreasing with dose.
Generally speaking, if we have d dose levels {x(1), . . . , x(d)} to be tested, the risk at
x(i) (1 ≤ i ≤ d) must satisfy the monotonic relationship with dose. For any dose
x(r) below x(i) (r ≤ i) and any dose x(s) above x(i) (s ≥ i), the pooled estimate of
risk can be expressed as
wr,i,s =
∑s
j=r number of toxicities at x
(j)∑s
j=r number of patients tested at x
(j)
. (2.1)
The estimate of the risk of toxicity at x(i) is obtained by using the isotonic regression
qˆi = min
i≤s≤d
max
1≤r≤i
wr,i,s. (2.2)
The idea is that qˆi must be at least as large as any of w1,i,s, w2,i,s, . . . , wi,i,s (or the
maximum of these) for any s (s ≥ i). Similarly, qˆi must be no larger than any of
wr,i,i, wr,i,i+1, . . . , wr,i,d (or the minimum of these) for any r (r ≤ i).
Starting with dose x(i), the algorithm for the design proceeds as follows:
1. Treat a cohort of c patients at dose x(i).
2. Evaluate the risk at diﬀerent doses by using (2.2). Choose the dose for which
qˆi is closest to the target toxicity rate γ, where i is the level of the last dose
used. If qˆi < γ, then escalate if γ− qˆi ≥ qˆi+1− γ for i < d; otherwise, continue
at the same dose. If qˆi ≥ γ, then de-escalate if γ − qˆi−1 < qˆi − γ for i > 1;
otherwise, continue at the same dose.
3. Repeat steps 1-2 until some pre-speciﬁed stopping criterion is met.
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Usually the target toxicity rate is set at γ = 0.33 and the cohort size is chosen to
be 3. Although the method allows starting with any dose level between 1 and d,
the safest option is to start with 1. The trial can be stopped based on two criteria:
if the same dose has been assigned consecutively to 3 or 4 cohorts or if the trial
reaches a sample of 24 patients. The MTD is the dose indicated for the next cohort
when the trial stops. This design has the ﬂexibility to choose any percentile as the
target risk of toxicity and usually more than six patients are treated at the MTD,
which lessens the variability of the estimate of the MTD.
The most attractive feature of the rule-based designs is that they are easy to imple-
ment and no specialised software is required for computation. But their operating
characteristics are not very attractive. The designs often allocate doses based on the
outcomes from the last cohort, rather than considering the cumulative data from
all of the treated cohorts. Some of these designs are unable to establish a dose that
meets any speciﬁc target toxicity. Despite all of these limitations, rule-based designs
have been used in many clinical trials.
2.2.2 Model-Based Designs
Model-based designs are alternatives to rule-based designs and they assume a para-
metric model to establish the dose-response relationship. Such designs select a dose
level that produces a target probability of toxicity using all of the accrued data in a
trial. These designs are usually implemented under the Bayesian framework, as the
sample size remains small at the early stages of a trial. The common model-based
designs include the continual reassessment method, escalation with overdose control
and others.
Continual Reassessment Method
The continual reassessment method (CRM) (O'Quigley et al., 1990) is a Bayesian
model-based procedure for dose escalation. The design aims to reduce the number of
patients at subtherapeutic doses and to obtain a more accurate estimate of the MTD.
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Assume that d pre-speciﬁed doses {x(1), . . . , x(d)} are available for an experimental
drug. Let Yk be the response from the kth patient (k = 1, 2, . . . , n), which may be
toxic or nontoxic with value 1 or 0, respectively. The method employs parametric
models, such as the hyperbolic tangent model, logistic model or power model to
characterise the dose-response relationship. For example, a one-parameter logistic
model is given as
ψ(xk, β) =
exp(3 + βxk)
1 + exp(3 + βxk)
, (2.3)
where 3 is the assumed value for the intercept parameter (Ishizuka and Ohashi,
2001), β is the unknown slope parameter, xk is the dose administered to the kth
patient and ψ denotes the probability of toxicity. The advantage of using a one-
parameter model is that it requires fewer patients to obtain precise estimate of the
unknown parameter. However, such a model may not be ﬂexible enough to represent
the dose-response relationship accurately.
Let us assume that Θ is the parameter space for β. Initially, a prior distribution
g(β) for β is considered, which is updated sequentially. Denote the prior distribution
for β for the kth patient by f(β, Sk) where Sk = {y1, y2, . . . , yk−1}. This prior is the
posterior distribution for β based on the outcomes from the ﬁrst k− 1 patients and
is obtained as
f(β, Sk) =
f(β, Sk−1) L(β|xk−1, yk−1)∫
Θ
f(β, Sk−1) L(β|xk−1, yk−1) dβ =
g(β)
∏k−1
l=1 L(β|xl, yl)∫
Θ
g(β)
∏k−1
l=1 L(β|xl, yl) dβ
, (2.4)
where L(β|xl, yl) = {ψ(xl, β)}yl {1 − ψ(xl, β)}1−yl is the likelihood function of β
given the response yl at xl, the dose received by the lth patient. The mean of the
posterior distribution of β, denoted by µk, is obtained as
µk =
∫
Θ
β f(β, Sk) dβ. (2.5)
With this mean, the risk of toxicity at each of the doses is updated by using the
equation
ψik = ψ(x
(i), µk), i = 1, 2, . . . , d. (2.6)
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For a pre-speciﬁed target probability of toxicity γ, the trial starts with the dose for
which the prior probability of toxicity is around γ. That dose is chosen for the kth
patient for which the absolute diﬀerence between the updated estimate of probabil-
ity of toxicity and the target toxicity rate is minimum. The process continues until
a ﬁxed sample size n is achieved and the MTD is the dose that would be allocated
to patient n+ 1 if he were in the trial.
To investigate how the CRM would perform if adopted in some completed trials,
O'Quigley and Zohar (2006) reported some retrospective analyses. Their reanalysis
of the studies in Giles et al. (2004), Gelmon et al. (2004), Bos et al. (2005), and
Okamoto et al. (2006) clearly show the advantage of using the CRM over the 3+3
design. That is, it reaches the MTD more quickly and treats more patients at and
close to the MTD.
There was considerable debate in the statistical literature about the original version
of the CRM, as it starts with the initial MTD and also many patients are likely to
be exposed to high toxicity because of skipping dose. Various modiﬁcations have
been suggested to make it safer. Some of these include: (1) treating the ﬁrst pa-
tient at the lowest dose level (Korn et al., 1994); (2) not allowing dose escalation
for the next patient if a patient experiences toxicity (Faries, 1994); (3) increasing
the dose by only one pre-speciﬁed level at a time (Goodman et al., 1995); and (4)
treating several patients at the same dose level, especially for the higher dose levels
(Goodman et al., 1995). Møller (1995) proposed a two-stage CRM in which the
ﬁrst stage involves an up-and-down method until the ﬁrst toxicity is observed. The
design then moves to the second stage and starts using the CRM. Also, it does not
allow skipping of more than one dose level at a time during the second stage. Heyd
and Carlin (1999) suggested stopping a trial if the estimated MTD achieves a pre-
speciﬁed precision. The time-to-event continual reassessment method (TITE-CRM)
is another modiﬁed version proposed by Cheung and Chappell (2000), which takes
into account the time to toxicity for each patient in the dose-escalation procedure.
21
These modiﬁcations have been implemented in clinical practice.
O'Quigley and Shen (1996) proposed a new version of the CRM based on the clas-
sical likelihood approach of parameter estimation which is known as the continual
reassessment maximum likelihood (CRML) method. There are some perceived diﬃ-
culties by clinicians regarding the original version of the CRM. These include starting
with the dose which is the best prior guess of the MTD, incorporating prior infor-
mation regarding the model parameters and the numerical integration necessary in
the implementation of the method. The CRML appears to deal with the above
three diﬃculties. Since initially the new design uses an up-and-down design which
starts with the lowest dose, it does not require the best prior guess of the MTD to
start with. Also, as the design is based on the frequentist approach, it ignores any
prior information regarding the parameters. The operating characteristics of the two
methods are very similar. Although simulation studies show some minor diﬀerences
in dose allocation during the trials, the ﬁnal recommendations are almost the same.
As the likelihood equation has no solution until a toxic outcome is observed, the
CRML can be applied only after the occurrence of such an outcome. To overcome
this, a suggestion is to initially use either a standard up-and-down procedure or the
CRM until a toxic outcome is observed, after which dose allocation can be based on
the CRML.
Escalation with Overdose Control
As the original version of the CRM received a lot of criticism for its potential for ex-
posing patients to overly toxic doses, various suggestions have been made to improve
it further as discussed earlier. In a further attempt, Babb et al. (1998) introduced
an alternative method that directly reduces the chance of overdosing. The main
argument is that allocating doses which are close to the MTD, as in the CRM, is
not attractive from an ethical point of view, and, therefore, their design tries to
allocate doses more cautiously.
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This new method is known in the statistical literature as escalation with overdose
control (EWOC) and it is designed to approach the MTD as fast as possible, subject
to the constraint that the predicted proportion of patients who receive an overdose is
equal to a speciﬁed value α, called the feasibility bound. The method is implemented
by computing the posterior cumulative distribution function of the MTD after each
assignment of a dose to a patient. At the kth stage of a trial, the posterior cumulative
distribution function of the MTD is a function given by
pik(xMTD) = P{MTD ≤ xMTD|Sk},
where xMTD is the dose expected to produce toxicity in a speciﬁed proportion γ of
patients and Sk denotes the responses available from the previous patients. The
EWOC method then selects the dose xk for the kth patient such that
pik(xk) = α.
That is, the method selects the dose for each patient so that the predicted proba-
bility that it exceeds the MTD is equal to α. Generally, a trial is continued until
the maximum sample size n is reached. Upon completion of the trial, the MTD
is estimated by minimising the posterior expected loss with respect to some choice
of loss function. One should consider asymmetric loss functions since underestima-
tion and overestimation have very diﬀerent eﬀects. The simulation study shown
in the paper revealed that, relative to the CRM, the EWOC method overdosed a
smaller proportion of patients, exhibited fewer toxicities and estimated the MTD
with slightly lower average bias and marginally higher mean square error. Similarly,
relative to designs based on up-and-down schemes, EWOC treated fewer patients
at subtherapeutic and toxic doses, treated a higher proportion of patients at doses
near the MTD and estimated the MTD with lower average bias and mean square
error.
Although the original paper suggested α to be 0.25, the feasibility of varying α dur-
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ing the trial has also been studied by diﬀerent authors. These include Babb and
Rogatko (2001, 2004) and Cheng et al. (2004). This approach is motivated by the
fact that, in the early stages of a trial, the uncertainty about the MTD remains
high and a small value of α can prevent the method from choosing doses higher
than the MTD. The uncertainty decreases with the advancement of a trial and the
likelihood of selecting a dose which is higher than the MTD becomes smaller. Chu
et al. (2009) proposed a hybrid method in which EWOC begins with α = 0.1 and
then α gradually increases according to a ﬁxed schedule up to α = 0.5.
Tighiouart et al. (2005) addressed the issue of the choice of prior distributions for
xMTD and ρ0, which are the MTD and the probability of toxicity at the starting
dose, respectively. They extended the class of restrictive priors used in the original
version of EWOC by relaxing some of the constraints placed on (ρ0, xMTD). Through
simulation, they showed that a candidate joint prior distribution for (ρ0, xMTD) with
negative a priori correlation between these two parameters could lead to a safer trial
than the one which assumes independent priors.
Babb and Rogatko (2001) extended the idea of EWOC further to include covariates,
so that patient-speciﬁc dose allocation is possible.
Cheung (2005) studied the coherence conditions of dose-ﬁnding studies in the context
of phase I clinical trials. Many phase I designs are outcome-adaptive, as the selection
of dose for the next patient depends on the accumulated observations. An escalation
of dose for the next patient is said to be coherent when the outcome from the previous
patient was not toxic. Similarly, a de-escalation is said to be coherent if the last
outcome was a toxic one. A design with these conditions is called coherent. The
feature limits the risk of exposing patients to highly toxic doses. As reported by
Cheung (2005), most of the phase I designs like the 3+3, the CRM and EWOC
have this attractive feature. Incoherence of these designs may happen due to ad hoc
24
modiﬁcations that are often made in the course of a trial.
2.3 Phase II Designs
In phase II studies, the focus moves from toxicity to eﬃcacy. The investigators want
to examine whether a drug has suﬃcient eﬃcacy to be studied in the next phase.
Phase II trials are mainly divided into two parts: IIA and IIB. The phase IIA trials
are usually single-arm studies and devoted to assessing the eﬃcacy of the experi-
mental drug with the goal of identifying the best dose. The phase IIB trials are
multi-arm studies and aim to compare the experimental drug with other standard
drugs, so that large-scale comparison is possible in phase III for the most promising
drug. Multi-stage designs are often useful in phase IIA trials, so that trials can stop
early due to futility or eﬃcacy.
A two-stage design is a special case of a multi-stage design. The essence of a two-
stage design is that in the ﬁrst stage a small group of patients are enrolled and
enrolment of another group of patients in the second stage depends on the outcomes
from the previous stage. The motivation behind a two-stage design is that we do
not want to enrol a large group of patients if a drug is not found to be promising.
A ﬁrst of this type of two-stage design was proposed by Gehan (1961). The method
received criticism since the sample size remains ﬁxed in the ﬁrst stage. Use of a ﬁxed
sample size ignores the possibility of stopping a trial early. Simon (1989) proposed
two approaches to ﬁnd a two-stage design. The ﬁrst one is the minimax design that
minimises the maximum trial sample size. The second is the optimal design that
minimises the expected sample size under the null hypothesis that the true response
probability is equal to a speciﬁed value.
Jung et al. (2001) proposed a graphical method to search for a design that is a com-
promise between the optimal and minimax designs. This approach helps in ﬁnding
a design that has sample size close to that of the minimax design and expected
sample size close to that of the optimal design. Jung et al. (2004) proposed a family
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of two-stage designs that are admissible according to a Bayesian decision-theoretic
criterion. It is based on an ethically justiﬁed loss function, which is a weighted
average of the maximum sample size and the expected sample size under the null
hypothesis. An admissible design is one that minimises the loss function for some
chosen weights. The family, as special cases, includes the minimax, optimal and
compromise designs. Mander et al. (2012) extended the methodology by incorpo-
rating an additional term in the loss function. More speciﬁcally, the expected sample
size under the alternative hypothesis that the true probability of response is above
the value speciﬁed in the null is also considered in the loss function.
Bryant and Day (1995) allowed the simultaneous monitoring of eﬃcacy and toxicity
in a two-stage design. Mander and Thompson (2010) suggested a two-stage design
for cancer clinical trials that minimises the expected sample size under the alterna-
tive hypothesis. The Simon two-stage design allows early stopping for futility only.
However, the above new design allows stopping for eﬃcacy. Wason et al. (2011)
showed that the consideration of a continuous endpoint in a two-stage cancer clini-
cal trial can reduce the sample size. This gain is signiﬁcant in the sense that it will
reduce the development time of a drug.
On the other hand, phase IIB is carried out if a drug passes through phase IIA. The
trials in this phase are smaller in comparison with the phase III trials. They are
often randomised, multi-arm trials with the aim of identifying the optimal dose for
extensive study in the next phase.
All of the phase I designs that we have described in the previous section utilise the
toxicity data only and make the implicit assumption that higher eﬃcacy rates are
associated with higher doses. This assumption may not be true for all classes of
drugs. Also, an independent study for establishing the eﬃcacy of the drug through
phase IIA trials can extend the time for development. To overcome all of these
shortcomings, we need designs that can take care of both toxicity and eﬃcacy data:
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see Section 1.2 for more explanation. In the following section, we describe some such
designs which combine the objectives of both phase I and phase II.
2.4 Designs using Eﬃcacy and Toxicity as Endpoints
These designs are appropriate when we have no reason to assume that both toxicity
and eﬃcacy follow the same pattern of relationship with dose, and we also want
to minimise the time and costs associated with the drug development. The main
essence of these designs is that they ﬁnd a dose for further studies which is both
safe and eﬃcacious.
Thall and Russell (1998) developed a dose-ﬁnding method that satisﬁes eﬃcacy
and also safety requirements. The dose-response outcome in this case is trinomial,
accounting for both eﬃcacy and toxicity. The outcome is categorised as neutral,
eﬃcacious or toxic. The dose-response relationship is modelled by assuming the
proportional odds (PO) model (McCullagh and Nelder, 1989). The trial starts with
the lowest dose assigned to a cohort of patients. At each step, it determines the set
of acceptable doses based on minimum eﬃcacy and maximum toxicity requirements.
The acceptable dose, for which the eﬃcacy criterion probability is largest, is allo-
cated to the next cohort. The trial terminates if none of the doses are acceptable;
otherwise, it continues until the maximum sample size is reached. The method treats
a suﬃcient number of patients to estimate the rates of eﬃcacy and toxicity at the
selected dose with a given reliability. But it suﬀers from the limitation that in the
settings where all of the doses have acceptable toxicity with higher eﬃcacy at the
higher doses, it does not escalate to the more desirable doses with high probability.
So the method often fails to detect the best dose in the presence of a number of
candidate doses.
Thall and Cook (2004) proposed another method based on the trade-oﬀs between
treatment eﬃcacy and toxicity. The method uses the previous methodology for
ﬁnding acceptable doses. However, it computes a desirability index for all of the
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acceptable doses. The index depends on the marginal probabilities of eﬃcacy and
toxicity of the corresponding doses. As in the previous case, if no acceptable dose is
available, the trial terminates and no dose is recommended for further evaluation.
Otherwise, the dose with maximum desirability is assigned to the next cohort, sub-
ject to the condition that no untried dose may be skipped when escalating. The trial
is continued until the maximum sample size is reached and the dose with maximum
desirability is recommended for further studies. It provides a substantial improve-
ment over the earlier version and also accommodates bivariate binary outcomes.
The method is known as EﬀTox in the statistical literature.
Zhang et al. (2006) proposed another such idea considering trinomial responses. The
design has a similar approach to that of Thall and Russell (1998), but it utilises a
more ﬂexible continuation ratio (CR) model. The design selects a dose based on
a optimal dose selection criterion that is expressed as the diﬀerence between the
probabilities of eﬃcacy and toxicity multiplied by a scalar in the range between
0 and 1. However, the advantage of this scale parameter is not clear. There are
dose-response scenarios where consideration of such an optimality criterion will lead
to the recommendation of doses which are far away from the true optimal dose.
The method is popularly known as TriCRM. The previous two approaches involve
considerable eﬀort to elicit priors. In that regard, TriCRM is a simple alternative.
Dragalin and Fedorov (2006) suggested an adaptive procedure considering eﬃcacy
and toxicity as endpoints. The modelling of these endpoints is based on either Gum-
bel bivariate binary logistic regression or the Cox bivariate binary model. They
express a dose-ﬁnding problem in terms of a penalised D-optimality criterion. The
design maximises the information under the control of a penalty function for treat-
ing patients at doses which are too low or too high.
Thall et al. (2008) presented a dose-ﬁnding procedure based on bivariate outcomes
that incorporates patient covariates and dose-covariate interactions. This is an ex-
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tension of the methodology in Thall and Cook (2004) to allow for covariate eﬀects.
More recently, Thall and Nguyen (2012) proposed a new approach based on elicited
utilities of the possible dose-response outcomes.
Since the model-based designs use all of the available data, they are eﬃcient in
ﬁnding the best dose for further studies. They also avoid treating many patients
at the subtherapeutic doses. Because most of the designs are based on a Bayesian
framework, the success of the trials depends on the assumed prior distribution for
the model parameters. Specialised software is required for identifying the best dose
at each step of a trial. Since these designs have attractive operating characteristics,
they are becoming more popular.
2.5 PK-Guided Designs
Although clinical researchers possess the opinion that PK information has an im-
portant role in clinical response (Govindarajulu, 1988), very little eﬀort has been
made so far to incorporate such information in dose-response studies. Piantadosi
and Liu (1998) described a method for incorporating PK information as a covariate
in a dose-response model suitable for binary toxicity responses. In particular, they
put the AUC in the dose-response model. Their objective is to consider drug con-
centration rather than just dose administered. They want to prevent patients from
receiving too high a dose of the experimental drug. The study demonstrates that the
eﬃciency and accuracy of phase I clinical trials can be improved by incorporating
such information. Although the implementation of the method requires accurate PK
data, they have not used the theory of optimal design to collect the data. Moreover,
estimating the AUC following the usual approaches will require many blood samples
to be collected.
Whitehead et al. (2007) presented an approach for phase I trials based on simulta-
neous monitoring of pharmacokinetic and pharmacodynamic responses. Following a
logarithmic transformation, a linear model is employed to relate dose to the pharma-
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cokinetic endpoint and a quadratic model to relate the pharmacokinetic endpoint to
the pharmacodynamic endpoint. A logistic model is used to relate the pharmacoki-
netic endpoint to the risk of an adverse event. The approach allows us to relate the
amount of drug absorbed, reﬂected by the AUC, rather than the dose, to the risk of
an adverse event. The doses which lead to an excessive plasma concentration or high
risk of toxicity are avoided during each stage of the trial. The ﬁnal dose at each stage
is selected based on the predictive distribution of the pharmacodynamic endpoint.
From the discussion, it appears that the method is appropriate for phase I trials only.
The methodology in Zhou et al. (2008) is for phase I trials in healthy volunteers. For
each individual in the trial, it monitors two continuous pharmacokinetic measures
AUC and Cmax, and a binary indicator variable for an undesirable event. The method
uses no dose for which the posterior value of P (AUC > LAUC), or P (Cmax > LC)
or P (DLT) is greater than 0.2. The safety limits LAUC and LC are set prior to the
start of a trial and are expected to be obtained from expert opinion in preclinical
studies. The smallest dose that satisﬁes all three conditions is recommended at the
end of each step of the trial.
Observe that the methods that incorporate PK measurements in dose-escalation
are mostly for phase I trials. To our knowledge, no method is available in the
literature that can explicitly take into account PK data along with eﬃcacy and
toxicity endpoints. Moreover, even in the methods for phase I trials, we have not
seen the use of population optimum design for PK sampling. The use of optimum
design can reduce the number of samples and can also provide precise estimates of
the model parameters. This is very important, as often the parameters have physical
meanings. Our design is diﬀerent, since it is for seamless phase IB/IIA trials and it
also considers population optimum design for PK sampling.
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Chapter 3
Population PK Models and Design
3.1 Introduction
The concentration of a drug depends on absorption, distribution, metabolism and
excretion. Since these mechanisms diﬀer among patients, an approach to describe
PK data should be such that it can capture the inter-patient variability. Moreover,
it should allow us to generalise the ﬁndings to a population of patients. Population
modelling, based on mixed eﬀects models, is one such approach that helps in under-
standing how the individuals from a population diﬀer from one another. Therefore,
this chapter begins with an introduction to the population approach to modelling
PK data.
Starting with the underlying idea, we introduce compartmental models that are
commonly used in the analysis of PK data. These models are based on the solutions
to diﬀerential equations representing the distribution of a drug in the body's com-
partments. Such models are non-linear in the parameters. Therefore, the population
approach in this thesis will lead us to non-linear mixed eﬀects models.
We introduce the general non-linear mixed eﬀects model and derive the associated
Fisher information matrix. To illustrate the general model, we consider two speciﬁc
PK models and the analytical forms are obtained for the information matrices. We
then discuss diﬀerent optimality criteria in the context of design. The properties of
the parameters AUC and Cmax are also studied in detail. The results will assist in
the optimum dose selection in an adaptive clinical trial.
3.2 Population Approach
The population approach to PK modelling quantiﬁes the eﬀect of a drug in a popu-
lation of patients. It allows the quantiﬁcation of variability in plasma concentration
over a patient population.
For a drug, the concentration proﬁles over individuals often have similar shapes but
they may vary: see Figure 3.1. The data presented are from an experiment on the
pharmacokinetics of the drug indomethacin (Kwan et al., 1976). The same dose was
given to six individuals through bolus intravenous injection. The plasma concentra-
tions of each of the individuals were then measured in mcg/ml 11 times during a
period of 8 hours and 15 minutes. The measurement time points were the same for
all six individuals. These data are also available in the R library nlme as the object
Indometh. Figure 3.1 indicates that the concentration curves have a similar shape
but they vary across the individuals. For instance, the peaks for individuals 1, 4
and 2 are close to each other, but they are lower than those for individuals 5, 6 and 3.
If we can assume the underlying mechanism is the same for all individuals, then we
can use the same regression function but with individual parameter values for each
subject. Thus, we can think of individual parameter values to be realisations of
random variables. The mean parameters provide a proﬁle for a typical individual.
The population approach is based on non-linear mixed eﬀects (NLME) models and
have been widely used in the literature for many years (Sheiner et al., 1972; Yuh
et al., 1994; Sheiner and Steimer, 2000).
Since sampling PK responses involves a cost, it is desirable to keep the number of
samples and the number of patients as low as possible during an experiment. Also,
a trial should be conducted in such a way that it ensures reliable estimates of the
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Figure 3.1: Concentration proﬁles of six individuals following the intravenous injec-
tion of indomethacin.
parameters. The theory of optimal design for non-linear mixed eﬀects models helps
to achieve this.
3.2.1 PK Compartmental Models
The recording of plasma concentration over time after the administration of a drug
gives a concentration proﬁle as in Figure 3.1. The concentration at any time de-
pends on dose and the processes of absorption, distribution, metabolism and excre-
tion. Therefore, the concentration of a drug at a given time point can be expressed
through a function that incorporates dose and the rates of ADME. The models
which serve this purpose are compartmental and are non-linear in the parameters.
In compartmental models, the body is thought to consist of several compartments.
The central compartment is the one that remains in any model. A compartment is
a homogeneous unit that is used to represent a group of tissues with similar rates of
drug distribution. Usually one- to three-compartment models are used to quantify
concentration-time proﬁles. If a drug is found to be distributed in the tissues of
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a body very quickly, we may use a one-compartment model. If it appears that
the drug is distributed at slower rates in diﬀerent tissues, use of either a two- or a
three-compartment model would be reasonable.
One-Compartment Model
In a one-compartment model, the body is regarded as a single compartment. The
tissues in that compartment have a high rate of drug intake. It is assumed that the
Figure 3.2: A one-compartment model.
drug is instantaneously distributed throughout the body after the administration
and also that it achieves equilibrium between the tissues. Figure 3.2 (Dubois et al.,
2011) depicts the structure for a one-compartment model, where the central com-
partment has the volume of distribution V of the drug. The drug is cleared from
that compartment at the rate ke.
One-Compartment Model without Absorption
Assume that a drug is administered intravenously with bolus injection. It is then
absorbed immediately in the central compartment. The drug is eliminated from
the body following the ﬁrst-order kinetics, where the speed of the elimination is
proportional to the amount of drug left in the compartment. This can be expressed
in terms of the equation
dX(t)
dt
= −keX(t),
where X(t) is the amount of drug in the central compartment at time t and ke is the
elimination rate. Initially, X(0) = x, where x is the dose that has been administered.
To obtain the solution to this diﬀerential equation, we integrate both sides of the
equation
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dX(t)
X(t)
= −kedt,
which leads to
X(t) = ce−ket,
where c is a constant. Using the initial condition at t = 0, the above equation gives
c = x, and so
X(t) = xe−ket.
Therefore, the concentration at time t can be written as
C(t) =
X(t)
V
=
x
V
e−ket =
x
V
e−
Cl
V
t, (3.1)
where Cl is the clearance of the drug, V is the volume of distribution and ke = Cl/V .
A description of these parameters is given in Section 3.3.
One-Compartment Model with First-Order Absorption
Now we assume that the administered drug has an absorption phase following the
ﬁrst-order kinetics. That is, the speed of the absorption is proportional to the
amount of drug that is yet to be absorbed. Then the processes of absorption and
elimination can be described by the following set of diﬀerential equations:
dX1(t)
dt
= kaX2(t)− keX1(t),
dX2(t)
dt
= −kaX2(t),
with initial conditions X1(0) = 0 and X2(0) = x. Here, X1(t) is the amount of drug
in the central compartment at time t, X2(t) is the amount of drug that is yet to be
absorbed and ka is the absorption rate. From the solution to this set of diﬀerential
35
equations given in Section A.1, it can be shown that the concentration at time t is
C(t) =
X1(t)
V
=
xka
V (ka − ke)(e
−ket − e−kat). (3.2)
Two-Compartment Model
For many drugs, the body cannot be assumed to be a single homogeneous unit, but
it is suﬃcient to consider two compartments: a central one and a peripheral one.
The tissues in the central compartment are highly perfused such as the heart, kidney,
liver, lung and brain. The peripheral compartment comprises of less perfused tissues
such as muscle and skin. So the tissues and plasma in the central compartment can
Figure 3.3: A two-compartment model.
absorb the drug rapidly, whereas those in the peripheral compartment absorb the
drug at a slower rate. The central and peripheral compartments have V1 and V2
as the volumes of distribution, respectively. The rates of transfer from the central
compartment to the peripheral compartment and back are k12 and k21, respectively.
The drug is eliminated from the central compartment at the rate ke. Figure 3.3
represents such a model.
Two-Compartment Model with First-Order Absorption
The drug is absorbed and eliminated via the central compartment. The exchange
between the central compartment and the peripheral compartment follows ﬁrst-order
kinetics. The overall process can be explained by the following set of diﬀerential
equations:
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dX1(t)
dt
= −(ke + k12)X1(t) + k21X2(t) + kaX3(t),
dX2(t)
dt
= k12X1(t)− k21X2(t),
dX3(t)
dt
= −kaX3(t),
with initial conditions X1(0) = 0, X2(0) = 0 and X3(0) = x. Here, X1(t) and X2(t)
are the amounts of drug in the central and peripheral compartments, respectively,
and X3(t) is the amount of drug to be absorbed at time t. The concentration in
the central compartment at a given time point after the administration of a dose
can obtained by solving the above set of diﬀerential equations. The derivation will
follow similar steps to the one shown in Section A.1.
Three-Compartment Model
This is an extension of the two-compartment model, where the drug is distributed
at a very slow rate to certain tissues such as fat and bone. These tissues constitute
the third compartment.
Figure 3.4: A three-compartment model.
The mechanism for such a three-compartment model is illustrated in Figure 3.4
(Dubois et al., 2011).
Three-Compartment Model with First-Order Absorption
For the three-compartment model when the drug is absorbed following the ﬁrst-
order absorption, the following set of diﬀerential equations express the structure of
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the process:
dX1(t)
dt
= −(ke + k12 + k13)X1(t) + k21X2(t) + k31X3(t) + kaX4(t),
dX2(t)
dt
= k12X1(t)− k21X2(t),
dX3(t)
dt
= k13X1(t)− k31X3(t),
dX4(t)
dt
= −kaX4(t),
with initial conditions X1(0) = 0, X2(0) = 0, X3(0) = 0 and X4(0) = x. Here,
X1(t), X2(t) and X3(t) are the amounts of drug in the central and two peripheral
compartments, respectively, and X4(t) is the amount of drug yet to be absorbed at
time t. This set of diﬀerential equations can be solved to obtain the concentration
in the central compartment at any time following the administration of a dose. The
derivation is similar to the one shown in Section A.1 for the one-compartment model.
Since most of the kinetic functions are derived from diﬀerential equations, as shown
above, they are non-linear in the parameters. These parameters often have physical
interpretations. For example, those in (3.1) and (3.2) have their own meanings, as
will be explained in Section 3.3.
From the discussion in Section 3.2, we know that variability in the concentration
proﬁles is very likely to be present among patients after receiving the same dose.
We always try to identify the sources of such variability in an attempt to model it
accurately. The theory of mixed eﬀects models allows us to do this. Since com-
partmental models, which are non-linear in the parameters, are to be used and as
inter-patient variability in the concentration proﬁles exists, we plan to use non-linear
mixed eﬀects models for the purpose of modelling PK data.
3.3 Important PK Parameters
In this section, we list some commonly used PK parameters that will be used
throughout the thesis. Some of these also appear in the functions that express
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concentration as a function of time.
Volume of Distribution
The volume of distribution is deﬁned as that volume of plasma in which the total
amount of drug in the body would be required to be dissolved in order to reﬂect the
drug concentration attained in plasma. It is denoted by V and quantiﬁes the distri-
bution of a medication between plasma and the rest of the body after dosing. It can
be calculated by dividing the amount of drug in the body (X) by the concentration
(C), that is,
V =
X
C
.
Clearance
The clearance is deﬁned as the amount of plasma that is cleared of the drug per
unit of time. It is denoted by Cl and its units are volume/time. Clearance can be
expressed as
Cl = V × ke,
where ke is the elimination rate.
Absorption Rate
The absorption rate, denoted by ka, determines the time required for the adminis-
tered drug to reach an eﬀective plasma concentration. Therefore, the rate inﬂuences
both the occurrence of the maximum concentration (Cmax) and the time to achieve
it (tmax).
Elimination Rate
The elimination rate describes the rate at which the drug is removed from the body
and is denoted by ke.
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Area Under the Concentration Curve
The area under the concentration curve (AUC) reﬂects the overall amount of drug
in the plasma after the administration of a dose. Its units are the product of con-
centration and time. For instance, they could be mg/l× hr. There are situations
where a small increment in dose may produce a large increase in AUC (Graham
and Workman, 1992). Also, drugs tend to produce toxicity at higher levels of AUC.
Therefore, a drug can be administered safely by monitoring plasma concentration.
The AUC can be regarded as one of the important PK parameters to guide in pre-
venting patients being allocated toxic doses.
A non-parametric approach is often used to obtain the AUC. It employs the trape-
zoidal rule (Gabrielsson and Weiner, 2000) and requires a large number of samples
per subject. An alternative is estimation based on a PK model. For many PK mod-
els, it is possible to obtain an analytical form for the AUC by integrating the model
function over the design region. Use of optimal sampling time points will reduce the
number of samples to be collected per subject, and so the parametric approach has
an advantage over the non-parametric one. Hence, the parametric approach will be
used here to ﬁnd the AUC.
Maximum Concentration
The maximum concentration, denoted by Cmax, is the peak in the concentration that
is achieved after the administration of a dose. The time at which this concentration
is observed is denoted by tmax. For a PK model, it is possible to ﬁnd tmax and thus
Cmax. A high value of Cmax is likely to produce side eﬀects and therefore monitoring
this parameter is often crucial in clinical practice.
Figure 3.5 shows the concentration proﬁles for diﬀerent individuals. Although they
receive the same dose, the proﬁles are diﬀerent. The shapes are similar but each
individual has distinct values for the parameters. The AUC and Cmax also vary
over the individuals. To model these variabilities, an appropriate choice would be a
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Figure 3.5: Concentration proﬁles for diﬀerent individuals following the model func-
tion in (3.21).
non-linear mixed eﬀects model.
3.4 Non-Linear Mixed Eﬀects Model
We have a PK response to be measured on each individual i (i = 1, . . . , N). The
response will be measured at ni sampling times denoted by ξi = (ti1, . . . , tini). We
describe the population design for the total number of observations n =
∑N
i=1 ni by
Ξ = {ξ1, . . . , ξN}.
The responses can be represented through a known function f : R+ → R+. Then,
for the ith individual, we can write f(ξi;θi) = (f(ti1;θi), . . . , f(tini ;θi))
T , where θi
is the vector of all the individual parameters. The vector θi has two components
β and bi, where β is the p-vector of mean population parameters and bi is the p-
vector of random eﬀects for the ith individual. These are related through a vector of
functions g, that is, θi = g(β, bi). The functions g are often chosen to be additive
or exponential. We consider the simple case of θi = β + bi. It is assumed that
bi ∼ Np(0,Ω), with Ω deﬁned as a p× p diagonal matrix. We denote the kth diag-
onal element of Ω by σ2k (k = 1, . . . , p), which is the variance of the kth component
of bi.
Let yi = (yi1, . . . , yini)
T represent the vector of observations for the ith individual.
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Then the statistical model is given by
yi = f(ξi; g(β, bi)) + i, (3.3)
where i = (i1, . . . , ini)
T is the vector of random errors associated with the re-
sponses. We assume that i ∼ Nni(0, σ2Ini). The vector of all the population param-
eters to be estimated is represented by Ψ = (βT ,λT )T , where λ = (σ21, . . . , σ
2
p, σ
2)T
is the vector of variances.
3.4.1 Linearisation of the Model
Since our model is non-linear in the parameters, derivation of an analytical expres-
sion for the log-likelihood function is not possible. Various approximations to the
information matrix have been proposed in the literature. A comparison of diﬀerent
methods is presented by Mielke (2012), who concludes that none of the methods is
uniformly best. Lindstrom and Bates (1990) use a ﬁrst-order Taylor series expansion
of the model function f about the ﬁxed parameters and the random eﬀects at their
estimates. At the design stage, there are no data to obtain the estimates, and so
we use pre-speciﬁed values β0 for the ﬁxed eﬀects and the expectation of the ran-
dom eﬀects. That is, we approximate the log-likelihood using the ﬁrst-order Taylor
series expansion of the function f(ξi;θi) = f(ξi; g(β, bi)) about φi = (β, bi)
T at
φ0 = (β0, E(bi))
T
= (β0,0)
T
.
Following the Taylor series expansion, we have
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f(ξi; g(β, bi)) ∼= f(ξi; g(β, bi))
∣∣∣∣
φ0
+
(
∂f(ξi; g(β, bi))
∂φi
)T ∣∣∣∣
φ0
(φi − φ0)
= f(ξi; g(β
0,0)) +
(
∂f(ξi; g(β, bi))
∂β
)T ∣∣∣∣
φ0
(β − β0)
+
(
∂f(ξi; g(β, bi))
∂bi
)T ∣∣∣∣
φ0
(bi − 0)
= µi +
(
∂f(ξi; g(β, bi))
∂β
)T ∣∣∣∣
φ0
β +
(
∂f(ξi; g(β, bi))
∂bi
)T ∣∣∣∣
φ0
bi,
where µi is a ni × 1 vector of constants. With this approximation, the model in
(3.3) becomes a linear mixed eﬀects model of the form
yi ∼= µi +
(
∂f(ξi; g(β, bi))
∂β
)T ∣∣∣∣
φ0
β +
(
∂f(ξi; g(β, bi))
∂bi
)T ∣∣∣∣
φ0
bi + i. (3.4)
With matricesHi = (∂f(ξi; g(β, bi))/∂β)
T
∣∣
φ0
and Li = (∂f(ξi; g(β, bi))/∂bi)
T
∣∣
φ0
,
the model can be written as
yi ∼= µi +Hiβ +Libi + i. (3.5)
Hence, we have
E(yi) ∼= Ei = µi +Hiβ (3.6)
and also, assuming that bi and i are independent, we obtain
Var(yi) ∼= Vi = LiΩLTi + σ2Ini . (3.7)
Since the matrices Hi and Li are evaluated at φ
0, they no longer depend on the
parameters. However, the design solution will depend on the assumed prior values
φ0.
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3.4.2 Fisher Information Matrix
The Fisher information matrix (FIM) for the ith individual and design ξi is given
by
Mi(Ψ, ξi) = E
[
−∂
2li(Ψ | yi)
∂Ψ∂ΨT
]
,
where li(Ψ | yi) is the log-likelihood function for individual i.
Since bi and i are assumed to be normal, the log-likelihood function is approximated
by
li(Ψ | yi) ∼= log
[
(2pi)−
ni
2 |Vi|− 12 exp{−1
2
(yi −Ei)TV −1i (yi −Ei)}
]
.
That is,
− 2li(Ψ | yi) ∼= ni log(2pi) + log |Vi|+ (yi −Ei)TV −1i (yi −Ei). (3.8)
Successive diﬀerentiation of (3.8) with respect to βl and βm gives
∂(−2li(Ψ | yi))
∂βl
∼= −2(yi −Ei)TV −1i
(
∂Ei
∂βl
)
and
∂2(−2li(Ψ | yi))
∂βm∂βl
∼= 2
(
∂Ei
∂βm
)T
V −1i
(
∂Ei
∂βl
)
.
Therefore,
E
(
−∂
2li(Ψ | yi)
∂βm∂βl
)
∼=
(
∂Ei
∂βm
)T
V −1i
(
∂Ei
∂βl
)
. (3.9)
Diﬀerentiation of (3.8) with respect to λl gives
∂(−2li(Ψ | yi))
∂λl
∼= tr
(
V −1i
∂Vi
∂λl
)
+ (yi −Ei)T
(
−V −1i
∂Vi
∂λl
V −1i
)
(yi −Ei), (3.10)
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since
∂ log |Vi|
∂λl
= tr
(
V −1i
∂Vi
∂λl
)
and
∂V −1i
∂λl
= −V −1i
∂Vi
∂λl
V −1i .
Also,
∂2(−2li(Ψ | yi))
∂βm∂λl
∼= 2(yi −Ei)T
(
−V −1i
∂Vi
∂λl
V −1i
)(
− ∂Ei
∂βm
)
.
Therefore,
E
(
−∂
2li(Ψ | yi)
∂βm∂λl
)
∼= 0. (3.11)
Again, diﬀerentiation of (3.10) with respect to λm yields
∂2(−2li(Ψ | yi))
∂λm∂λl
∼= −tr
(
V −1i
∂Vi
∂λm
V −1i
∂Vi
∂λl
)
+ (yi −Ei)T
(
V −1i
∂Vi
∂λm
V −1i
∂Vi
∂λl
V −1i + V
−1
i
∂Vi
∂λl
V −1i
∂Vi
∂λm
V −1i
)
(yi −Ei),
so that
E
(
∂2(−2li(Ψ | yi))
∂λm∂λl
)
∼= −tr
(
∂Vi
∂λm
V −1i
∂Vi
∂λl
V −1i
)
+ 2 tr
(
∂Vi
∂λm
V −1i
∂Vi
∂λl
V −1i
)
,
since, for a quadratic form, we have
E(XTAX) = tr(AΣ) + µTAµ,
where µ and Σ are the mean and variance of X, respectively.
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Therefore,
E
(
−∂
2li(Ψ | yi)
∂λm∂λl
)
∼= 1
2
tr
(
∂Vi
∂λm
V −1i
∂Vi
∂λl
V −1i
)
. (3.12)
Then the FIM for individual i can be approximated by the block diagonal matrix
Mi(Ψ, ξi) ∼=
 Ai 0
0 Bi
 , (3.13)
where the elements of matrices Ai and Bi are
(Ai)ml =
(
∂Ei
∂βm
)T
V −1i
∂Ei
∂βl
for m, l = 1, . . . , p,
and
(Bi)ml =
1
2
tr
(
∂Vi
∂λm
V −1i
∂Vi
∂λl
V −1i
)
for m, l = 1, . . . , p+ 1.
The population FIM for the design Ξ is deﬁned as the sum of N elementary Fisher
information matrices, that is,
M(Ψ,Ξ) =
N∑
i=1
Mi(Ψ, ξi).
For a single group of N individuals with identical designs, the population FIM is
M(Ψ,Ξ) = NM (Ψ, ξ). (3.14)
Unlike in linear models, here the FIM depends on the parameters of the model.
This is important as most of the criteria for design optimality are functions of the
information matrix, as is explained in the next section.
Retout et al. (2001) use a ﬁrst-order Taylor series expansion of the model function
f about the expectation of the parameters to linearise the model. Although their
linearised model is diﬀerent from ours in (3.5), we have found that the FIMs in
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both cases are the same. To derive the FIM in their approach, one needs to assume
that Vi is independent of β. But their expression for Vi clearly indicates that this
will not be the case. However, in our approach, we do not need to make any such
assumption. Both FIMs produce the same design. This is because, in the criteria for
design optimality, only a function of the FIM is used and it will not matter whether
the two linearised models are exactly the same.
3.5 Optimal Experimental Designs
Optimal design depends on the statistical model and it optimises a chosen design
criterion. Compared to an optimal design, a non-optimal one requires a greater
number of experimental runs to provide the same statistical eﬃciency. Use of optimal
design thus reduces the cost of conducting an experiment. Utmost care should be
taken in the choice of an optimality criterion so that it is consistent with the objective
of an experiment.
3.5.1 Optimality Criteria
In this section, we discuss some widely used design criteria which are based on the
books by Atkinson et al. (2007), Fedorov (1972), Berger and Wong (2009), and
Fedorov and Hackl (1997). Out of all of the optimality criteria to be presented, our
work only uses the D-criterion, since the objective is to minimise the variability in
the parameter estimates.
D-Criterion
The uncertainty in a set of parameter estimators can be expressed in terms of the vol-
ume of a conﬁdence ellipsoid. The precision of the estimators increases as the volume
decreases. The D-optimality criterion minimises the volume of the conﬁdence ellip-
soid, which is a function of the determinant of the covariance matrix. More specif-
ically, a design ξ∗D is called D-optimal if it minimises ΦD{M (ξ)} = log |M−1(ξ)|,
where M (ξ) is the FIM. That is,
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ξ∗D = arg min
ξ
log |M−1(ξ)|.
One important feature of the D-criterion is that the design obtained is invariant
under linear transformations of the scale of the explanatory variables. This im-
plies that, if the design region is changed, we can directly deduce the D-optimal
design from the one previously constructed. This property may not hold for other
optimality criteria.
A-Criterion
The A-optimality criterion minimises the sum or average of the variances of the
parameter estimators. A design ξ∗A is called A-optimal if it minimises ΦA{M (ξ)} =
trace{M−1(ξ)}. That is,
ξ∗A = arg min
ξ
trace{M−1(ξ)}.
This criterion suﬀers from a few drawbacks. Firstly, it is not invariant under lin-
ear transformations of the scale of the explanatory variables. Secondly, sometimes
the variances of the parameter estimator may have very diﬀerent magnitudes and
therefore minimising the sum may mislead.
G-Criterion
Sometimes interest lies in predicting the response over the design region eﬃciently. A
G-optimum design minimises the maximum standardised variance of the predicted
response over the design region. A design ξ∗G is called G-optimal if it minimises
ΦG{M(ξ)} = max
t∈T
ηT (t)M−1(ξ)η(t). That is,
ξ∗G = arg min
ξ
max
t∈T
{ηT (t)M−1(ξ)η(t)},
where η(t) = (∂f/∂θ1, . . . , ∂f/∂θp)
T is the vector of parameter sensitivities and T
is the design region. This criterion has a connection to the D-optimality criterion.
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Kiefer and Wolfowitz (1960) showed that the D- and G-optimality criteria are equiv-
alent in the case of so-called continuous designs, which are probability measures on
the discrete support of the design points. It is also known from their equivalence
theorem that the standardised variance function for a continuous G-optimum design
ξ∗ is always less than or equal to the number of parameters p in the model, that is,
d(t, ξ∗) ≤ p, with equality at the design points, where d(t, ξ∗) = ηT (t)M−1(ξ∗)η(t)
and d(t∗, ξ∗) = p.
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Figure 3.6: Standardised variance function plot for a continuous D-optimum design
for the model in (3.15).
To give an illustration, let us consider the one-compartment PK model with bolus
input and ﬁrst-order elimination given by
yi =
x
V
exp
(
−Cl
V
ti
)
+ i, i = 1, . . . , N, (3.15)
where yi is the concentration of a drug in the blood for the ith individual observed
at time ti, x is the dose received, V and Cl are the two parameters volume of
distribution and clearance, and i is the random error term. Figure 3.6 presents
the standardised variance function plot for the evenly distributed D-optimal time
points ξ∗ = {0, 6.627}, obtained for the values β0 = (0.4, 0.06)T of the parameters.
The ﬁgure indicates that the design has a standardised variance function satisfying
d(t, ξ∗) ≤ 2, where 2 is the number of parameters in the model, and also that equality
holds at the design points. So the design is both G- and D-optimal. This property
is quite often used to check the D-optimum designs obtained numerically and it is
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used for constructing algorithms to calculate D-optimum designs. The equivalence
theorem holds for continuous designs only. The D-optimum design that we use in
the thesis is of discrete type and hence we cannot employ the theorem to judge the
optimality of the design.
c-Criterion
When interest lies in a design to estimate a linear combination of the parameters,
cTβ, with minimum variance, the criterion to be used is c. A design ξ∗c is called
c-optimal if it minimises Φc{M(ξ)} = cTM−1(ξ)c. That is,
ξ∗c = arg min
ξ
{cTM−1(ξ)c}.
This criterion can also be used to estimate a non-linear function of the parameters
with minimum variance. For instance, assume that we have a non-linear function
g(β) to be estimated eﬃciently. The function can be linearised by a Taylor series
expansion to give the components of vector c as
cj(β) =
∂g(β)
∂βj
, j = 1, . . . , p,
evaluated at prior values β0.
3.5.2 Locally Optimal Design
In linear models, the information matrix does not depend on the model parameters.
However, for non-linear models, the information matrix depends on the prior values
of the model parameters. Therefore, the optimal design that we derive for a non-
linear model is optimal locally only for a set of values of the parameters (Chernoﬀ,
1953). Since the parameters are unknown and we want to estimate these through
the experiment in an optimal way, the search for an optimal design starts with some
prior values of the parameters.
Diﬀerent approaches are available in the literature to overcome the dependence of
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an optimum design on the unknown parameters. These include a sequential design,
a Bayesian design and a maximin design (Atkinson et al., 2007). The sequential
approach starts with some guess for the parameter values and as soon as the new
estimates are available, they are replaced. The process continues until the parameter
estimates are suﬃciently precise or the experimental resources are exhausted. In
the thesis, we employ the sequential approach for constructing designs. Since, in an
adaptive dose-ﬁnding design, we update the estimates of the model parameters at
each stage, they are likely to stabilise after several stages of the trial, as will the
design points.
Optimisation Algorithms
In our work, we want to minimise the variability in the PK parameter estimates,
and therefore the appropriate criterion for design optimality is D. The Cramér-Rao
inequality tells us that the covariance matrix of the parameter estimators is greater
than, and asymptotically approaches, the inverse of the FIM. Therefore, by min-
imising the inverse of the FIM through the D-criterion, we minimise the asymptotic
lower bound for the variance of the estimated model parameters.
It has already been mentioned that the derived FIM for our non-linear mixed eﬀects
model has the same expression as in Retout, Duﬀull, and Mentré (2001). Bazzoli
et al. (2010) developed PFIM 3.2, an R package, to evaluate and optimise designs
in the context of population PK/PD experiments. It has a library of PK models
with FIMs in Retout et al. (2001). Since both FIMs are the same, we can compute
the D-optimum design for PK responses using PFIM 3.2.
The package applies two algorithms for design construction: the Fedorov-Wynn al-
gorithm (Wynn, 1972) and the simplex algorithm (Nelder and Mead, 1965). The
Fedorov-Wynn algorithm relies on the equivalence theorem of Kiefer and Wolfowitz
(1960). It is an iterative algorithm that maximises the determinant of the FIM
within a ﬁnite set of possible designs. It is important to note that maximisation of
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the determinant of the FIM is equivalent to the minimisation of the determinant of
the inverse of the FIM. Prior to the optimisation, one needs to provide the set of
possible time points. It is therefore possible to avoid clinically unfeasible sampling
times in this approach. Starting with an initial design, the algorithm then ﬁnds a
design iteratively which satisﬁes the optimality criterion.
In many cases, feasible sampling times may not be known and therefore one can
assume a continuous interval of time as the design region. The algorithm to be
used in that case is the simplex algorithm, which is based on the method by Nelder
and Mead (1965). The method uses the concept of a simplex, which is a generalised
triangle in N dimensions. It iteratively generates a sequence of simplices to approxi-
mate an optimal point. An initial design is required to start the optimisation. From
this initial design, initial vertices for the simplex algorithm are derived. At each
iteration, the vertices of the simplex are ordered according to the objective function
values. The worst vertex, where the function has the maximum value, is rejected
and replaced with a new one. A new simplex is formed and the search is continued.
The method thereby produces a sequence of simplices for which the function values
at the vertices get smaller and smaller. The size of the simplex is reduced and the
coordinates of the optimum point are found. In our work, we employ the simplex
algorithm for the construction of designs, as the feasible sampling times are not
known.
3.6 Parameter Estimation in NLME Models
A number of methods are available in the literature for ﬁtting non-linear mixed ef-
fects models with ongoing debate as to which is the most accurate method. Sheiner
and Beal (1980), Wolﬁnger and Lin (1997), and Lindstrom and Bates (1990) pro-
posed methods based on linearisation. Pinheiro and Bates (1995), Vonesh (1996)
and Wolﬁnger (1993) developed integral approximation methods. Kuhn and Lavielle
(2005), Walker (1996) and Wang (2007) proposed methods that use the expectation-
maximisation (EM) algorithm.
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In the linearisation method, an approximate linear model is derived using a ﬁrst-
order Taylor series expansion of the model to obtain the analytical form for the
likelihood function. A Laplace approximation, Gaussian quadrature or importance
sampling are used in the integral approximation methods to obtain the marginal
distribution of the response variable. The method then maximises the likelihood
directly. Instead of a direct approximation to the marginal likelihood, the EM algo-
rithm approximates the conditional expectation of the log-likelihood in the E-step
and then maximises the expected log-likelihood to estimate the parameters in the
M-step. Of these, the linearisation methods are the most popular due to their nu-
merical simplicity.
The linearisation methods diﬀer with respect to the expansion locus of the random
eﬀects. Beal and Sheiner (1982) suggested a method in which the likelihood function
is based on a ﬁrst-order Taylor series expansion of the model function about the
mean of the random eﬀects. Beal and Sheiner (1992) implemented this method in
the software package NONMEM. Lindstrom and Bates (1990) developed a method
in which the model function is expanded about the current estimate of the ﬁxed
parameters and their random eﬀects. Pinheiro and Bates (2000) implemented the
method in the package nlme, which is available in both the package S-PLUS and
in R. This is the method which we use for estimation of the PK parameters in
the examples presented in Chapter 6. It is worth mentioning that two diﬀerent
linearisation approaches are used in our work. These should not make a diﬀerence
as one is for designing purposes and the other is related to parameter estimation.
3.7 PK Mixed Eﬀects Model Examples
This section describes two models that we use for the concentrations for the purpose
of simulations in Chapter 6. Although the route of administration of the dose is
diﬀerent, both models treat the whole body as a single compartment.
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3.7.1 One-Compartment Model with Bolus Input and First-
Order Elimination
The one-compartment PK mixed eﬀects model with bolus input and ﬁrst-order
elimination is deﬁned as
yil = f(til;θi) + il
=
x
Vi
exp
(
−Cli
Vi
til
)
+ il for i = 1, . . . , N and l = 1, . . . , ni,
(3.16)
where yil is the concentration of a drug in the blood for the ith individual observed
at time til, x is the dose received by the individual, and θi = β + bi = (Vi, Cli)
T is
the vector of parameters with β = (V,Cl)T and bi = (bVi , bCli)
T . We assume that
i ∼ Nni(0, σ2Ini) and bi ∼ N2(0,Ω), where Ω = diag(σ21, σ22). We can write,
f(ξi;θi) = f(ξi; g(β, bi)) =

x
Vi
exp
(
−Cli
Vi
ti1
)
x
Vi
exp
(
−Cli
Vi
ti2
)
...
x
Vi
exp
(
−Cli
Vi
tini
)

. (3.17)
To linearise the model, we expand it using a ﬁrst-order Taylor series about φi =
(V,Cl, bVi , bCli)
T at φ0 = (V 0, Cl0, 0, 0)T. We obtain as an approximation the linear
mixed eﬀects model
yi ∼= µi +Hiβ +Libi + i,
where µi, Hi and Li are as in Section 3.4.1. For this speciﬁc model, we have
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Hi =

∂f(ti1; g(β, bi))
∂V
∂f(ti1; g(β, bi))
∂Cl
...
...
∂f(tini ; g(β, bi))
∂V
∂f(tini ; g(β, bi))
∂Cl

φ0
=

x
(V 0)2
exp
(
−Cl
0
V 0
ti1
)(
Cl0
V 0
ti1 − 1
)
− x ti1
(V 0)2
exp
(
−Cl
0
V 0
ti1
)
...
...
x
(V 0)2
exp
(
−Cl
0
V 0
tini
)(
Cl0
V 0
tini − 1
)
−x tini
(V 0)2
exp
(
−Cl
0
V 0
tini
)

.
Since θi = β + bi, we have Hi = Li, where
Li =

∂f(ti1; g(β, bi))
∂bVi
∂f(ti1; g(β, bi))
∂bCli
...
...
∂f(tini ; g(β, bi))
∂bVi
∂f(tini ; g(β, bi))
∂bCli

φ0
.
Furthermore, E(yi) ∼= Ei = µi + Hiβ and Var(yi) ∼= Vi = LiΩLTi + σ2Ini . Ac-
cording to (3.13), the FIM for the ith individual can be approximated by the block
diagonal matrix
Mi(Ψ, ξi) ∼=
 Ai 0
0 Bi
 , (3.18)
where
(Ai)ml =
(
∂Ei
∂βm
)T
V −1i
∂Ei
∂βl
for m, l = 1, 2 and β1 = V, β2 = Cl,
and
(Bi)ml =
1
2
tr
(
∂Vi
∂λm
V −1i
∂Vi
∂λl
V −1i
)
for m, l = 1, 2, 3 and λ = (σ21, σ
2
2, σ
2)T .
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Diﬀerentiation of Ei and Vi with respect to the components of β and λ, respectively,
gives
∂Ei
∂V
= Hi
1
0
 , ∂Ei
∂Cl
= Hi
0
1
 ,
∂Vi
∂σ21
= Li
 1 0
0 0
LTi , ∂Vi∂σ22 = Li
 0 0
0 1
LTi and ∂Vi∂σ2 = Ini .
Therefore,
(Ai)12 =
[
1 0
]
Di
0
1
 = (Di)12,
where Di = H
T
i V
−1
i Hi.
Altogether, we have Ai = H
T
i V
−1
i Hi, since e
T
i Xej = xij, where ei is a unit vector
with 1 in the ith position and zeros elsewhere, and X is a matrix with elements xij.
Continuing,
(Bi)12 =
1
2
tr
(
∂Vi
∂σ21
V −1i
∂Vi
∂σ22
V −1i
)
=
1
2
tr
Li
 1 0
0 0
LTi V −1i Li
 0 0
0 1
LTi V −1i

=
1
2
tr
Wi
 1 0
0 0
Wi
 0 0
0 1

 ,
where Wi = L
T
i V
−1
i Li. Thus (Bi)12 =
1
2
(Wi)12(Wi)21. Similarly, (Bi)11 =
1
2
{(Wi)11}2, (Bi)22 = 12{(Wi)22}2 and (Bi)21 = 12(Wi)12(Wi)21. Also,
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(Bi)13 =
1
2
tr
(
∂Vi
∂σ21
V −1i
∂Vi
∂σ2
V −1i
)
=
1
2
tr
Li
 1 0
0 0
LTi V −1i IniV −1i

=
1
2
tr
Pi
 1 0
0 0

 ,
where Pi = L
T
i V
−2
i Li. Thus (Bi)13 =
1
2
(Pi)11. Similarly, (Bi)23 =
1
2
(Pi)22, (Bi)31 =
1
2
(Pi)11 and (Bi)32 =
1
2
(Pi)22. Furthermore, (Bi)33 =
1
2
tr
(
V −2i
)
. All of these
expressions assist in obtaining (3.18), the approximate FIM for individual i as
Mi(Ψ, ξi) ∼=
 HTi V −1i Hi 0
0 Bi
 , (3.19)
where
Bi =
1
2

{(Wi)11}2 (Wi)12(Wi)21 (Pi)11
(Wi)12(Wi)21 {(Wi)22}2 (Pi)22
(Pi)11 (Pi)22 tr
(
V −2i
)
 .
For a single group of N individuals with identical designs, the FIM simpliﬁes to
M (Ψ,Ξ) = N
 HTi V −1i Hi 0
0 Bi
 . (3.20)
The information matrix in (3.20) is used to obtain the D-optimum time points to
measure the concentration of a drug in the blood for a cohort of N patients. We
compute the D-optimum time points using the R package PFIM 3.2 (Bazzoli et al.,
2010). Figure 3.7 shows the optimum time points for our model for the true values
of the parameters. We assume that the dose 0.5 mg/kg body weight has been
administered to a cohort of size 3.
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Figure 3.7: Location of optimum design points in the mean concentration proﬁle
for collecting blood samples. True parameter values are assumed as prior, that is,
Ψ0 = (0.5, 0.06, 0.004, 0.00005, 0.000225)T .
The block diagonal form of the information matrix is useful in examining the sensi-
tivity of the design to the prior parameter values β0. This is because
∣∣∣∣∣∣∣
Ai 0
0 Bi
∣∣∣∣∣∣∣ = |Ai| |Bi|,
which decreases the dimensions of the determinant. Keeping the prior values of the
variances ﬁxed and varying V and Cl, we can numerically obtain the values of the
criterion for a given design for a range of V and Cl. The sensitivity factor in this
case is the relative eﬃciency, deﬁned as
Efficiency =
(
|M(Ψ˜, ξ∗true)|
|M(Ψtrue, ξ∗true)|
) 1
5
,
where Ψtrue = (0.5, 0.06, 0.004, 0.00005, 0.000225)
T , Ψ˜ = (V,Cl, 0.004, 0.00005, 0.00
0225)T and ξ∗true is the D-optimum design obtained for Ψtrue. Figure 3.8 shows the
relative eﬃciencies of the designs for various choices of V and Cl that are within the
three standard deviation of the means. It is clear that the design is not very sensitive
to the parameter values, since the eﬃciency value is always very high, irrespective
of the choice.
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Figure 3.8: Sensitivity of the design to the assumed prior values of the parameters.
3.7.2 One-Compartment Model with First-Order Absorption
The one-compartment PK model with ﬁrst-order absorption is deﬁned as
yil = f(til;θi) + il
=
xkai
Vi(kai − kei)
(
e−kei til − e−kai til)+ il for i = 1, . . . , N and l = 1, . . . , ni,
(3.21)
where yil is the concentration of a drug in the blood for the ith individual observed
at time til, x is the dose received by the individual, and θi = β+bi = (Vi, kei , kai)
T is
the vector of parameters with β = (V, ke, ka)
T and bi = (bVi , bkei , bkai )
T . We assume
that i ∼ Nni(0, σ2Ini) and bi ∼ N3(0,Ω), where Ω = diag(σ21, σ22, σ23). We can
write
f(ξi;θi) = f(ξi; g(β, bi)) =

xkai
Vi(kai − kei)
(
e−kei ti1 − e−kai ti1)
xkai
Vi(kai − kei)
(
e−kei ti2 − e−kai ti2)
...
xkai
Vi(kai − kei)
(
e−kei tini − e−kai tini)

. (3.22)
To linearise the model, we expand it using a ﬁrst-order Taylor series about φi = (V,
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ke, ka, bVi , bkei , bkai )
T at φ0 = (V 0, k0e , k
0
a, 0, 0, 0)
T , where V 0, k0e and k
0
a are some
prior values of the population mean parameters. We obtain as an approximation
the linear mixed eﬀects model
yi ∼= µi +Hiβ +Libi + i,
where µi, Hi and Li are as in Section 3.4.1. In particular, we have
Hi =

∂f(ti1; g(β, bi))
∂V
∂f(ti1; g(β, bi))
∂ke
∂f(ti1; g(β, bi))
∂ka
...
...
...
∂f(tini ; g(β, bi))
∂V
∂f(tini ; g(β, bi))
∂ke
∂f(tini ; g(β, bi))
∂ka

φ0
.
The elements of Hi are given as

∂f(til; g(β, bi))
∂V
∂f(til; g(β, bi))
∂ke
∂f(til; g(β, bi))
∂ka

φ0
=

− xk
0
a
(V 0)2(k0a − k0e)
(
e−k
0
etil − e−k0atil
)
xk0a
V 0(k0a − k0e)
(
e−k
0
etil − e−k0atil
k0a − k0e
− tile−k0etil
)
x
V 0(k0a − k0e)
−k
0
e
(
e−k
0
etil − e−k0atil
)
k0a − k0e
+ k0atile
−k0atil


.
Similar to Section 3.7.1, since θi = β + bi, here we also have Hi = Li, where
Li =

∂f(ti1; g(β, bi))
∂bVi
∂f(ti1; g(β, bi))
∂bkei
∂f(ti1; g(β, bi))
∂bkai
...
...
...
∂f(tini ; g(β, bi))
∂bVi
∂f(tini ; g(β, bi))
∂bkei
∂f(tini ; g(β, bi))
∂bkai

φ0
.
Following analogous derivations to those in Section 3.7.1, we obtain the approximate
FIM for individual i as
Mi(Ψ, ξi) ∼=
 HTi V −1i Hi 0
0 Bi
 , (3.23)
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where
Bi =
1
2

{(Wi)11}2 (Wi)12(Wi)21 (Wi)13(Wi)31 (Pi)11
(Wi)12(Wi)21 {(Wi)22}2 (Wi)23(Wi)32 (Pi)22
(Wi)13(Wi)31 (Wi)23(Wi)32 {(Wi)33}2 (Pi)33
(Pi)11 (Pi)22 (Pi)33 tr
(
V −2i
)

,
(Wi)lk for l, k = 1, 2, 3 are elements of Wi = L
T
i V
−1
i Li and (Pi)ll are diagonal
elements of Pi = L
T
i V
−2
i Li.
Since matrix Mi is 7 × 7, it is even more useful for numerical calculations to have
a block diagonal structure to the matrix. The sensitivity analysis can be performed
as in the previous case, but the graphical representation here would not be so clear.
3.8 Properties of the Derived PK Parameters
It is very common that, even if the same dose is given to a group of patients, the
concentration proﬁles are diﬀerent. This is due to the diﬀerences in biological factors
among the patients. As the proﬁles vary, so do the AUC and Cmax. An obvious issue
then is to quantify the variability in these parameters.
We employ a non-linear mixed eﬀects model for the concentration data. The purpose
is to describe the situation in a better way, since one can assume that each individual
has distinct values for the model parameters. Because the AUC and Cmax are derived
from the model function, they rely on its parameters. This section describes way to
ﬁnd the variability in these PK parameters following the administration of a dose.
Quantifying the variability is particulary important for two reasons. Firstly, it will
tell us the extent of the variability from patient to patient, and, secondly, it may
guide us in the selection of doses in a clinical trial design. Our purpose is to use it
in the dose selection.
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3.8.1 Area Under the Concentration Curve
Assume that the dose x is given to a cohort of patients and that h(x,θi) is the AUC
for individual i in that group based on a PK model. Here, θi is the vector of random
PK parameters introduced in Section 3.4 and h is a diﬀerentiable function of the
parameters. Since the parameters are random, individuals in the cohort will have
diﬀerent AUC values. We want to derive an expression so that the variability can
be assessed. Since a PK model is non-linear in the parameters, the AUC will be
too. Therefore, we linearise the function using a ﬁrst-order Taylor series expansion
of h(x,θi) about θi at E(θi) to obtain
h(x,θi) ∼= h(x,θi)
∣∣∣∣
E(θi)
+
(
∂h(x,θi)
∂θi
)T ∣∣∣∣
E(θi)
(θi − E(θi))
= h(x,β) +
(
∂h(x,θi)
∂θi
)T ∣∣∣∣
E(θi)
bi,
where θi = β + bi and E(θi) = β. Since bi ∼ Np(0,Ω), h(x,θi) will be approxi-
mately normally distributed as well.
Therefore,
E{h(x,θi)} ∼= h(x,β) (3.24)
and
Var{h(x,θi)} ∼=
(
∂h(x,θi)
∂θi
)T ∣∣∣∣
E(θi)
Var(bi)
(
∂h(x,θi)
∂θi
) ∣∣∣∣
E(θi)
=
(
∂h(x,θi)
∂θi
)T ∣∣∣∣
E(θi)
Ω
(
∂h(x,θi)
∂θi
) ∣∣∣∣
E(θi)
. (3.25)
This derivation is based on the δ-method (Oehlert, 1992). The general expres-
sion in (3.25) can be used to ﬁnd the variability in the AUC for a population
based on a PK model after the administration of a dose. Also, we have h(x,θi) ∼
N [h(x,β),Var{h(x,θi)}] approximately.
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Example 1
For the one-compartment PK model with bolus input and ﬁrst-order elimination in
(3.16), the AUC for individual i over the range [0, t1] is deﬁned as
h(x,θi) =
∫ t1
0
f(t;θi) dt
=
∫ t1
0
x
Vi
exp
(
−Cli
Vi
t
)
dt
=
x
Cli
{
1− exp
(
−Cli
Vi
t1
)}
. (3.26)
Assuming that E(Vi) = V and E(Cli) = Cl, we obtain
E{h(x,θi)} ∼= h(x,β) = x
Cl
{
1− exp
(
−Cl
V
t1
)}
. (3.27)
Also,
Var{h(x,θi)} ∼=
(
∂h(x,θi)
∂θi
)T ∣∣∣∣
E(θi)
Ω
(
∂h(x,θi)
∂θi
) ∣∣∣∣
E(θi)
=
(
∂h(x,θi)
∂Vi
∂h(x,θi)
∂Cli
)
E(θi)
 σ21 0
0 σ22


∂h(x,θi)
∂Vi
∂h(x,θi)
∂Cli

E(θi)
=
{
∂h(x,θi)
∂Vi
∣∣∣∣
E(θi)
}2
σ21 +
{
∂h(x,θi)
∂Cli
∣∣∣∣
E(θi)
}2
σ22. (3.28)
Furthermore,
∂h(x,θi)
∂Vi
∣∣∣∣
E(θi)
= −xt1
V 2
exp
(
−Cl
V
t1
)
and
∂h(x,θi)
∂Cli
∣∣∣∣
E(θi)
=
x
Cl
exp
(
−Cl
V
t1
)(
1
Cl
+
t1
V
)
− x
Cl2
.
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Hence, we obtain the approximate variance of the AUC as
Var{h(x,θi)} ∼=
{
−xt1
V 2
exp
(
−Cl
V
t1
)}2
σ21
+
{
x
Cl
exp
(
−Cl
V
t1
)(
1
Cl
+
t1
V
)
− x
Cl2
}2
σ22.
The approximate AUC and its variance are used to impose a constraint in Section
5.5.1 in order to ﬁnd optimal doses for the cohorts in a trial. The essence of the con-
straint is to be careful during dose escalation by taking into account the variability
in the AUC among the patients in a cohort after receiving a dose.
Example 2
For the one-compartment PK model with ﬁrst-order absorption that was introduced
in (3.21), the AUC for individual i over the range [0, t1] is deﬁned as
h(x,θi) =
∫ t1
0
f(t;θi) dt
=
∫ t1
0
xkai
Vi(kai − kei)
(e−kei t − e−kai t) dt
=
xkai
Vi(kai − kei)
(
1− e−kei t1
kei
− 1− e
−kai t1)
kai
)
. (3.29)
Assuming that E(Vi) = V , E(kei) = ke and E(kai) = ka, we obtain
E{h(x,θi)} ∼= h(x,β) = xka
V (ka − ke)
(
1− e−ket1
ke
− 1− e
−kat1
ka
)
. (3.30)
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Also,
Var{h(x,θi)} ∼=
(
∂h(x,θi)
∂θi
)T ∣∣∣∣
E(θi)
Ω
(
∂h(x,θi)
∂θi
) ∣∣∣∣
E(θi)
=
{
∂h(x,θi)
∂Vi
∣∣∣∣
E(θi)
}2
σ21 +
{
∂h(x,θi)
∂kei
∣∣∣∣
E(θi)
}2
σ22
+
{
∂h(x,θi)
∂kai
∣∣∣∣
E(θi)
}2
σ23. (3.31)
Putting z1 = 1− e−ket1 and z2 = 1− e−kat1 , we obtain
∂h(x,θi)
∂Vi
∣∣∣∣
E(θi)
= − xka
V 2(ka − ke)
(
z1
ke
− z2
ka
)
,
∂h(x,θi)
∂kei
∣∣∣∣
E(θi)
=
xka
V (ka − ke)2
(
z1
ke
− z2
ka
)
+
xka
V (ka − ke)
(
− z1
k2e
+
t1e
−ket1
ke
)
and
∂h(x,θi)
∂kai
∣∣∣∣
E(θi)
= − xke
V (ka − ke)2
(
z1
ke
− z2
ka
)
+
xka
V (ka − ke)
(
z2
k2a
− t1e
−kat1
ka
)
.
These partial derivatives enable us to ﬁnd the approximate variance in (3.31). The
approximate mean and variance thus obtained can help in implementing the PK
constraint in Section 5.5.1 when the model of interest is for one compartment with
ﬁrst-order absorption.
3.8.2 Maximum Concentration
Assume that l(x,θi) represents the maximum concentration for individual i for a
given dose x, based on a PK model. Here, θi is the vector of random PK parameters
introduced in Section 3.4 and l is a diﬀerentiable function of those parameters. The
main motivation is to derive an expression to assess the variability in l(x,θi). Since
the PK models are non-linear in the parameters, the maximum concentration will
be too. To obtain the inter-patient variability in Cmax, we linearise the function
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using a ﬁrst-order Taylor series expansion of l(x,θi) about θi at E(θi) as
l(x,θi) ∼= l(x,θi)
∣∣∣∣
E(θi)
+
(
∂l(x,θi)
∂θi
)T ∣∣∣∣
E(θi)
(θi − E(θi))
= l(x,β) +
(
∂l(x,θi)
∂θi
)T ∣∣∣∣
E(θi)
bi,
where θi = β + bi and E(θi) = β.
Therefore,
E{l(x,θi)} ∼= l(x,β) (3.32)
and
Var{l(x,θi)} ∼=
(
∂l(x,θi)
∂θi
)T ∣∣∣∣
E(θi)
Var(bi)
(
∂l(x,θi)
∂θi
) ∣∣∣∣
E(θi)
=
(
∂l(x,θi)
∂θi
)T ∣∣∣∣
E(θi)
Ω
(
∂l(x,θi)
∂θi
) ∣∣∣∣
E(θi)
. (3.33)
The general expression in (3.33) can be used to ﬁnd the variability in Cmax for
a population based on a PK model for a given dose x. Here, also, l(x,θi) ∼
N [l(x,β),Var{l(x,θi)}] approximately.
Example 2
We are interested in the value of the concentration at a time point, denoted by
tmax, at which it is the largest at a given time interval. The tmax is obtained by
diﬀerentiating the model function with respect to t and Cmax is found by substituting
that value for t into the model function. For a simple decay function, as in Example
1, it is always at t = 0. Here, we present a more interesting case of the one-
compartment PK model with ﬁrst-order absorption. The tmax is a solution of the
equation
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df(t;θi)
dt
= 0.
That is, solving
xkai
Vi(kai − kei)
(−kei e−kei t + kai e−kai t) = 0
for t, we obtain
tmaxi =
log(kai)− log(kei)
kai − kei
.
Therefore, Cmax for this model has the form
l(x,θi) =
xkai
Vi(kai − kei)
(
e−kei tmaxi − e−kai tmaxi) . (3.34)
Assuming that E(Vi) = V , E(kei) = ke and E(kai) = ka, we have
E{l(x,θi)} ∼= l(x,β) = xka
V (ka − ke)
(
e−ketmax − e−katmax) . (3.35)
Also,
Var{l(x,θi)} ∼=
(
∂l(x,θi)
∂θi
)T ∣∣∣∣
E(θi)
Ω
(
∂l(x,θi)
∂θi
) ∣∣∣∣
E(θi)
=
{
∂l(x,θi)
∂Vi
∣∣∣∣
E(θi)
}2
σ21 +
{
∂l(x,θi)
∂kei
∣∣∣∣
E(θi)
}2
σ22
+
{
∂l(x,θi)
∂kai
∣∣∣∣
E(θi)
}2
σ23. (3.36)
After some simpliﬁcation, it can be shown that
∂l(x,θi)
∂Vi
∣∣∣∣
E(θi)
= − xka
V 2(ka − ke)
(
e−ketmax − e−katmax) ,
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∂l(x,θi)
∂kei
∣∣∣∣
E(θi)
=
xka
V (ka − ke)2
[
e−ketmax(2− katmax)− e−katmax
{
1 +
ka(1− ketmax)
ke
}]
and
∂l(x,θi)
∂kai
∣∣∣∣
E(θi)
=
x
V (ka − ke)2
[
kee
−ketmax {−1 + ka(katmax − 1)}+ e−katmax {ke − ka(ketmax − 1)}
]
.
These partial derivatives are plugged into (3.36) to obtain the approximate variance
of Cmax among the patients following the adminstration of a dose. The approximate
mean and variance in (3.35) and (3.36) aid in implementing the constraint deﬁned
in Section 5.5.2.
It is clear from the above expressions that the mean and variance of the AUC and
Cmax depend on the unknown parameters β and λ associated with the PK model.
We use D-optimum design to collect blood samples to measure the concentrations.
Since the AUC and Cmax, together with their variances, are non-linear functions of
the model parameters, a natural question arises about the suitability of c-optimum
design. We have three issues here: model parameter estimation, and estimation
of the mean and variance of the derived PK parameters. It will be quite diﬃcult,
or even impossible, to ﬁnd a design that will minimise the variability of each of
these. Therefore, we rely on D-optimum design only to estimate precisely the model
parameters. We believe that with such a set of estimates, it is also possible to obtain
precise estimates for the derived PK parameters and their variances.
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Chapter 4
Dose-Response Models
4.1 Introduction
This chapter introduces two dose-response models that will be used in the simu-
lation studies in Chapter 6. We assume that the dose range is pre-speciﬁed from
pre-clinical studies. The aim is to select the dose level which can be recommended
for further investigation on a larger group of patients in a phase IIB trial, where it
is compared with other standard treatments.
We consider adaptive designs in Chapter 5 in that context, where an analysis of the
data is performed after treating each cohort of patients, and a decision on the dose
to be allocated is made for the next cohort based on the updated knowledge of the
responses. The ﬁrst model assumes trinomial responses representing eﬃcacy, toxicity
and a neutral response. The second one assumes binary outcomes for eﬃcacy and
toxicity end points.
4.2 Trinomial Response
4.2.1 Model
We assume a trinomial response Y = (Y0, Y1, Y2)
T for a given dose for each patient,
where Yi takes values 0 or 1 for i = 0, 1, 2 depending on the patient's response to
the drug. Here, Y0 = 1 when neither toxicity nor eﬃcacy occurs, Y1 = 1 when
eﬃcacy occurs without toxicity and Y2 = 1 when toxicity is the outcome, irrespec-
tive of the eﬃcacy. Throughout the thesis, we call an eﬃcacious but non-toxic
response a success, since it is the outcome indicating some beneﬁt from taking the
drug. The probability of each of these outcomes depends on dose. It is commonly
accepted that a drug's toxicity increases with dose. The probability of success also
increases in many cases. However, it is possible for some drugs that it attains a
plateau or increases and then decreases, as the dose is increased. For an exper-
imental drug, let us assume that the probability of a neutral response decreases
monotonically with dose and that the probability of toxicity increases monotoni-
cally with dose. The probability of success may be non-monotonic, increasing or
decreasing. The corresponding cell probabilities are ψ0(x,ϑ), ψ1(x,ϑ) and ψ2(x,ϑ),
so that ψ0(x,ϑ) + ψ1(x,ϑ) + ψ2(x,ϑ) = 1 for a given dose x, where ϑ denotes the
vector of dose-response parameters.
The continuation ratio model of McCullagh and Nelder (1989) is used to model the
responses, and is given by
log
(
ψ1(x,ϑ)
ψ0(x,ϑ)
)
= ϑ1 + ϑ2x (4.1)
and
log
(
ψ2(x,ϑ)
1− ψ2(x,ϑ)
)
= ϑ3 + ϑ4x, (4.2)
where ϑ = (ϑ1, ϑ2, ϑ3, ϑ4)
T is the vector of parameters to be estimated. The param-
eter ϑ1 represents the baseline log-relative probability, ϑ2 reﬂects the contribution
of dose in the log-relative probability of a success relative to the probability of a
neutral outcome, ϑ3 is the baseline log odds and ϑ4 is the contribution of dose in the
log odds when interest lies in the occurrence of a toxic outcome relative to a neutral
outcome or a success.
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From (4.1), we have
ψ1(x,ϑ) = ψ0(x,ϑ) e
ϑ1+ϑ2x,
and, from (4.2),
ψ2(x,ϑ) = {ψ0(x,ϑ) + ψ1(x,ϑ)} eϑ3+ϑ4x
= ψ0(x,ϑ)(1 + e
ϑ1+ϑ2x)eϑ3+ϑ4x.
Since ψ0(x,ϑ) + ψ1(x,ϑ) + ψ2(x,ϑ) = 1, we obtain
ψ0(x,ϑ) =
1
(1 + eϑ1+ϑ2x)(1 + eϑ3+ϑ4x)
.
Therefore,
ψ1(x,ϑ) =
eϑ1+ϑ2x
(1 + eϑ1+ϑ2x)(1 + eϑ3+ϑ4x)
and
ψ2(x,ϑ) =
eϑ3+ϑ4x
1 + eϑ3+ϑ4x
.
These three non-linear functions represent the probabilities for the trinomial re-
sponses. The selection of dose depends on the parameters in ϑ. Diﬀerent values of
ϑ will lead to diﬀerent dose-response curves, as shown in Figure 4.1.
4.2.2 Parameter Space
Deﬁning the dose-response parameter space is an essential part in ensuring that the
three non-linear functions exhibit the assumed behaviour.
Diﬀerentiation of ψ2(x,ϑ) with respect to x gives
dψ2(x,ϑ)
dx
=
ϑ4 e
−(ϑ3+ϑ4x)
{1 + e−(ϑ3+ϑ4x)}2 ,
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Figure 4.1: Dose-response scenarios for the continuation ratio model. The respective
parameter values are: Scenario 1, ϑ = (1.44, 0.26,−1.70, 0.25)T ; Scenario 2, ϑ =
(−3.50, 1.00,−6.00, 0.72)T ; Scenario 3, ϑ = (−0.80, 0.50,−3.80, 0.30)T ; and Scenario
4, ϑ = (−6.50, 0.75,−8.00, 0.65)T .
which is positive only if ϑ4 > 0. Therefore, ψ2(x,ϑ) is an increasing function of dose
only if ϑ4 > 0.
Equation (4.1) indicates that ϑ2 is the change in the log-relative probability due
to a unit change in dose. Since we expect dose to have a positive impact on the
transition from a neutral response to a success, we should have ϑ2 > 0.
When x = 0, we have
log
(
ψ1(0,ϑ)
ψ0(0,ϑ)
)
= ϑ1, that is,
ψ1(0,ϑ)
ψ0(0,ϑ)
= eϑ1
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and
log
(
ψ2(0,ϑ)
ψ0(0,ϑ) + ψ1(0,ϑ)
)
= ϑ3,
from which it follows that
ψ2(0,ϑ)
ψ0(0,ϑ)
= eϑ3(1 + eϑ1).
We assume that, at very small doses, ψ1 ≥ ψ2. Consequently,
ψ1(0,ϑ)
ψ0(0,ϑ)
≥ ψ2(0,ϑ)
ψ0(0,ϑ)
,
which reduces to
ϑ1 − ϑ3 ≥ log(1 + eϑ1) > 0.
Therefore, we can conclude that ϑ1 > ϑ3.
Since ψ2 represents the probability of toxicity, we expect it to be low at very small
doses. This function reduces to ψ2(0,ϑ) = e
ϑ3/(1 + eϑ3) when x = 0 and further
reduces to 1
2
when ϑ3 = 0. For any ϑ3 > 0, this probability is greater than
1
2
. Thus,
the only choice to keep this probability low at the small doses is ϑ3 < 0.
So, the parameter space can be written as
Θ = {(ϑ1, ϑ2, ϑ3, ϑ4) : ϑ1 > ϑ3, ϑ3 < 0 and ϑ2, ϑ4 > 0} . (4.3)
Figure 4.1 shows some plausible dose-response scenarios for diﬀerent choices of the
parameters in the continuation ratio model. These scenarios will be investigated in
the simulation study in Chapter 6. It should be mentioned that diﬀerent assumptions
about the shapes of the functions ψ0, ψ1 and ψ2 would give diﬀerent parameter spaces
Θ. Although the method of adaptive design that we propose in this thesis does not
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depend on the choice of Θ, still it has to be speciﬁed.
4.2.3 Likelihood Function
Let us assume that we are at the kth stage in an adaptive clinical trial and that
we want to conduct an interim analysis of the data. This means that k cohorts
have been treated so far with selected doses from the dose range X . Let x be a
k × 1 dose vector with components xl and let R be a k × 3 outcome matrix with
R˜l = (Rl0, Rl1, Rl2) as the lth row (l = 1, . . . , k). It is important to note that
Rl0 + Rl1 + Rl2 = c, where c is the number of subjects in a cohort treated at dose
xl. The successive components of R˜l are the counts of neutral, success and toxic
responses for the lth cohort. Thus, for our dose-response model, the likelihood
function is
Lk(ϑ | x,R) ∝
k∏
l=1
{ψ0(xl,ϑ)}Rl0{ψ1(xl,ϑ)}Rl1{ψ2(xl,ϑ)}Rl2 .
The parameters in ϑ can be estimated using either a Bayesian or frequentist ap-
proach. Since maximum likelihood estimation is unsuitable because of small sample
sizes in the early stages of a trial, we employ a Bayesian approach.
The posterior estimates of the components of ϑ = (ϑ1, ϑ2, ϑ3, ϑ4)
T at the kth stage
are obtained as
ϑˆik =
∫
Θ
ϑi p(ϑ)Lk(ϑ | x,R)dϑ∫
Θ
p(ϑ) Lk(ϑ | x,R) dϑ , i = 1, 2, 3, 4, (4.4)
where p(ϑ) is the prior distribution of the parameters. We assume a uniform distri-
bution on a restricted parameter space Θ˜. Let 0 < ϑ2 < u1, 0 < ϑ4 < u2, l1 < ϑ1 < l2
and l3 < ϑ3 < l4. Then the condition ϑ1 > ϑ3 leads to l3 < ϑ3 < ϑ1 < l2. We deﬁne
Θ˜ as
Θ˜ = {ϑ : l3 < ϑ3 < ϑ1 < l2, 0 < ϑ2 < u1, 0 < ϑ4 < u2} .
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As the probability density function for a uniform distribution is constant, we let
p(ϑ) = A and can write
∫
Θ˜
A dϑ3 dϑ1 dϑ4 dϑ2 = 1.
It follows that
A
∫ u1
0
∫ u2
0
∫ l2
l3
∫ ϑ1
l3
dϑ3 dϑ1 dϑ4 dϑ2 = 1,
which yields A = 2/{u1u2(l2 − l3)2}. Therefore,
p(ϑ) =
2
u1u2(l2 − l3)2 , ϑ ∈ Θ˜. (4.5)
This function will be used in our example of simulating clinical trials in Section 6.3.
4.2.4 Fisher Information Matrix
The likelihood function for a single cohort at dose x is
L(ϑ|x, R˜) = c!
R0!R1!R2!
(ψ0)
R0 (1− ψ0 − ψ2)c−R0−R2 (ψ2)R2 ,
and so the log-likelihood function can be written as
l(ϑ|x, R˜) = constant +R0 log(ψ0) + (c−R0 −R2) log(1− ψ0 − ψ2) +R2 log(ψ2).
The information matrix associated with ϑ can be obtained as
I(x,ϑ) =
(
∂ψ
∂ϑ
)T
I(x,ψ)
(
∂ψ
∂ϑ
)
, (4.6)
where
I(x,ψ) = E
[
−∂
2l(ϑ|x, R˜)
∂ψ ∂ψT
]
and ψ = (ψ0, ψ2). The second-order partial derivatives of the components of
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l(ϑ|x, R˜) are
∂2 log(ψ0)
∂ψ ∂ψT
=
 − 1ψ20 0
0 0
 ,
∂2 log(1− ψ0 − ψ2)
∂ψ ∂ψT
= − 1
(1− ψ0 − ψ2)2
 1 1
1 1

and
∂2 log(ψ2)
∂ψ ∂ψT
=
 0 0
0 − 1
ψ22
 .
Therefore,
I(x,ψ) = E
[
−∂
2l(ϑ|x, R˜)
∂ψ ∂ψT
]
= E(R0)
 1ψ20 0
0 0
+ E(c−R0 −R2) 1
(1− ψ0 − ψ2)2
 1 1
1 1

+E(R2)
 0 0
0
1
ψ22
 . (4.7)
Using a property of the trinomial distribution, we have E(R0) = cψ0, E(c − R0 −
R2) = c(1− ψ0 − ψ2) and E(R2) = cψ2. Thus, (4.7) reduces to
I(x,ψ) = c


1
ψ0
0
0
1
ψ2
+ 1
(1− ψ0 − ψ2)
 1 1
1 1


=
c
(1− ψ0 − ψ2)

1− ψ2
ψ0
1
1
1− ψ0
ψ2
 . (4.8)
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Furthermore,
∂ψ
∂ϑ
=

∂ψ0
∂ϑ1
∂ψ0
∂ϑ2
∂ψ0
∂ϑ3
∂ψ0
∂ϑ4
∂ψ2
∂ϑ1
∂ψ2
∂ϑ2
∂ψ2
∂ϑ3
∂ψ2
∂ϑ4
 ,
where the derivatives are
∂ψ0
∂ϑ1
= − e
ϑ1+ϑ2x
(1 + eϑ1+ϑ2x)2 (1 + eϑ3+ϑ4x)
= − ψ1
1 + eϑ1+ϑ2x
,
∂ψ0
∂ϑ2
= − xe
ϑ1+ϑ2x
(1 + eϑ1+ϑ2x)2 (1 + eϑ3+ϑ4x)
= x
∂ψ0
∂ϑ1
,
∂ψ0
∂ϑ3
= − e
ϑ3+ϑ4x
(1 + eϑ1+ϑ2x) (1 + eϑ3+ϑ4x)2
= −ψ0ψ2,
∂ψ0
∂ϑ4
= − xe
ϑ3+ϑ4x
(1 + eϑ1+ϑ2x) (1 + eϑ3+ϑ4x)2
= x
∂ψ0
∂ϑ3
,
∂ψ2
∂ϑ1
= 0,
∂ψ2
∂ϑ2
= 0,
∂ψ2
∂ϑ3
=
eϑ3+ϑ4x
1 + eϑ3+ϑ4x
−
(
eϑ3+ϑ4x
1 + eϑ3+ϑ4x
)2
= ψ2(1− ψ2)
and
∂ψ2
∂ϑ4
= x
{
eϑ3+ϑ4x
1 + eϑ3+ϑ4x
−
(
eϑ3+ϑ4x
1 + eϑ3+ϑ4x
)2}
= x
∂ψ2
∂ϑ3
.
77
That is, we have the matrix of derivatives
∂ψ
∂ϑ
=
 −
ψ1
1 + eϑ1+ϑ2x
x
∂ψ0
∂ϑ1
−ψ0ψ2 x∂ψ0
∂ϑ3
0 0 ψ2(1− ψ2) x∂ψ2
∂ϑ3
 .
Applying the results to (4.6), after some simpliﬁcation, we obtain the FIM for ϑ as
I(x,ϑ) = c

ψ1(1− ψ2)
ψ0(1 + eϑ1+ϑ2x)2
xψ1(1− ψ2)
ψ0(1 + eϑ1+ϑ2x)2
0 0
xψ1(1− ψ2)
ψ0(1 + eϑ1+ϑ2x)2
x2ψ1(1− ψ2)
ψ0(1 + eϑ1+ϑ2x)2
0 0
0 0 ψ2(1− ψ2) xψ2(1− ψ2)
0 0 xψ2(1− ψ2) x2ψ2(1− ψ2)

.
. (4.9)
This matrix is of rank 2. It is block diagonal and has non-zero submatrices of rank
1. So we need at least two diﬀerent doses, say x1 and x2, to obtain a combined
nonsingular information matrix I(x1,ϑ) + I(x2,ϑ). This is important when con-
sidering D-optimum dose selection, where the optimality criterion is deﬁned as the
determinant of the FIM. We present such criteria in Sections 5.3.2 and 5.3.3. In
Section 6.6, we apply this form of the FIM to determine the optimum dose in an
adaptive clinical trial.
4.3 Bivariate Binary Response
4.3.1 Model
Here, we assume that eﬃcacy and toxicity are two 0/1 binary variables and denote
these by Y and Z, respectively. This will result in four possible (y, z) outcomes
(0,0), (0,1), (1,0) and (1,1). The Cox model (Cox, 1970) treats each of the four
possible outcomes as a separate response category. The corresponding cell probabil-
ities are ψ00(x,ϑ), ψ01(x,ϑ), ψ10(x,ϑ) and ψ11(x,ϑ), so that ψ00(x,ϑ)+ψ01(x,ϑ)+
78
ψ10(x,ϑ) + ψ11(x,ϑ) = 1.
The probabilities of the four outcomes are given by
ψ00(x,ϑ) =
1
1 + eϑ1+ϑ2x + eϑ3+ϑ4x + eϑ5+ϑ6x
,
ψ01(x,ϑ) =
eϑ1+ϑ2x
1 + eϑ1+ϑ2x + eϑ3+ϑ4x + eϑ5+ϑ6x
,
ψ10(x,ϑ) =
eϑ3+ϑ4x
1 + eϑ1+ϑ2x + eϑ3+ϑ4x + eϑ5+ϑ6x
and
ψ11(x,ϑ) =
eϑ5+ϑ6x
1 + eϑ1+ϑ2x + eϑ3+ϑ4x + eϑ5+ϑ6x
,
where ϑ = (ϑ1, ϑ2, ϑ3, ϑ4, ϑ5, ϑ6)
T is the vector of parameters.
Table 4.1: Relation between trinomial and bivariate binary responses.
Binary responses
Eﬃcacy Toxicity
Trinomial Neutral No No
responses Success Yes No
Toxic No Yes
Yes Yes
In this set up, we call the outcome (1,0) a success, since it is the outcome that pro-
duces eﬃcacy without exposing a patient to toxicity. The trinomial response model
that was introduced in Section 4.2.1 considers (0,1) and (1,1) as a single category,
toxic, irrespective of the eﬃcacy. Thus, it ignores the simultaneous occurrence of
eﬃcacy and toxicity as an individual category, as shown in Table 4.1. This is im-
portant when toxicity is a serious concern and compromising it may lead to serious
health issues.
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Figure 4.2: Dose-response scenarios for the Cox model. The respective parameter
values are ϑ = (0.0, 1.0, 4.0, 2.0, 3.0, 3.0)T , ϑ = (−0.5, 1.0, 0.5, 1.0, 0.0, 2.0)T , ϑ =
(−1.0, 2.0, 1.0, 2.0, 1.0, 4.0)T and ϑ = (−2.0, 0.5, 0.0, 0.5, 4.0, 4.0)T .
As before, we are interested in designing the trial so that the recommended dose
maximises the probability of success. However, this model gives more ﬂexibility to
consider other outcomes.
Again, we want to avoid doses with too high a risk of toxicity. Hence, we consider
the total risk of toxicity. Also, we may be interested in the probability of eﬃcacy,
whatever the toxicity outcome. In Figure 4.2, we present three curves for various
scenarios: the probability of success ((1,0) outcome), the probability of toxicity
((0,1) or (1,1) outcomes) and the probability of eﬃcacy ((1,0) or (1,1) outcomes).
We are primarily interested in the ﬁrst one. However, the toxicity curve is used to
control the risk of undesired side eﬀects. The eﬃcacy curve is included for additional
information.
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For the simulation study in Section 6.4, we consider some plausible dose-response
scenarios, as shown in Figure 4.2, which are taken from Dragalin and Fedorov (2006).
The doses in these scenarios are on a log scale. The curve which is labelled as success
is simply obtained by plotting ψ10(x,ϑ) against x. The other two curves are the
marginal probabilities of eﬃcacy and toxicity, obtained as ψ1.(x,ϑ) = ψ10(x,ϑ) +
ψ11(x,ϑ) and ψ.1(x,ϑ) = ψ01(x,ϑ) + ψ11(x,ϑ), respectively.
4.3.2 Properties
This section introduces some properties of the Cox model. Although these are not
explicitly used in our work, they give some insight into the nature of the model. In
this model, the marginal probabilities for Y and Z are neither logistic nor necessarily
monotonic in dose. Rather, it is the conditional probabilities of the responses that
are logistic in dose. For example,
P (Y = 1|Z = 0, x) = e
ϑ3+ϑ4x
1 + eϑ3+ϑ4x
.
According to Murtaugh (1989), the Cox bivariate binary model has the following
properties:
1. If ϑ1 + ϑ3 = ϑ5 and ϑ2 + ϑ4 = ϑ6, then the marginal probabilities for Y and Z
are logistic in dose.
2. If the marginal dependence of Y and Z on x is logistic and ϑ2 6= 0 or ϑ4 6= 0,
then ϑ1 + ϑ3 = ϑ5 and ϑ2 + ϑ4 = ϑ6.
3. The variables Y and Z are independent if and only if ϑ1 + ϑ3 = ϑ5 and
ϑ2 + ϑ4 = ϑ6.
4. The correlation between eﬃcacy and toxicity has the form
Corr(Y, Z|x) = e
z3 − ez1+z2√
(ez2 + ez3)(1 + ez1)(ez1 + ez3)(1 + ez2)
,
where z1 = ϑ1 + ϑ2x, z2 = ϑ3 + ϑ4x and z3 = ϑ5 + ϑ6x.
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In the continuation ratio model case, we derived the parameter space under some
assumptions about the shapes of the functions. Although we have tried a similar
approach here, we could not obtain any solution, since the Cox model is more
complex with more functions and parameters than the previous one. Therefore, we
use the unrestricted parameter space
Θ = {(ϑ1, ϑ2, ϑ3, ϑ4, ϑ5, ϑ6) : −∞ < ϑi <∞ for i = 1, . . . , 6} . (4.10)
4.3.3 Likelihood Function
With the advancement of an adaptive clinical trial, we update the likelihood func-
tion, and hence obtain up-to-date estimates of the model parameters. Assume that
diﬀerent doses from the dose range X have been assigned to the successive cohorts
up to the kth stage of a trial. Denote the k-dimensional column vector of the as-
signed doses by x. The responses of the cohorts to the doses are represented through
a k×4 matrix R. More speciﬁcally, each row R˜l = (Rl0, Rl1, Rl2, Rl3) consists of the
outcomes that result upon receiving dose xl (l = 1, . . . , k). The successive elements
in R˜l are the counts of (0,0), (0,1), (1,0) and (1,1) responses for the lth cohort.
Moreover, Rl0 +Rl1 +Rl2 +Rl3 = c, where c is the number of subjects in a cohort.
Thus, the likelihood function for our model is
Lk(ϑ | x,R) ∝
k∏
l=1
{ψ11(xl,ϑ)}Rl3{ψ10(xl,ϑ)}Rl2{ψ01(xl,ϑ)}Rl1{ψ00(xl,ϑ)}Rl0 .
Since at an early stage in a trial the sample size is small, the Bayesian approach
is employed to estimate the parameters. We obtain the posterior estimates of the
components of ϑ = (ϑ1, ϑ2, ϑ3, ϑ4, ϑ5, ϑ6)
T at the kth stage as
ϑˆik =
∫
Θ
ϑi p(ϑ)Lk(ϑ | x,R)dϑ∫
Θ
p(ϑ) Lk(ϑ | x,R) dϑ , i = 1, 2, 3, 4, 5, 6, (4.11)
where p(ϑ) is the prior distribution of the parameters. Let us assume that li1 <
ϑi < li2 for i = 1, . . . , 6 and that the prior joint probability density function of the
parameters is uniform. Deﬁne Θ˜ = {ϑ : li1 < ϑi < li2 for i = 1, . . . , 6}. Then we
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have
p(ϑ) =
1
(l12 − l11)(l22 − l21)(l32 − l31)(l42 − l41)(l52 − l51)(l62 − l61) , ϑ ∈ Θ˜.
(4.12)
This function will be used in our example of simulating clinical trials in Section 6.4.
4.3.4 Fisher Information Matrix
The likelihood function for a single cohort at dose x is
L(ϑ|x, R˜) = c!
R0!R1!R2!R3!
(ψ11)
R3(ψ10)
R2(ψ01)
R1(1− ψ11 − ψ10 − ψ01)(c−R3−R2−R1),
and so the log-likelihood function is
l(ϑ|x, R˜) = constant +R3 log(ψ11) +R2 log(ψ10) +R1 log(ψ01)
+(c−R3 −R2 −R1) log(1− ψ11 − ψ10 − ψ01).
As before, the information matrix associated with ϑ can be obtained using the
formula (4.6) for ψ = (ψ11, ψ10, ψ01). Analogous derivations as for the previous
model, presented below, lead to the form of the FIM which can further be used in
optimal dose selection. The partial derivatives are
∂2 log(ψ11)
∂ψ ∂ψT
=

− 1
ψ211
0 0
0 0 0
0 0 0
 , ∂
2 log(ψ10)
∂ψ ∂ψT
=

0 0 0
0 − 1
ψ210
0
0 0 0
 ,
∂2 log(ψ01)
∂ψ ∂ψT
=

0 0 0
0 0 0
0 0 − 1
ψ201

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and
∂2 log(1− ψ11 − ψ10 − ψ01)
∂ψ ∂ψT
= − 1
(1− ψ11 − ψ10 − ψ01)2

1 1 1
1 1 1
1 1 1
 .
Therefore,
I(x,ψ) = E
[
−∂
2l(ϑ|x, R˜)
∂ψ ∂ψT
]
= E(R3)

1
ψ211
0 0
0 0 0
0 0 0
+ E(R2)

0 0 0
0
1
ψ210
0
0 0 0
+ E(R1)

0 0 0
0 0 0
0 0
1
ψ201

+E(c−R3 −R2 −R1) 1
(1− ψ11 − ψ10 − ψ01)2

1 1 1
1 1 1
1 1 1
 . (4.13)
Since E(R3) = cψ11, E(R2) = cψ10, E(R1) = cψ01 and E(c − R3 − R2 − R1) =
c(1− ψ11 − ψ10 − ψ01) , after some simpliﬁcation, (4.13) reduces to
I(x,ψ)
= c


1
ψ11
0 0
0
1
ψ10
0
0 0
1
ψ01
+
1
(1− ψ11 − ψ10 − ψ01)

1 1 1
1 1 1
1 1 1


=
c
(1− ψ11 − ψ10 − ψ01)

1− ψ10 − ψ01
ψ11
1 1
1
1− ψ11 − ψ01
ψ10
1
1 1
1− ψ11 − ψ10
ψ01
 .
(4.14)
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It can also be shown that
(
∂ψ
∂ϑ
)T
=

−ψ11ψ01 −ψ10ψ01 ψ01 − ψ201
−xψ11ψ01 −xψ10ψ01 x(ψ01 − ψ201)
−ψ11ψ10 ψ10 − ψ210 −ψ01ψ10
−xψ11ψ10 x(ψ10 − ψ210) −xψ01ψ10
ψ11 − ψ211 −ψ10ψ11 −ψ01ψ11
x(ψ11 − ψ211) −xψ10ψ11 −xψ01ψ11

.
Furthermore, we have
I(x,ψ)
(
∂ψ
∂ϑ
)
= c

0 0 0 0 1 x
0 0 1 x 0 0
1 x 0 0 0 0
 .
Finally, we obtain the FIM for a cohort of patients as
I(x,ϑ) =
(
∂ψ
∂ϑ
)T
I(x,ψ)
(
∂ψ
∂ϑ
)
= c

ψ01 − ψ201 x(ψ01 − ψ201) −ψ01ψ10 −xψ01ψ10 −ψ01ψ11 −xψ01ψ11
x(ψ01 − ψ201) x2(ψ01 − ψ201) −xψ01ψ10 −x2ψ01ψ10 −xψ01ψ11 −x2ψ01ψ11
−ψ10ψ01 −xψ10ψ01 ψ10 − ψ210 x(ψ10 − ψ210) −ψ10ψ11 −xψ10ψ11
−xψ10ψ01 −x2ψ10ψ01 x(ψ10 − ψ210) x2(ψ10 − ψ210) −xψ10ψ11 −x2ψ10ψ11
−ψ11ψ01 −xψ11ψ01 −ψ11ψ10 −xψ11ψ10 ψ11 − ψ211 x(ψ11 − ψ211)
−xψ11ψ01 −x2ψ11ψ01 −xψ11ψ10 −x2ψ11ψ10 x(ψ11 − ψ211) x2(ψ11 − ψ211)

.
The information matrix I(x,ϑ) has rank 3, since it has three linearly independent
rows or columns. Therefore, we require at least three diﬀerent doses to be assigned to
the cohorts to obtain a nonsingular information matrix. This is particularly impor-
tant as both D and the combined criterion are deﬁned in terms of the determinant
of the FIM.
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Chapter 5
Adaptive Designs
5.1 Introduction
This chapter introduces approaches for dose ﬁnding in phase IB/IIA clinical trials.
In one of the approaches, along with dose-response outcomes, we also incorporate
PK information in dose escalation. The aim is to develop an eﬃcient dose-ﬁnding
method, so that it exposes not too many patients to either subtherapeutic or toxic
doses and also it can identify the best dose for further study in the next phase.
We begin with the general algorithm in Section 5.2. Assume that the patients
enter a clinical trial sequentially and cohorts of the same size are treated with a
dose level determined from the updated information. The choice of dose level for
each cohort is model based and satisﬁes an optimisation criterion. There are various
possible criteria, such as the maximum tolerated dose, the biologically optimum dose
or the D-optimum dose. The maximum tolerated dose is the dose level for which
the probability of toxicity attains a maximum permissible value. This criterion is
often used in oncology trials, as it is usually assumed that both the eﬃcacy and
toxicity probabilities increase with dose level. However, in cases where we can
observe eﬃcacy with no toxicity, the outcome which we call a success, it makes
sense to consider a criterion which allows for the highest chance of such an outcome.
Alternatively, one can consider a criterion which in principle should lead to the best
dose-response model prediction and so the best indication of the eﬃcacious dose
level.
5.2 General Algorithm
The proposed method is model based. Hence, we assume that a dose-response model
and a PK model, when appropriate, are known apart from the parameters. The
choice of these models for a speciﬁc drug is generally elicited from the experts in the
area. Pre-clinical studies of the candidate drug or previous studies of similar drugs
can provide guidance. We assume that the set of d ordered doses X = {x(1), . . . , x(d)}
of a candidate drug is available for experimentation. The goal is to ﬁnd the best
of these doses, which we call the optimum dose (OD), for further study in the next
phase. Below we present the main steps of the adaptive design, where k represents
the stage in a trial. We set k = 1 initially.
Step 1: Treat cohort k with the current best dose.
Step 2: Observe the PK responses at the locally D-optimal sampling time points,
when appropriate.
Step 3: Observe the dose-response outcomes.
Step 4: Estimate the model parameters and update the models.
Step 5: Select the best dose for the next cohort based on the chosen dose optimi-
sation criterion and constraints.
Step 6: Stop if the stopping rule is met, otherwise set k = k + 1 and repeat Steps
1-5.
Step 7: Carry out a complete analysis of the data to recommend a dose for further
study.
At any stage of the trial, if it is found that none of the available doses satisfy the
constraints, then we assign the lowest dose to the next cohort. The above adaptive
procedure requires estimation of the dose-response model parameters, and also the
PK parameters in the case when PK constraints are used. With a small cohort
size, we need to gather data from a few cohorts before we estimate any parame-
ters. Hence, we start the trial with an up-and-down procedure, which is run for the
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ﬁrst four cohorts before we start the fully adaptive parametric algorithm described
above. This is similar to the procedure of Ivanova (2006), where a dose is increased,
stays at its present level or is decreased depending on the responses of the most
recent cohort. Here, however, we take into account responses from all cohorts up to
the most recent one (Bogacka et al., 2014). The basis of the method lies in the toxic
outcomes, which can stop the trial if toxicity is above the acceptable level.
Assume that we are at the kth stage in a trial and that patients in the successive k
cohorts have received doses from a pre-speciﬁed sequence of doses X , the same dose
within a cohort. Let us denote the proportion of toxic responses up to cohort k by
pˆk, that is,
pˆk =
1
kc
k∑
i=1
Rtoxi ,
where c is the cohort size and Rtoxi is the number of toxic responses for the ith
cohort upon receiving a dose. The algorithm starts with the lowest dose from X .
Then, for given thresholds pL, pM and pU , we increase, stay at the same dose level,
decrease or stop the trial, depending on the value of pˆk. In our study, we set
pL = γ/3, pM = 2γ/3 and pU = γ, where γ is the maximum acceptable level for the
probability of toxicity. More speciﬁcally, the algorithm has the following structure
to follow:
pˆk

≤ pL increase the dose to the next level if not at the highest
level, otherwise stay at the highest level,
∈ (pL, pM) stay at the current dose,
∈ [pM , pU) decrease the dose by one level if not at the lowest
level, otherwise stay at the lowest level,
≥ pU stop the trial.
Although we choose the above steps to be 1/3, it can be changed if some indications
of the chances of toxicity suggest that other thresholds may be more appropriate.
The main underlying idea of this stage of the trial is to gather information on the
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responses, and thus on the parameters without exposing many patients to a risk of
toxicity.
Once the trial is ﬁnished with the up-and-down stage, it moves to the adaptive
parametric algorithm. As we have seen in Chapter 4, since the FIMs for a cohort
are singular, to facilitate the computation of the D-optimum design for the contin-
uation ratio model, we ensure that at least two of the four doses are diﬀerent in
the up-and-down stage. Assume that a trial stops after revisiting the above two
algorithms K times. Then we will have K cohorts treated at the doses x1, . . . , xK ,
selected from X in the diﬀerent stages. A ﬂow chart indicating diﬀerent steps of the
proposed design is given in Section A.2.
Since the PK models are non-linear in the parameters, the search for the optimal
time points depends on the parameter values. As they are unknown initially, we
begin with some guesses, which may be quite inaccurate. It is therefore important
to check the sensitivity of the design to appreciate the impact of such a choice of
parameter values. However, as the trial proceeds, more accurate estimates are cal-
culated and hence we obtain more reliable optimal sampling time points.
The dose-selection criteria at each stage and also the stopping rule are important
decision functions. They will depend on the objective of the trial.
5.3 Criteria for Dose Optimisation
At each stage in the trial, we select that dose for the next cohort for which the
desired criterion is maximised, subject to the condition that a number of constraints
are satisﬁed. Often, it is not advisable to skip dose levels when they are increased for
application in the next cohort. Therefore, in our method, we introduce an option
of constraining the increase by any number of dose levels. However, we impose
no such constraint on the levels when they are decreased. For example, the next
best dose could be ﬁve levels higher then the previous one, but with a constraint
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of not skipping more than one dose level, we apply the one two levels higher than
the previous one. The following sections describe some possible dose-optimisation
criteria that can be used in a trial. We use these criteria in the simulation studies
in Chapter 6.
5.3.1 Maximisation of Probability of Success
This criterion is based on the probability of success. Recall that a success is deﬁned
as that outcome which produces a desired level of eﬃcacy without severe toxicity.
Assume that we are at the kth stage in a trial and based on the current data, we
have the estimates ϑˆk of the dose-response parameters. Then we select the dose
xk+1 for the next cohort of patients so that
xk+1 = arg max
x∈X
ψS(x, ϑˆk), (5.1)
where ψS is the probability of success at a given dose. In the trinomial dose-response
model introduced in Chapter 4, ψ1 is taken as ψS. For bivariate binary outcomes,
it is ψ10.
The above criterion is deﬁned so that it allocates the most eﬃcacious doses to the
cohorts during a trial. The issue of allocating the most eﬃcacious doses during a
trial is very important from an ethical point of view. The criterion, by deﬁnition,
does not take into account the eﬃciency of parameter estimation. As mentioned in
Chapter 4, the estimates ϑˆk can be obtained by using either a Bayesian or frequen-
tist approach. Some authors (Pronzato, 2000; Fedorov et al., 2011) report that the
above algorithm may converge to a sub-optimal dose. These studies are based on
the frequentist approach, the least squares or the maximum likelihood estimates of
the parameters.
We are using Bayesian parameter estimation, and, to our knowledge, the convergence
properties are not known. The above algorithm may converge to a sub-optimal dose
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due to the possibility of poor estimates of the parameters. This possibility is em-
bedded in the criterion (5.1), which chooses the best dose for the eﬃcacy purpose
rather than for precise estimation of the parameters. It may happen that, when the
responses are eﬃcacious for the same dose given to a number of consecutive cohorts,
the algorithm will not explore other doses very much and consequently will choose
that dose as the optimum one. Hence, for a small number of cohorts, we observe
that on some occasions the algorithm chooses a sub-optimal dose. However, in the
majority of cases, the algorithm stops at the true optimum dose, as shown in Figures
6.2-6.5 and 6.15-6.18.
Fedorov et al. (2011) showed that the convergence property holds for the penalised
D-optimum design in Section 5.3.3 when a large number of patients, such as 400, are
enrolled in the trial. For small numbers of patients, all known methods can lead to a
sub-optimal dose. The criterion in (5.1) has been found to outperform the penalised
D-optimum design in (5.8) for three of the presented scenarios: see Tables 6.13-6.16.
This provides evidence of where a design with the convergence property may end
up with a sub-optimal dose. Employing a very large number of patients is diﬃcult,
as most of the early phase designs aim for a small number like 30-60. Consequently,
in a practical situation, there will always be a risk of selecting a sub-optimal dose
whatever the convergence properties of the applied method.
5.3.2 Maximisation of Determinant of FIM
This approach allocates those doses to the cohorts which contribute most to the
eﬃcient estimation of the dose-response parameters. Assume that we are at the kth
stage in a trial. So, the doses allocated to the cohorts are ξk = {x1, x2, . . . , xk}.
Also, based on the data so far we have the estimates ϑˆk. Let us deﬁne
M(x|ξk, ϑˆk) = k
k + 1
M(ξk, ϑˆk) +
1
k + 1
I(x, ϑˆk), (5.2)
where M(ξk, ϑˆk) =
∑k
i=1 I(xi, ϑˆk) and I(x, ϑˆk) is the Fisher information matrix
for a cohort which received the dose x. For both of our dose-response models, the
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expressions for I(x,ϑ) are shown in Chapter 4. Atkinson et al. (2014) discuss the
construction of designs based on augmented FIMs. Bogacka et al. (2014) use the
same approach for the construction of design.
Then we select the dose xk+1 for the next cohort of patients such that
xk+1 = arg max
x∈X
ΦD{M(x|ξk, ϑˆk)}, (5.3)
where ΦD{M} = |M |. It is well known that a D-optimum design tends to assign
doses from the extremes of X . Therefore, patients are likely to receive non-eﬃcacious
and toxic doses during a trial.
5.3.3 Combined Criterion
Clinicians may be interested in achieving several objectives, such as eﬃcient esti-
mation of the model parameters and allocation of the most eﬃcacious doses to the
cohorts during a clinical trial. The combined criterion in (5.6) and the penalised
version in (5.9) balance these two objectives. The criterion is deﬁned so that one can
obtain the design which ensures either eﬃcient parameter estimation or eﬃcacious
dose allocation or a combination of both.
The combined criterion that we want to utilise for dose selection is a linear com-
bination of the determinant of the Fisher information matrix for the dose-response
model and the probability of success. At each stage of the trial, we will be selecting
that dose for which the criterion is maximised. The main idea is to ﬁnd a dose that
will be appropriate from the eﬃcacy point of view and will also lead to the eﬃcient
estimation of the dose-response parameters.
To implement the method, we initially determine the doses that maximise the de-
terminant of the FIM and the probability of success
xDk+1 = arg max
x∈X
ΦD{M(x|ξk, ϑˆk)}
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and
xψSk+1 = arg max
x∈X
ψS(x, ϑˆk),
where M(x|ξk, ϑˆk) is deﬁned in (5.2). Since the determinant and the probability of
eﬃcacy may have quite diﬀerent magnitudes, we scale them at the dose x as
ED(x) =
ΦD{M(x|ξk, ϑˆk)}
ΦD{M(xDk+1|ξk, ϑˆk)}
(5.4)
and
EψS(x) =
ψS(x, ϑˆk)
ψS(x
ψS
k+1, ϑˆk)
. (5.5)
The combined criterion then selects the dose xk+1 for the next cohort of patients so
that
xk+1 = arg max
x∈X
{aED(x) + (1− a)EψS(x)} , (5.6)
where a is some weight such that 0 ≤ a ≤ 1 .
It is clear that, when a = 1, the combined criterion is simply the D-criterion.
Similarly, for a = 0, we have dose selection based on the probability of success
only. This design is expected to allocate the most eﬃcacious doses to the cohorts
compared to the D-optimum design and also to recommend the best dose for further
study.
Penalty Function
In the D-optimal design for the dose-response model, deﬁned in (5.3), the doses allo-
cated to the cohorts are often found at the extremes of the design region. Therefore,
such a design suﬀers from the limitation that patients in a trial may be exposed to
non-eﬃcacious or highly toxic doses. To reduce the possibility of exposing patients
to such doses, we introduce a penalty function in the search for D-optimum doses
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and consider a penalised D-optimum design (Dragalin and Fedorov, 2006).
We denote the penalty function for an observation taken at the design point x by
ϕ(x,ϑ). Following Dragalin and Fedorov (2006), a simple choice for that function
would take the form
ϕ(x,ϑ) = {ψS(x,ϑ)}−CS{1− ψT (x,ϑ)}−CT , (5.7)
where ψS and ψT are the probabilities of success and toxicity at a given dose, respec-
tively, CS and CT are control parameters used to construct an appropriate penalty
function at the low and high dose levels. The function is deﬁned so that the lower
the probability of success and/or the higher the probability of toxicity at the as-
signed dose, the higher the penalty for the observation taken.
For a given x and ϑ, the larger the values of CS and CT , the higher the value of the
penalty function will be, and thus the design will avoid allocating doses with a low
probability of eﬃcacy or a high probability of toxicity to the patients. Assume that
CS = CT = C = 0, which in turn means no penalty. Then this will lead to the D-
optimum design. The larger the value of C is, the further it is from the D-optimum
design and the less eﬃcient the parameter estimation.
Penalised D-Criterion
The penalised D-criterion takes into account a penalty function, as shown in (5.7).
In this version of the D-optimum design, we select the dose as
xk+1 = arg max
x∈X
ΦPD{M(x|ξk, ϑˆk)}, (5.8)
where ΦPD{M} = |M/ϕ|.
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The matrix M(x|ξk, ϑˆk) is deﬁned in (5.2) and also
ϕ(x|ξk, ϑˆk) = k
k + 1
ϕ(ξk, ϑˆk) +
1
k + 1
ϕ(x, ϑˆk),
where
ϕ(ξk, ϑˆk) =
k∑
i=1
ϕ(xi, ϑˆk).
Penalised Combined Criterion
The penalised combined criterion is similar to the one in (5.6). The only diﬀerence
is that, instead of the D-criterion, we are considering here the penalised D-criterion.
As before, we need to determine the doses based on the maximisation of the deter-
minant of the FIM and the probability of success. The penalised D-optimal dose at
stage k of the adaptive procedure is obtained as
xPDk+1 = arg max
x∈X
ΦPD{M(x|ξk, ϑˆk)}.
We scale the determinant value at the dose x as
EPD(x) =
ΦPD{M(x|ξk, ϑˆk)}
ΦPD{M(xPDk+1|ξk, ϑˆk)}
.
Then the penalised combined criterion selects the dose xk+1 such that
xk+1 = arg max
x∈X
{aEPD(x) + (1− a)EψS(x)}, (5.9)
where EψS(x) is obtained as in (5.5). If a = 1, then (5.9) simply becomes the pe-
nalised D-criterion. For a = 0, the dose selection is based on the probability of
success only. When a = 0.5, it gives equal weight to both.
Although the penalised D-criterion introduces a penalty function to improve the
quality of treatments during dose escalation, we have found the quality not to be
improved as expected. Therefore, further eﬀort has been taken through the above
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combined criterion. Although the probability of success appears twice in the crite-
rion, through EPD(x) and EψS(x), the roles they play are diﬀerent. In the penalised
D-criterion, the probability of success is used to scale the FIM so that doses with low
eﬃcacy or high toxicity result in small values for the determinant of the FIM. The
EPD part of the criterion guides us to choose the dose that will provide maximum
information regarding parameter estimation taking into account the eﬃcacy levels
of all of the available doses. The maximisation of the probability of success on the
other hand tends to choose a dose from the eﬃcacy view point, without caring for
parameter estimation. A combination of them, as presented above, is expected to
facilitate a balance between the two approaches.
A design is presented in Section 6.6 that utilises the penalised combined criterion.
The gains over the penalised D-criterion are quite evident from the results in Ta-
bles 6.13-6.16. All of the performance measures are found to be improved there.
Most importantly, we notice an appreciable improvement in the quality of treat-
ment allocation, reﬂected through the sampling eﬃciency measure, SE. The quality
of optimum dose selection for the next phase, presented through DE, is also found
to be improved.
5.4 Constraint on Probability of Toxicity
Let γ be the maximum acceptable level for the probability of toxicity. Then, for
the next cohort of patients, we select the dose xk+1 for which the chosen dose-
optimisation criterion is maximised subject to the constraint
ψT (xk+1, ϑˆk) ≤ γ, (5.10)
where ψT is the probability of toxicity evaluated at the current estimates of the
parameters. In the trinomial dose-response case, ψT is simply ψ2. But, in the case
of bivariate binary outcomes, it is the marginal probability of toxicity obtained as
ψ.1 = ψ01 + ψ11.
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The main purpose of introducing this constraint is to select a subset of doses which
are safe, and then to administer one of them to the next cohort based on a dose-
optimisation criterion. The constraint restricts us from choosing a dose for which
the estimated probability of toxicity is above the acceptable level.
5.5 PK-Constrained Dose Optimisation
Here, we focus on the constrained dose-optimisation algorithm based on pharma-
cokinetic parameters, such as the AUC and Cmax. Too low a concentration provides
no eﬀect and similarly too high a concentration leads to a toxic outcome. It is
possible to avoid excessive drug concentration by putting restrictions on the AUC
or Cmax. Therefore, from the safety point of view, restricting these parameters will
be worthwhile. Although one can restrict the choice of a dose by the probability
of toxicity constraint, it does not take into account population variability in PK
measures. However, the additional PK constraint incorporates this variability.
5.5.1 Area Under the Concentration Curve
We have explained how the concentration of a drug contributes towards the eﬀects in
Section 1.1.1. The area under the concentration curve is an important PK parameter
and it depends on the concentration: see Section 3.3. The outcomes in dose-ﬁnding
studies are often dichotomised, and, as a result, we lose some information. In par-
ticular, an outcome which is not toxic may be just below the cut-oﬀ point or a toxic
outcome may be far above the cut-oﬀ point. Similarly, the eﬃcacy is dichotomised.
Usually these issues are not considered in the dose-escalation methods. However,
they can be considered implicitly by taking into account continuous measures like
the AUC in the dose-ﬁnding methods.
The proposed constraint is related to the total concentration of the drug in the body
so that the curative purpose is likely to be achieved, and this is expressed by the
area under the concentration curve over time. We select a dose xk+1 so that the
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chosen criterion is maximised subject to the condition
h(xk+1, βˆk)− AUC0
ŜD{h(xk,θi)}
≤ δ(xk, ϑˆk). (5.11)
The vector of estimates of the population mean PK parameters is βˆk and h(x, βˆk) is
the estimate of the approximate population mean AUC at stage k. The estimate of
the approximate standard deviation of the AUC is denoted by ŜD{h(xk,θi)}. This
notation is explained in Section 3.8.1. Also, AUC0 is a value for the AUC that is
considered to be desirable and δ(xk, ϑˆk) = 1/ψS(xk, ϑˆk). A desirable AUC is one for
which the curative purpose is likely to be achieved, allowing some acceptable level
of toxicity. The choice of such a value will require expert opinion. Previous studies
of similar drugs or pre-clinical studies can help in this context.
The left-hand side of (5.11) represents a relative diﬀerence between h(xk+1, βˆk) and
AUC0. We constrain the choice of xk+1 so that, for large values of the estimated
probability of success, this diﬀerence is small. This `forces' convergence of the dose
to the one giving the required exposure to the drug. On the other hand, when the
estimated probability of success is small, the constraint is weak, allowing for a wider
choice for the next dose level. The PK constraint (5.11) is dynamic, that is, the
value of δ(xk, ϑˆk) changes during the trial according to the current estimate of the
probability of success. This gives some ﬂexibility to the algorithm. A ﬁxed δ might
lead to choosing a sub-optimal dose, and, in any case, it would be diﬃcult to decide
on its value.
Hence, instead of using a ﬁxed δ, we are expressing it in terms of ψS, whose value is
updated after each cohort. Further justiﬁcation for choosing δ as the reciprocal of
ψS is that, for a dose at which the probability of success is high, we can assume that
the optimum dose is in the neighbourhood of the current dose and therefore would
like to restrict the search through the small value of δ. On the other hand, for a
dose with a small probability of success, we want the algorithm to be able to search
a wide dose region. The δ can be regarded as the tolerance, since its values have
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an impact on the selection of the optimum dose. The relationship between δ and
ψS is intended to have small tolerance towards the end of a trial, so that it enables
the choice of a dose which has a mean AUC close to the target. If the tolerance is
high, the margin to the right of the target will be high, and there is a possibility to
choose a dose which is excessively toxic.
It follows from the constraint that h(xk+1, βˆk) ≤ AUC0 +δ(xk, ϑˆk) ŜD{h(xk,θi)}. If
ψS(xk, ϑˆk) attains the maximum possible value 1, then δ(xk, ϑˆk) will have the value
1 and consequently we will choose a dose with a mean AUC within one standard
deviation of the target, which accommodates the population variability. However,
in the majority of cases, δ will have a larger value than 1. Therefore, we will usually
be selecting a dose with a mean AUC within more than one standard deviation of
the target value. This constraint, as well as the next, is introduced as an additional
precaution against allocation of too toxic doses. They work diﬀerently to (5.10),
which is the constraint on the estimated probability of toxicity. The AUC and Cmax
not only take into account the population variability, but also directly constrain the
pharmacokinetic parameters responsible for the drug's action.
To the best of our knowledge, such constraints have not been considered before in
the adaptive design set-up. We have tried other functions of ψS for a choice of δ,
such as δ = 1/2ψS and δ = 1/(1 +ψS), but they were too conservative in identifying
the optimum dose.
5.5.2 Maximum Concentration
The quantity Cmax is related to the side eﬀects that may result from excessive drug
concentration. Therefore, it is required to be maintained at a level to ensure safety.
We introduce another dynamic constraint for Cmax to avoid unacceptable adverse
events. The criterion tells us to select the dose xk+1 based on a dose-optimisation
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criterion so that
l(xk+1, βˆk)− C0max
ŜD{l(xk,θi)}
≤ δ(xk, ϑˆk). (5.12)
The vector of estimates of the population mean PK parameters is βˆk, l(x, βˆk) is the
estimate of the approximate population mean Cmax at stage k and ŜD{l(xk,θi)} is
the estimate of the approximate standard deviation of the maximum concentration:
see Section 3.8.2. Also, C0max is a value for the Cmax that is considered to be desir-
able, and, as before, we have δ(xk, ϑˆk) = 1/ψS(xk, ϑˆk).
It is important to note that the constraints alone are not used for dose ﬁnding,
but rather together with a dose-optimisation criterion, they help in dose ﬁnding.
The choice of optimisation criterion and constraints depends on the purpose to be
achieved.
5.6 Stopping Rules
A variety of stopping rules are possible and the choice of one solely depends on
the purpose of a trial. In many of the designs, a trial is run for a ﬁxed number of
cohorts. O'Quigley and Reiner (1998) stop the trial early on the basis that con-
tinuing it would not lead to a change in the dose recommendation. The essence of
the method is that, before recruiting all of the patients, if we can predict with high
probability what the ﬁnal recommendation will be, the trial can stop. This early
stopping rule is based on precise probabilistic calculations and not straightforward
to implement. Heyd and Carlin (1999) recommend a stopping rule based on an
approximate conﬁdence interval for the probability of toxicity at the recommended
dose. A trial is stopped if this conﬁdence interval contains some pre-speciﬁed range
of target toxicities. However, the approach suﬀers from the limitation that reaching
a precise interval would require a reasonable number of patients to be recruited in
the trial. Also, ﬁnding the range for target toxicities is a major concern. A simple
rule is proposed by O'Quigley (2002). It stop the trial if the dose recommended to
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the next patient has already been allocated m times, where m is some number ﬁxed
at the beginning of the trial. Zhang et al. (2006) terminate a trial after treating at
least n1 patients, provided at least n0 are treated at the recommended dose, or a
maximum number of n2 subjects are treated. Dragalin and Fedorov (2006) stop a
trial after reaching a ﬁxed sample size.
A simple rule is employed in our examples in Chapter 6. We stop a trial when the
same dose is repeated for r cohorts or when the trial reaches the maximum number
of m cohorts, whichever comes ﬁrst. The idea behind early stopping is the saving of
resources if it is found that the same dose is being selected repeatedly. The assump-
tion is that no further improvement is possible for the current trial. Otherwise, it
will run for the maximum number of cohorts available. For early stopped trials, the
OD is deﬁned as the dose that has been repeated r times. However, for the trials
that reach the maximum number of cohorts m, we carry out a complete analysis of
the data and deﬁne the OD as the dose that would be allocated to cohort m + 1 if
that cohort were in the trial.
5.7 Evaluation of the Designs
To compare the produced adaptive designs based on diﬀerent criteria and con-
straints, we introduce some performance measures. The measures are based on
the simulation results. By a simulation, we refer to the completion of the up-and-
down procedure and the adaptive algorithm to recommend a dose. We have two
dose-response models and diﬀerent dose-response scenarios for each of them, which
were introduced in Chapter 4. For each of the scenarios, we have the true values
of the dose-response parameters ϑ. The following sections deﬁne the performance
measures.
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5.7.1 Distribution of Dose Allocation
To ﬁnd the distribution of the allocated doses to the cohorts over all simulations,
we deﬁne
ξ¯ =
 x
(1) , . . . , x(d)
w(1) , . . . , w(d)
 , (5.13)
where w(j) is the proportion of times that dose x(j) was allocated to the cohorts over
all simulated trials, j = 1, . . . , d, and d is the number of available dose levels. So
w(j) =
1
ntotal
U∑
i=1
nji, (5.14)
where ntotal =
∑U
i=1 n(i) and n(i) denotes the number of cohorts used in the ith
simulated trial. Thus, ntotal is the total number of cohorts used in all simulations
and nji is the number given dose x
(j) in the ith simulation.
5.7.2 Distribution of Optimum Dose
The distribution of the OD is presented as
ξ˜ =
 x
(1) , . . . , x(d)
w˜(1) , . . . , w˜(d)
 , (5.15)
where w˜(j) denotes the proportion of times that dose x(j) was recommended for the
next phase. It is obtained as
w˜(j) =
qj
U
, (5.16)
where qj is the number of times that dose x
(j) was recommended for the next phase
in U trials.
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5.7.3 Decision Eﬃciency
Since, at the end of each trial a dose is recommended for the next phase, we introduce
an eﬃciency criterion which is called the decision eﬃciency (DE). Denote the ratio
of ψS at a recommended dose x for the next phase to ψS at the dose xOD by ρ.
The latter dose is the true OD obtained from a scenario assumed for the simulation
study. Therefore, we have
ρ(x,ϑtrue) =
ψS(x,ϑtrue)
ψS(xOD,ϑtrue)
. (5.17)
The ratio assesses how good the recommended dose level is. To measure the global
eﬃciency of choosing the OD, we calculate the weighted sum
DE =
d∑
j=1
w˜(j) ρ(x(j),ϑtrue) IA(x
(j)), (5.18)
where IA(x
(j)) is an indicator function deﬁned as
IA(x
(j)) =
 1 if x
(j) /∈ A,
0 if x(j) ∈ A,
(5.19)
and A is the set of doses for which the probability of toxicity is above the acceptable
level. If xOD is recommended in each of the simulated trials, then the weight is 1
corresponding to the OD and 0 for all other dose levels, and henceDE = 1. Similarly,
if all of the recommended doses are from the toxic region, then the indicator function
takes the value 0 for each of them, and hence DE = 0. In general, 0 ≤ DE ≤ 1.
5.7.4 Sampling Eﬃciency
We deﬁne the sampling eﬃciency (SE) based on the information on the allocated
doses to the cohorts over the simulations. With the w(j) deﬁned in (5.14), we have
SE =
d∑
j=1
w(j) ρ(x(j),ϑtrue) IA(x
(j)). (5.20)
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This criterion assesses the quality of treatment received by the patients during the
trials. If the cohorts in the trials only receive the OD, then the SE will have the
value 1. In that case, there will be no experimental variation in the dose level. In
general, we can expect the SE to be appreciably less than the DE, unless the vari-
ation in ψS over X is small. We have 0 < SE ≤ 1.
Hardwick et al. (2003) consider similar eﬃciency measures. However, they do not
penalise for doses which have a probability of toxicity above the acceptable level.
We have found that, in some dose-response scenarios, ρ may be greater than 1 for
a few doses which have a probability of toxicity above the acceptable level. As a
consequence, a design choosing these doses more frequently will have larger values
for the eﬃciency measures than one that does not. This should not be the case,
since these are the doses which a good design should not choose because of their
toxicity. Therefore, we have presented measures that penalise for toxic doses. Our
measures are capable of judging a design selecting low eﬃcacious or high toxic doses
as a poor one.
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Chapter 6
Simulation Studies
6.1 Introduction
This chapter aims to study the operating characteristics of the designs obtained
using the various dose-optimisation criteria and constraints introduced in the previ-
ous chapter. We present three examples utilising the PK and dose-response models
introduced in Chapters 3 and 4. The ﬁrst example comprises a one-compartment
PK model with bolus input and ﬁrst-order elimination and the continuation ratio
model for the probabilities of the dose-response outcomes. The second one uses one-
compartment PK model with ﬁrst-order absorption and the Cox bivariate binary
model as the dose-response model. The third example only uses dose-response data
and the continuation ratio model is employed.
Section 6.2 gives a detailed description of the software used. For both dose-response
models, in Chapter 4, we presented some plausible scenarios. Simulation studies
are based on those scenarios to explore the behaviour of the designs. Section 6.3
contains a detailed description of the ﬁrst example. The second example is presented
in Section 6.4. Since the presented designs depend on various parameters, we also
conduct sensitivity analyses to assess the robustness of the designs, the results of
which are given in Section 6.5. The simulation results for the third example are
presented in Section 6.6. Finally, there is a discussion in Section 6.7.
6.2 Software Used
All of the computations involved in the simulation studies are conducted using code
written in R (R Core Team, 2014), which is available in Appendix B. The com-
puter program follows the adaptive procedure which is shown schematically in the
ﬂow chart in Appendix A. The program has the following major parts: running the
up-and-down design; obtaining the D-optimal time points for measuring concen-
tration; the generation of the concentrations and dose-response outcomes; PK and
dose-response parameter estimation; dose selection for the next cohort; checking the
stopping rules; and identifying the OD.
The D-optimal time points for PK sampling are obtained by using PFIM 3.2 (Baz-
zoli et al., 2010), an R package to evaluate and optimise designs in the context
of population PK/PD experiments. The package PFIM 3.2 includes two folders:
PFIM 3.2 and examples. Some illustrations of the package using various models are
available in the folder examples. The folder PFIM 3.2 contains three principal ﬁles:
PFIM3.2.r, model.r and Stdin.r. These are the main program ﬁle, the model ﬁle and
the input ﬁle, respectively. They need to be put in a working directory. Then we
specify the working directory and the program directory in the ﬁle PFIM3.2.r. The
package has a library of PK and PD models. In addition to these, users can deﬁne
their own model. Since our models are available in the library, we can specify them
in the model ﬁle. The input ﬁle requires speciﬁcation of the optimisation method
and essential parameter values to obtain the optimal time points. We have kept the
model ﬁle general, so that the current estimates from the trial can be fed into it to
ﬁnd the locally optimal time points.
To obtain the maximum likelihood estimates of the PK parameters, we employ the
R procedure nlme (Pinheiro and Bates, 2000). Bayesian estimates of the dose-
response parameters are obtained by numerical integration using cubature, an R
package (Johnson and Narasimhan, 2013). The combined criterion for dose opti-
misation requires the penalised D-optimal dose to be found, which is achieved by
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some further code written in R. Here, we search for the dose, out of a set of discrete
doses, for which the determinant of the FIM is maximum.
The program is structured in such a way that one has to ﬁrst specify the dose range,
acceptable level for the probability of toxicity, cohort size, dose-response and PK
models, true parameter values, prior values, steps for the up-and-down design, dose-
optimisation criterion and constraints, target values for the AUC and Cmax, early
stopping rule and maximum number of cohorts to be employed. At the end of each
simulation, it records the OD, the allocated doses to the cohorts and the parameter
estimates. The simulations were implemented on a DELL PC with an Intel Core
2 Duo processor running at 3.00 GHz and RAM 4.00 GB. The processing time for
1,000 simulations depends on the choice of the models. It takes 6-8 hours when we
only consider dose-response data. For both dose-response and PK data, it takes
10-15 hours.
6.3 Example 1
We assume a one-compartment model with bolus input and ﬁrst-order elimination,
introduced in Section 3.7.1, for modelling the concentrations of the experimental
drug collected from the patients. The dose-response outcomes are assumed to be
trinomial and the continuation ratio model, introduced in Section 4.2.1, is used to
model the outcomes. Based on the updated information, we select a new dose for
the next cohort so that the estimated probability of success is maximum, subject to
a set of constraints. The trial stops according to the stopping rules described in the
previous chapter.
6.3.1 Simulation Settings
Choice of Design Parameters
We assume that the set of doses of an experimental drug is X = {0.5, 1.0, . . . , 10.0}.
Four hypothetical dose-response scenarios are considered: see Figure 4.1. Scenario
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1 has a monotonically decreasing eﬃcacy curve with dose 0.5 as the OD. Scenarios
2 and 3 depict non-monotonic eﬃcacy curves with respective ODs of 5.5 and 6.5.
A monotonically increasing eﬃcacy curve is considered in Scenario 4 with 10 as the
OD. Two kinds of responses need to be generated for the simulation study: the
concentration of the drug in the blood and the trinomial dose-response outcomes.
The values of the PK parameters for the simulation study are V = 0.5, Cl = 0.06,
σ21 = 0.004, σ
2
2 = 0.00005 and σ
2 = 0.000225. The parameter values are chosen such
that the coeﬃcient of variation is around 12%.
Each trial starts with the lowest dose of 0.5 mg/kg body weight. The acceptable
toxicity level γ is taken to be 0.2. Doses for the ﬁrst four cohorts in each trial are
allocated according to the up-and-down design in Section 5.2. The value of AUC0
is taken to be the AUC obtained from (3.27) for the true OD in the scenario and
the true mean PK parameters. Although we consider the same γ for each scenario,
we have diﬀerent values of AUC0. The doses which satisfy the safety level γ = 0.2
are 1 mg/kg, 6 mg/kg, 8 mg/kg and 10 mg/kg for the four scenarios, respectively.
For each trial, we set the maximum number of cohorts to be m = 20. To allow the
trials to stop early when it is found that no further improvement in dose selection
is possible, we set r = 6.
Generation of PK and Dose-Response Outcomes
A vector of random eﬀects bi for individual i is generated from the normal dis-
tribution N2(0,Ω), where Ω = diag(0.004, 0.00005). The PK parameters for that
individual are then obtained as θi = β + bi, where β = (0.5, 0.06)
T . The next step
is to ﬁnd the individual concentrations at the D-optimal time points. The design
region for the sampling times is T = [0, t1] hours, where t1 = 30. To decide what
is the best number of sampling times, we use the relative eﬃciency deﬁned in (6.1).
Although we consider the prior Ψ0 in each case, the designs have a diﬀerent number
of design points. It has been found that the eﬃciency of a 3-point design relative to
a 2-point one is double. The eﬃciency of a 4-point design relative to a 3-point one
108
falls to 1.15. As we increase the number of design points, such eﬃciencies become
closer to 1: see Figure A.1. This means that the gain is substantial if we consider
3 design points rather than 2. The increase from 3 design points to 4, or from 4 to
5 is negligible. The model has two so-called parameter sensitivities, which are the
partial derivatives of the model function with respect to the parameters V and Cl.
It is known from Section 3.7 that the FIM depends on the parameter sensitivities.
For one of them, the maximum lies at the beginning of the design region, while, for
the other, it is towards the end. Therefore, if the number of design points is in-
creased, a more uniform distribution of the points over the region can be expected,
as shown in Figure A.1. Furthermore, collecting many blood samples is often not
possible. Therefore, three optimal time points are considered for the individuals in
each cohort of size c = 3, and so ni = 3 for all i. We use the R package PFIM
3.2 (Bazzoli et al., 2010) to ﬁnd these optimal time points. The random errors
of the observations at the optimal sampling time points are then generated from
N3(0, σ
2I3), where σ
2 = 0.000225, and added to the previously generated individual
concentrations to produce the simulated PK responses for individual i. The same
scheme is followed to simulate the responses for all individuals in each cohort. Figure
6.1 shows the generated concentrations for a cohort of three patients who received
the dose 0.5 mg.
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Figure 6.1: Simulated concentrations following the administration of the lowest dose
to a cohort. The black curve indicates the true mean PK proﬁle.
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Under each of the scenarios in Figure 4.1, we have speciﬁc probabilities at each dose
to generate the trinomial dose-response outcomes, that is, we also assume some true
values for the model parameters.
Priors
We chose the prior values Ψ0 = (V 0, Cl0, (σ21)
0, (σ22)
0, (σ2)0)
T
= (0.1, 0.005, 0.0007,
0.0000006, 0.000004)T to obtain the optimal time points for the ﬁrst four cohorts
in the up-and-down stage of the trial. The prior values are quite far away from
the true values Ψ = (0.5, 0.06, 0.004, 0.00005, 0.000225)T of the parameters, which
would normally be unknown and could be wrongly assumed at the beginning of the
trial. For the ﬁfth cohort onwards, the current maximum likelihood estimates are
used.
We use a joint uniform prior distribution for ϑ, given in (4.5). The parameter space
Θ˜ is chosen for each scenario so that the true values of the parameters lie in the
middle of the corresponding intervals. For instance, since Scenario 1 has the true
parameters ϑ = (1.44, 0.26,−1.70, 0.25)T , Θ˜ has 0 < ϑ1 < 2.88, 0 < ϑ2 < 0.52,
−3.40 < ϑ3 < 0 and 0 < ϑ4 < 0.50. More speciﬁcally, u1 = 0.52, u2 = 0.50, l1 =
0, l2 = 2.88, l3 = −3.40 and l4 = 0 in (4.5). The same approach is followed for
the other scenarios. The chosen priors allow for any extreme scenario, as shown
in Figure A.2. Since the parameters ϑ2 and ϑ4 have the value 0 in each case, the
graphs in the left panel are identical. In evaluating the integrals in (4.4) with the
uniform distribution speciﬁed in (4.5), the prior distributions in the numerator and
denominator cancel out, as they are constants.
Model Fitting
Once we have data on the concentrations and the dose-response outcomes, we can
update the ﬁtted model. We obtain the maximum likelihood estimates of the PK
parameters using the R procedure nlme (Pinheiro and Bates, 2000). The posterior
estimates of the dose-response parameters in (4.4) are obtained by numerical inte-
gration using cubature, an R package (Johnson and Narasimhan, 2013). The package
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carries out the adaptive multidimensional integration over hypercubes. One needs
to specify the tolerance limit and the maximum number of function evaluations de-
sired. The smaller the tolerance limit or the larger the maximum number of function
evaluations, the more accurate an estimate is. Since the computational time is also
an important consideration, we set these to be 0.001 and 5,000, respectively.
Dose Selection for the Next Cohort
Once we have the updated PK and dose-response parameter estimates, we select the
dose for the next cohort based on the dose-optimisation criterion in (5.1), subject
to two diﬀerent sets of constraints in two separate runs of the simulations, that is,
subject to (5.10) and to (5.10) together with (5.11). As discussed in Section 5.3,
we do not allow the design to skip more than one dose level at a time when it is
increased.
Checking the Stopping Rules and the OD Selection
We continue the process of allocating doses to the cohorts until the stopping rules
in Section 5.6 are satisﬁed. Once a trial reaches m cohorts, we carry out a complete
analysis to ﬁnd the OD. At the end of each trial, we record the doses allocated to the
cohorts, the PK and dose-response parameter estimates, whether the trial stopped
early or not and the OD selected. Each of the four scenarios is investigated through
1,000 simulated trials. The following section summarises the results.
6.3.2 Numerical Results
We compare the operating characteristics of the PK-guided design, incorporating the
AUC constraint, with the one that does not take into account the PK information.
Dose selection in the latter design is based on the estimated probability of success
and the toxicity condition only, deﬁned in (5.1) and (5.10). Although the method
is similar to the one presented by Zhang et al. (2006), their design criterion is the
maximisation of the diﬀerence between the estimated probabilities of success and
toxicity, subject to a toxicity constraint. The simulation results for our two designs
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are presented in Table 6.1 and Figures 6.2-6.5. In these ﬁgures, the ﬁrst row shows
the summaries when the additional PK constraint is employed. The summaries in
the second row are based on the toxicity constraint only. The bars in the left panel
represent the proportions of the doses selected as the OD in the simulations and
those in the right panel represent the proportions of the cohorts treated at the allo-
cated doses during the trials. The acceptable level for the probability of toxicity is
indicated by the horizontal dashed line.
Table 6.1 clearly shows the advantages of incorporating the additional constraint on
the AUC proﬁle. The gain in percentage of the doses correctly recommended for
further studies depends on the scenario, but, in all cases considered, the PK-guided
designs are uniformly better.
Table 6.1: Percentage of best doses recommended for further studies (%BD), per-
centage of doses recommended as optimum, but carrying the probability of toxicity
above the maximum allowed threshold (%TD), and percentage of cohorts treated at
the best doses throughout the trials (%AD).
Scenario Best Doses %BD %TD %AD
PK No PK PK No PK PK No PK
1 0.5 99.0 52.4 0.6 32.7 65.3 31.8
2 5.5 and 6.0 80.2 66.2 0.9 9.5 41.1 33.5
3 5.5-7.5 91.7 85.7 0.0 2.5 52.4 49.2
4 10.0 47.9 46.3 0.0 0.0 17.8 17.5
As seen in Table 6.1, as well as in the left panels of Figure 6.2, the largest beneﬁt
is shown in Scenario 1, where the best dose is the ﬁrst one and small doses have a
high probability of toxicity. Scenario 1 is an example of a dose range which is not
well deﬁned, as the smallest dose level gives the highest probability of success and
all other doses give toxicity rates too high with a lower chance of success. Such a
situation may be rather rare in real applications, though it is not unlikely to hap-
pen. Hence, it is important to know how the methodology works in such an extreme
scenario. The PK-guided design avoids doses with a high chance of toxicity, while
the other design has not prevented this from happening. Despite the toxicity prob-
ability increasing sharply with dose levels in the upper dose range, there are still
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high doses allocated to patients when only the toxicity condition restricts the design.
The dose range is well chosen in Scenario 2, where the best dose levels are in the
middle of the range. Although the rate of success is very similar for two middle dose
levels, it drops oﬀ rather fast on both sides of the middle dose range. The PK-guided
approach in Scenario 2 selects 5.5 as the OD in 39.7% of the trials. It selects dose
6.0 in 40.5% of the trials. This happens as the true probabilities of success at these
doses are quite close. These two ﬁgures together make 80.2% of what we call in
Table 6.1 best doses. The corresponding ﬁgure for the other approach is 66.2%.
Again, we observe that the PK-guided design avoids recommending doses with a
high probability of toxicity, and, moreover, such doses are used much less in the
simulated trials in this case: see Figure 6.3.
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Figure 6.2: Scenario 1 with the OD at 0.5.
The new approach in Scenario 3 identiﬁes exactly 6.5 as the OD in 17.8% of the trials.
Because of the ﬂat shape of the success curve, this scenario has a number of doses
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Figure 6.3: Scenario 2 with the OD at 5.5.
with probabilities of success quite close to that for the OD. The doses are 5.5, 6.0,
6.5, 7.0 and 7.5, and these best doses are selected in 91.7% of the trials. Although
the other approach selects these doses in 85.7% of the trials, it recommends doses
above the toxicity probability threshold in 2.5% of cases. Furthermore, from Figure
6.4, the allocation of doses in the trials is again more ethical in the PK-guided design.
There is little diﬀerence between the two designs in Scenario 4, as shown in Table
6.1 and also in Figure 6.5. This is the case where both the probability of success
and the probability of toxicity increase with dose, where only higher doses have a
better chance of having an eﬀect and all doses are below the toxicity threshold. This
scenario illustrates a very cautiously chosen dose range. As a consequence, this leads
to slow learning in the trial and requires the collection of a lot of information before
a recommendation can be made.
This is also shown in Figure 6.8, where, for this scenario, all available cohorts were
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Figure 6.4: Scenario 3 with the OD at 6.5.
used almost all of the time. This is in contrast to Scenario 1, where, especially in
the PK-guided design, the learning process was fast and there were much smaller
numbers of cohorts required in the trials. The other two scenarios use slightly lower
numbers of cohorts than the maximum, since the OD lies in the middle of the dose
range.
Now we try to understand how the eﬃciency of the design and also the optimal
sampling time points change in successive stages of a trial. We deﬁne the relative
D-eﬃciency of a design ξ∗k to ξ
∗
true as
Relative Efficiency =
(
|M(Ψˆk, ξ∗k)|
|M (Ψtrue, ξ∗true)|
) 1
p
, (6.1)
where ξ∗k is the optimum design obtained at the kth stage of a trial using the cur-
rent estimates of the parameters Ψˆk, ξ
∗
true is the optimum design obtained for the
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Figure 6.5: Scenario 4 with the OD at 10.0.
true values of the parameters and p is the number of parameters in the model. In
both cases, dose remains ﬁxed and it is the dose administered to the cohort at the
kth stage. Since both designs depend on the parameter values, it is possible, with
completely diﬀerent parameter values to the true ones, to have a design for which
the relative eﬃciency is very high. A larger determinant of the information matrix
means a smaller general variance of the estimators. But, in our case, that will mean
that the variance is underestimated. Hence, we want the numerator to be close to the
denominator in (6.1). This, in turn, means that we want to have an optimum design
which is obtained for values around the true values of the parameters. This can be
achieved in a trial as we update the parameter estimates at each stage. After a suﬃ-
cient number of stages, the estimates will be stable and the design points will be too.
Figure 6.6 shows the relative D-eﬃciency of the designs computed at each of the
stages using (6.1) for Scenario 2. Though not presented, we have found underes-
timated variances for the initial four stages. Recall that we use the up-and-down
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Figure 6.6: Relative D-eﬃciency in a randomly selected trial from Scenario 2.
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Figure 6.7: Optimal design points in a trial. The left one shows the points for the
true values of the PK parameters and the one on the right gives the points using
the current estimates.
design for the ﬁrst four cohorts and that blood samples for these cohorts are collected
at the optimal time points which are based on an initial guess about the parameter
values. From the ﬁfth cohort onwards, we use the current estimates obtained from
the trial data. Here, we observe a decreasing trend in the eﬃciency. Since the es-
timates stabilise as the trial proceeds, there is not much change at the later stages
and also the eﬃciency approaches to one.
The design points are displayed in Figure 6.7. With the true values of the parame-
ters, the design points are very similar at the various doses received by the cohorts
in the trial. This is because the shape of the concentration proﬁle does not change
much with dose. But, of course, the amount of concentration changes rapidly with
dose. There is good agreement between the time points at the later stages with the
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corresponding true ones. This suggests that, after a reasonable number of steps, the
optimal time points stabilise.
It has already been mentioned that we stop a trial early if the same dose is repeated
for six of the cohorts and that we call the associated dose the OD. We have found
that, as the location of the OD moves from left to right in the dose region of a
scenario, more cohorts are needed to stop early. Most of the early stopped trials
identify the OD accurately. Figure 6.8 compares the average numbers of cohorts
used by the two approaches. It is observed that the PK-guided approach utilises
fewer cohorts in each scenario.
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Figure 6.8: Average numbers of cohorts used in the four scenarios by the two dose-
allocation methods.
Figures 6.9 and A.3 indicate a small bias and variance for the PK parameter esti-
mates for all of the scenarios. Since the design employs theD-criterion for measuring
the PK responses, it is ensuring accuracy and eﬃciency in parameter estimation.
Figures 6.10, A.4 and A.5 show that the dose-response parameter estimates obtained
from the two approaches are similar. Obviously, they are not as good as the PK es-
timates. This is due to the fact that the information on the trinomial dose-response
model is not gathered in a way that would be optimum for parameter estimation.
Here, we focussed on the criterion which would provide a good dose for further
studies in an ethical trial, which is particularly important in classes of drugs where
toxicity can be very serious.
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The decision and sampling eﬃciencies of the designs, obtained using (5.18) and
(5.20), are presented in Table 6.2. Both measures are larger for the PK-guided de-
sign than for the other design. These again reﬂect the fact that the former design
is capable of identifying the OD more accurately and also allocating the most eﬃ-
cacious doses to the cohorts in a trial.
We have checked the sensitivity of the optimal design to the prior values of the
parameters in Section 3.7.1. It has been found that the design is not sensitive to the
values. We now check the sensitivity of our dose-ﬁnding design to the target value
of the AUC.
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Figure 6.9: Boxplots of the PK parameter estimates obtained from the simulations
for Scenario 1. The horizontal dashed lines indicate the true parameter values.
Table 6.2: Decision and sampling eﬃciencies of the designs.
Scenario DE SE
PK No PK PK No PK
1 0.994 0.670 0.778 0.522
2 0.975 0.882 0.694 0.608
3 0.991 0.964 0.859 0.830
4 0.806 0.796 0.453 0.449
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Figure 6.10: Boxplots of the dose-response parameter estimates obtained from the
simulations for Scenario 1. The horizontal dashed lines indicate the true parameter
values. For each parameter, the left boxplot corresponds to the design which takes
into account the AUC and the right boxplot to the one which ignores it.
Sensitivity to Target AUC
The PK-guided design depends on the target value of the AUC. In our simulations
so far, we have considered it as the one at the true OD. To assess the sensitivity of
the design to the target value, we set it at doses other than the true OD. Scenario
2 is studied for this purpose. This scenario has 5.5 and 6.0 as the best doses. Table
6.3 gives a summary of the results. The notation in the table is deﬁned as follows:
percentage of best doses recommended for further studies (%BD), percentage of
doses recommended as optimum, but carrying the probability of toxicity above the
maximum allowed threshold (%TD), and percentage of cohorts treated at the best
doses throughout the trials (%AD). Also, % of 3-BD is the percentage of the three
best doses. DE and SE are the decision and sampling eﬃciencies, respectively.
Table 6.3: Sensitivity of the design to the assumed target for AUC in Scenario 2.
Dose %BD % of 3-BD %TD %AD DE SE
4.5 0.5 88.0 0.0 2.0 0.948 0.647
5.0 72.7 96.0 0.1 33.6 0.983 0.696
5.5 80.2 94.0 0.9 41.1 0.973 0.694
6 72.0 93.1 3.5 34.2 0.950 0.697
6.5 62.9 84.8 8.5 34.0 0.892 0.633
No PK 66.2 81.7 9.5 33.5 0.882 0.608
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By the three best doses, we mean the doses 5.0, 5.5 and 6.0, since the probabilities
of success at these are close to each other. The ﬁgures in the table indicate that
the design is sensitive to the choice of target value for the AUC. %BD is smaller as
the target is further away from that at the true OD. If we choose a target below
that at the true OD, the design will avoid recommending a toxic dose as the OD
and will also not allocate toxic doses to the cohorts. But that will have a neg-
ative impact on the correct identiﬁcation of the optimum dose. The distributions
of optimum dose selection and dose allocation are presented in Figures 6.11 and 6.12.
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Figure 6.11: Optimum dose selection and dose allocation when the target AUC is
taken at the doses below the true optimum dose.
Sensitivity to Dose-Skipping Constraint
Section 5.3 discusses a restriction of not skipping more than one dose level at a time
when the level is increased. This is to make the design more cautious to avoid any
unacceptable toxicity from a high dose following a relatively small dose. In both
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Figure 6.12: Optimum dose selection and dose allocation when the target AUC is
taken at the true optimum dose and also at the doses above it.
PK-guided and other designs, we have employed this skipping constraint. To see the
impact, we compare them with those that do not employ any such constraint. Again,
we study Scenario 2. Tables 6.4 and 6.5 summarise the results from 1,000 simulated
trials. It is found that there is no appreciable diﬀerence between the ﬁgures under
the two diﬀerent situations, except for dose allocation. That might be due to the
reason that, when there is no constraint to avoid dose skipping, the cohorts after
the up-and-down phase receive doses which are close to the most eﬃcacious ones.
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Therefore, patients are likely to be treated more often at the optimum dose at an
earlier stage of the trial than in the case of a slow-dose increase.
Figure 6.13 shows the dose allocation to successive cohorts for four randomly chosen
trials for both cases. As we can see, there may be situations when there is a sharp
increase in the dose level to the upper end of the dose range, which has a very high
Table 6.4: Sensitivity of the PK-guided design to the dose-skipping constraint.
Constraint %BD %TD %AD DE SE
Yes 80.2 0.9 41.1 0.975 0.694
No 79.0 0.7 47.3 0.979 0.692
Table 6.5: Sensitivity of the design to the dose-skipping constraint in the absence
of PK information.
Constraint %BD %TD %AD DE SE
Yes 66.2 9.5 33.5 0.882 0.608
No 67.3 9.5 40.0 0.886 0.582
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Figure 6.13: Dose allocation to successive cohorts in four randomly chosen trials for
the PK-guided design for Scenario 2.
probability of toxicity. This kind of event is avoided by the dose-skipping restriction.
In some cases, where toxicity is of less concern, a clinician may choose to skip more
than one dose level. This is one of the input parameters in the computer program.
To summarise the ﬁrst example, we have seen that the eﬃciency of a dose-ﬁnding
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design can be improved by the use of pharmacokinetic information. Such a design
can restrict the recommendation of toxic doses for further studies and also allow
allocation of more eﬃcacious doses to the cohorts. We have found the design to be
sensitive to the choice of the target AUC and therefore care is needed in setting it.
6.4 Example 2
In this example, we assume that the drug is administered orally and that the whole
body is a single compartment. Assume that the dose-response outcomes are bivariate
binary. The Cox model for bivariate binary responses is used to model the dose-
response outcomes. This is accompanied by the one-compartment PK model with
ﬁrst-order absorption. The details of these models are given in Sections 4.3 and 3.7.2,
respectively. Here, we present two adaptive designs: one considers PK data and the
other does not. The dose-optimisation criterion in both cases is the same, which is
the maximisation of the estimated probability of success, discussed in Section 5.3.1.
The toxicity constraint in Section 5.4 is also common to both designs. However, the
PK-guided design considers an additional constraint, introduced in Section 5.5.2,
that is, the constraint on the maximum concentration. The aim is to study the
operating characteristics of these designs and also to compare them.
6.4.1 Simulation Settings
Choice of Design Parameters
Assume that our experimental drug has 11 available doses on the log scale be-
tween -3 and 3 with a grid width of 0.6. Therefore, the set of doses is X =
{−3.0,−2.4, . . . , 3.0}. We investigate four plausible dose-response scenarios, as
shown in Figure 4.2, and taken from Dragalin and Fedorov (2006). We assume
that the acceptable level for the probability of toxicity is γ = 0.33. The assumed
optimal dose that maximises the probability of success in the ﬁrst three scenarios
is -0.6 and in Scenario 4, is -1.8. These scenarios have doses 0, -0.6, -0.6 and -1.2
for which the probability of toxicity is no larger than γ. The PK parameter values
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assumed for the simulation study are V = 2.0, ke = 0.05, ka = 0.50, σ
2
1 = 0.16,
σ22 = 0.0001, σ
2
3 = 0.01 and σ
2 = 0.00005. The parameters are chosen in such a way
that the coeﬃcient of variation is 20%.
Starting with the lowest dose -3.0, the up-and-down design in Section 5.2 continues
for the ﬁrst four cohorts to gather information prior to any parameter estimation.
The target value of Cmax is taken to be the Cmax at the true OD in the scenario,
obtained from (3.35) for the true mean PK parameters.
Generation of PK and Dose-Response Outcomes
Following the administration of a dose to a cohort of patients, we observe the concen-
tration of the drug in the blood samples and the dose-response outcomes. The design
that considers PK data also requires the population D-optimal time points to collect
blood samples to measure the concentrations. The purpose is to ensure eﬃciency
in the estimation of model parameters, even if we collect only a few samples from
each patient. As before, the time points are obtained using the R package PFIM 3.2
(Bazzoli et al., 2010). The PK sampling region is assumed to be T = [0, 50] hours.
To decide on the optimal number of sampling points, we have checked the eligibility
of either 3, 4, 5 or 6 points. A 2-point design is not possible, as the model has more
parameters, and therefore has been avoided as a candidate. As shown in Figure
A.6, the eﬃciency of a 4-point design relative to a 3-point one is much higher. If
we increase the number of design points, the eﬃciency at each point relative to the
previous point decreases. The PK model has three parameter sensitivities for its
parameters V , ke and ka. We have checked that two of the sensitivities have an ex-
tremum at the beginning, while the other has an minimum further to the right of the
design region. Some graphical investigation of the concentration proﬁles with ran-
dom parameters, chosen within three standard deviations of the means, also showed
the variability to be high in those areas. Therefore, consideration of many design
points will lead to the choice of design points from those neighbourhoods. Since
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patients are usually unwilling to give many samples and also not much is gained by
considering many design points, we decide to collect blood samples at the four op-
timal time points for the individuals in each cohort of size c = 3. More speciﬁcally,
ni = 4 for all i in (3.21).
To obtain the concentrations at these time points, we generate a vector of ran-
dom eﬀects bi for individual i from the normal distribution N3(0,Ω), where Ω =
diag(0.16, 0.0001, 0.01). The random PK parameters are then obtained as θi =
β+bi, where β = (2.0, 0.05, 0.50)
T . We generate the random errors fromN4(0, σ
2I4),
where σ2 = 0.00005. These are added to the generated concentrations to produce
the simulated PK responses for an individual. The same principle is adopted to
generate responses for the remaining individuals in a cohort. Such generated con-
centrations for a cohort are presented in Figure 6.14.
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Figure 6.14: Simulated concentrations at the locally D-optimum time points follow-
ing the administration of the lowest dose to a cohort. The true mean PK proﬁle is
indicated by the black curve.
The dose-response scenarios to be used in the simulation study are presented in
Figure 4.2. We have the true parameter value ϑ for each of these scenarios. The
true probabilities of the four possible dose-response outcomes are then available
corresponding to the doses in X . Thus, the dose-response outcomes are generated
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from a multinomial distribution with four categories having these probabilities.
Priors
To obtain the optimal time points for the ﬁrst four cohorts in the up-and-down
stage of a trial, we chose the values Ψ0 = (V 0, k0e , k
0
a, (σ
2
1)
0, (σ22)
0, (σ23)
0, (σ2)0)T =
(3.20, 0.08, 0.80, 0.04, 0.000025, 0.0025, 0.0000125)T for the PK parameters. The pri-
ors are chosen such that the mean PK parameters are three standard deviations
above the true values, and the variance components and error variance are one
quarter of the true values. The motivation behind choosing such priors is to make
them as vague as possible, since in reality these would normally be unknown and
could be wrongly assumed at the beginning of the trial. For any cohort after the
up-and-down stage, the current maximum likelihood estimates of the parameters
are used.
A joint uniform prior distribution for ϑ, given in (4.12), is used for Bayesian esti-
mation of the dose-response parameters. The parameter space Θ˜ is chosen for each
scenario so that the margin is 3 on either side of the true values. As Scenario 1
has the true parameters ϑ = (ϑ1, ϑ2, ϑ3, ϑ4, ϑ5, ϑ6)
T = (0.0, 1.0, 4.0, 2.0, 3.0, 3.0)T , Θ˜
takes the values −3 < ϑ1 < 3, −2 < ϑ2 < 4, 1 < ϑ3 < 7, −1 < ϑ4 < 5, 0 < ϑ5 < 6
and 0 < ϑ6 < 6. The other scenarios follow the same approach. As we utilise the
uniform prior distribution, the distributions cancel out in evaluating the integrals
in (4.11).
Model Fitting
Upon receiving the PK and dose-response data, we update the estimates of the
model parameters. A similar approach to that described for Example 1 is used for
ﬁtting the models.
Dose Selection for the Next Cohort
Dose selection for the ﬁrst four cohorts is based on the up-and-down design in Section
5.2. After the up-and-down stage, we estimate the PK and dose-response parameters
127
based on the data to hand and proceed to select the dose for the next cohort.
The dose-optimisation criterion to be used is the maximisation of the estimated
probability of success. Assume that we are at the kth stage of the trial, and, based
on the current data, we have the estimates Ψˆk and ϑˆk of the PK and dose-response
parameters, respectively. Then we select the dose xk+1 for the next cohort of patients
based on the dose-optimisation criterion in Section 5.3.1, subject to two diﬀerent
sets of constraints in two separate runs of the simulations, that is, subject to (5.10),
and to (5.10) and (5.12).
Checking the Stopping Rules and the OD Selection
The same approach as was applied in the previous example is used for stopping a
trial and in identifying the optimum dose. Like before, we have r = 6 and m = 20
in this example. Each scenario is investigated through 1,000 simulated trials.
6.4.2 Numerical Results
The performance of the PK-guided design, which constrains Cmax, is compared with
the one which does not use such a constraint. Other than this constraint, the designs
are the same. Tables 6.6-6.7 and Figures 6.15-6.18 summarise the simulation results
for the four scenarios. As before, in these ﬁgures, the bars in the left panel represent
the proportions of the doses selected as the OD in the simulations and those in the
right panel represent the proportions of the cohorts treated at these doses during
the trials. The acceptable level for the probability of toxicity is indicated by the
horizontal dashed line.
Table 6.6 shows the results for the designs in terms of three performance measures:
percentage of best doses recommended for further studies (%BD), percentage of
doses recommended as optimum, but carrying the probability of toxicity above the
maximum allowed threshold (%TD), and percentage of cohorts treated at the best
doses throughout the trials (%AD). The higher the values of %BD and %AD, the
better the design is. Similarly, we would expect %TD to be as small as possible.
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Except for Scenario 4, the advantage of the PK-guided design is clearly illustrated
by the ﬁgures in the table. However, in Scenario 4, there is a slight improvement in
avoiding the doses with a high chance of toxicity.
Table 6.6: Percentage of best doses recommended for further studies (%BD), per-
centage of doses recommended as optimum, but carrying the probability of toxicity
above the maximum allowed threshold (%TD), and percentage of cohorts treated at
the best doses throughout the trials (%AD).
Scenario Best Doses %BD %TD %AD
PK No PK PK No PK PK No PK
1 -0.6 62.9 54.0 2.0 5.6 37.5 32.6
2 -0.6 63.1 46.1 1.5 21.7 35.6 26.9
3 -0.6 94.8 83.1 0.0 11.5 52.4 43.9
4 -1.8 and -1.2 80.7 88.2 0.1 1.1 62.2 66.6
Figure 6.15 shows the distributions of optimum dose selection and dose allocation
for Scenario 1. The left panel shows the OD selection and the right panel shows the
dose allocation for the two diﬀerent adaptive designs. The ﬁgures are obtained by
following Sections 5.7.1 and 5.7.2. The scenario has -0.6 as the true OD. The PK-
guided approach selects this as the OD in 62.9% of the trials compared to 54.0% by
the other approach. The designs also select -1.2 as the OD in an appreciable number
of trials. This is due to the fact that the probabilities of success at these doses are
quite close. These two doses are selected in 90.2% of the trials, while the ﬁgure
is 82.3% for the other approach. The PK-guided approach lessens the selection of
highly toxic doses as the OD. It also allocates more patients to the most eﬃcacious
doses.
The PK approach in Scenario 2 identiﬁes -0.6 as the OD in 63.1% of the trials.
Since its probability of success is close, it selects -1.2 in 26.7% of the trials. These
two doses are recommended in 89.8% of the trials. The design is very careful in
recommending toxic doses as the OD. It also treats a good proportion of cohorts
with the best dose throughout the trials. The corresponding ﬁgure for the doses -1.2
and -0.6 in the other approach is 68.1%.
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Figure 6.15: Scenario 1 with the OD at -0.6.
The dose -0.6 has been chosen in 94.8% of the trials in Scenario 3 by the PK-guided
approach. The other approach selects it in 83.1% of the trials. More than half of the
cohorts have been treated at the best dose in the simulated trials. The PK approach
avoids selecting toxic doses as the OD in a good percentage of trials.
In Scenario 4, the true OD is -1.8. But the doses -1.2 and -1.8 have probabilities of
success which are quite close. These two doses are selected in 80.7% of the trials.
The other approach selects these in 88.2% of the trials. This is the scenario where
the PK approach is not performing more satisfactorily than the other approach.
Since we put the PK constraint on the true OD, the design fails to select -1.2, which
is next to -1.8.
As we move through the scenarios, the steepness of the toxicity curve increases.
The diﬀerences in the results for diﬀerent scenarios can be related to this. We see
that gradually more patients are saved from toxic doses by the PK-guided approach.
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Figure 6.16: Scenario 2 with the OD at -0.6.
Figure 6.19 gives the relative eﬃciencies at successive stages of a trial in Scenario 1
using (6.1). Although there are ﬂuctuations at the beginning, the eﬃciency measure
stabilises at the later stages. This, in turn, means that the parameter estimates are
becoming close to the true values towards the end of the trial. Also, the associated
design points stabilise as the trial proceeds: see Figure 6.20.
Figure 6.21 shows the average numbers of cohorts used in a trial by the dose-ﬁnding
approaches. The diﬀerence in the numbers of cohorts is not signiﬁcant, since the
ﬁgures are quite similar for the two approaches. The most noticeable feature is that,
although we allow a trial to use a maximum number of 20 cohorts, the average in
all scenarios is far less. This indicates that most of the trials stop before reaching
the maximum sample size.
Table 6.7 presents the decision and sampling eﬃciencies for the scenarios, obtained
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Figure 6.17: Scenario 3 with the OD at -0.6.
using (5.18) and (5.20). The decision eﬃciencies are usually higher in the PK-
guided design than in the design which does not constrain Cmax. The largest dif-
ference between the DEs is seen in Scenario 2. Since the PK-guided design does
not recommend toxic doses as the OD many times compared to the other design,
it gives the maximum gain in decision eﬃciency. The DEs for the two designs are
close in Scenario 4. This is because the optimum dose selection is more accurate in
the other approach, and also the diﬀerence in %TD between the two designs is small.
The sampling eﬃciency for the PK-guided design is also higher than that of the
other design for all of the scenarios. However, in Scenario 4, they are quite close.
This is the case since the distribution of dose allocation in the two designs is very
similar: see Figure 6.18.
Figure 6.22 summarises the distribution of the PK parameter estimates obtained
from simulations for Scenario 1. We see some outliers in the estimates for each of
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Figure 6.18: Scenario 4 with the OD at -1.8.
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Figure 6.19: Relative eﬃciencies in a randomly selected trial from Scenario 1.
the parameters. Apart from these, the bias and variance of the estimates are small.
The distributions for the other scenarios are shown in Figures A.7-A.8. We ﬁnd
a similar behaviour of the estimates as in the ﬁrst scenario. Since the approach
utilises D-optimal time points for collecting concentrations, it ensures accuracy and
eﬃciency in parameter estimation. Figure 6.23 displays the distribution of the dose-
response parameter estimates for Scenario 1. We have considered wide uniform
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Figure 6.20: Optimal design points in a trial. The left one shows the points for the
true values of the PK parameters and the one on the right gives the points using
the current estimates.
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Figure 6.21: Average numbers of cohorts used by the two dose-allocation methods.
priors for the scenarios to allow extreme cases that might possibly occur.
Table 6.7: Decision and sampling eﬃciencies of the designs.
Scenario DE SE
PK No PK PK No PK
1 0.925 0.875 0.774 0.743
2 0.882 0.679 0.685 0.540
3 0.974 0.858 0.629 0.525
4 0.939 0.944 0.887 0.882
As a consequence, we have found outliers in the estimates of the parameters. A
similar pattern is seen for the other scenarios presented in Figures A.9-A.10. These
estimates are not as good as the PK estimates. The reason is that we have allocated
doses to the cohorts so that the estimated probability of success is maximum, rather
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Figure 6.22: Boxplots of the PK parameter estimates obtained from the simulations
for Scenario 1. The horizontal dashed lines indicate the true parameter values.
than allocating doses for which the eﬃciency in parameter estimation is maintained.
Moreover, the dose-response parameter estimates obtained from the PK-guided ap-
proach are similar to those from the other approach. These indicate that consider-
ation of PK data is not improving the estimates of the dose-response parameters.
The percentages of the trials that stopped in the up-and-down stage are 15, 10, 3
and 8, respectively, for the four scenarios. The ﬁgures are almost identical for the
two approaches. Scenario 3 has the lowest percentage, since the probabilities of
toxicity at the early doses are very low compared with the other scenarios.
We have learnt from this example that a dose-ﬁnding design can be made more
eﬃcient if we can allocate doses to the cohorts entering a trial around a target value
for Cmax. Of course, the gain in eﬃciency depends on the underlying scenario. The
gain is maximum in a scenario with a steep toxicity curve. Along with dose-response
data, both examples have utilised pharmacokinetic information. They are similar
in both cases apart from the diﬀerent PK constraint. The intention is to keep the
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Figure 6.23: Boxplots of the dose-response parameter estimates obtained from the
simulations for Scenario 1. The horizontal dashed lines indicate the true parameter
values. For each parameter, the left boxplot corresponds to the design which takes
into account Cmax and the right boxplot to the one which ignores it.
method a ﬂexible one, so that one can constrain either of the PK parameters AUC
and Cmax, depending on the availability of the information and the interest of the
researchers.
6.5 Sensitivity Analysis
In this section, we present the sensitivity analysis of the proposed design to the
diﬀerent parameters via simulation studies. We restrict ourselves to Scenario 1 in
Example 2, since checking all of the scenarios involves considerable computational
time. However, we would expect similar results for the other scenarios. There are a
number of parameters in the design that one can vary. However, we are particularly
interested in the most crucial ones. These include the priors for the PK and dose-
response parameters, and also the target value for the maximum concentration.
Each case is investigated through 1,000 simulated trials. All other parameters are
kept ﬁxed during the simulations to see the eﬀect of the parameter being varied.
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6.5.1 Priors for Dose-Response Parameters
The prior distribution plays an important role in Bayesian estimation of parameters.
Here, we express the uncertainty about the parameters in terms of a probability dis-
tribution and combine this with the new data to form the posterior distribution.
Then we ﬁnd the posterior means of the parameters, which we call the Bayesian
estimates. It is always a good idea to assess the sensitivity of the estimates to the
assumed prior values. To ensure the prior has less eﬀect and the data dominate,
we use non-informative priors in both examples presented in Sections 6.3 and 6.4.
More speciﬁcally, we use the uniform distribution over some sensible range of values
as the prior. The ranges are chosen in such a way that they encompass any possible
extreme case.
In the simulation studies in Section 6.4, we assumed priors with a margin of 3 on
either side of the true values. These priors are wide enough. To see what happens
in the presence of narrower priors, we plan to employ priors which have margins of 2
and 1. The true parameter values in Scenario 1 are ϑ = (0.0, 1.0, 4.0, 2.0, 3.0, 3.0)T .
The margin 3 allows the parameter space Θ˜ to have the values −3 < ϑ1 < 3,
−2 < ϑ2 < 4, 1 < ϑ3 < 7, −1 < ϑ4 < 5, 0 < ϑ5 < 6 and 0 < ϑ6 < 6. Similarly, for
margin 2, the parameter space consists of the values −2 < ϑ1 < 2, −1 < ϑ2 < 3,
2 < ϑ3 < 6, 0 < ϑ4 < 4, 1 < ϑ5 < 5 and 1 < ϑ6 < 5. The margin 1 gives the values
−1 < ϑ1 < 1, 0 < ϑ2 < 2, 3 < ϑ3 < 5, 1 < ϑ4 < 3, 2 < ϑ5 < 4 and 2 < ϑ6 < 4.
The possible scenarios that might occur at the boundaries of these priors are shown
in Figure 6.24. The graphs in the right panel are fairly similar and also similar to
the original scenario. We have found that the graphs keep a similar shape for any
margin above the true values of the parameters. Although the graphs in the left
panel are diﬀerent in shape, if we increase the margin further, they converge to a
shape where the marginal probability of toxicity decreases as dose increases. This
contradicts the usual form of toxicity curves. Also, in all of the current left-panel
graphs, toxicity decreases initially and then increases with dose. Moreover, since
there are six parameters, any change in one of the parameters will lead to a change
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in the shape of the curves. With all of these considerations, the set of priors that
we are going to use can be regarded as vague enough.
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Figure 6.24: Possible dose-response curves for margins of 3, 2 and 1 on either side of
the true parameter values. The left panel represents the cases where the parameter
values are below the true values and those in the right panel represent the cases
where the parameter values are above the true values.
Figure 6.25 shows the distributions of optimum dose selection and dose allocation
for the PK-guided design for various prior distributions. Table 6.8 summarises the
results. All of the performance measures improve as the margin decreases.
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Figure 6.25: Optimum dose selection and dose allocation under diﬀerent prior values
for Scenario 1 in Example 2.
Table 6.8: Sensitivity of the design to the assumed priors for the dose-response
parameters in Scenario 1 that takes into account PK information.
Margin %BD %TD %AD DE SE
3 62.9 2.0 37.5 0.925 0.774
2 71.6 0.6 42.5 0.977 0.799
1 82.3 0.0 47.9 0.989 0.803
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Table 6.9: Sensitivity of the design to the assumed priors for the dose-response
parameters in Scenario 1 that ignores PK information.
Margin %BD %TD %AD DE SE
3 54.0 5.6 32.6 0.875 0.743
2 71.3 0.2 41.3 0.956 0.737
1 81.7 0.0 49.0 0.971 0.780
The correctness in the optimum dose selection (%BD) increases as the ranges of the
parameter values decrease. Fewer trials recommend a dose for further studies which
carries the probability of toxicity above the acceptable level. The percentage of such
trials completely disappears for a margin of 1. Also, the allocation of the best doses
to the cohorts over the trials increases quite signiﬁcantly for the dense priors. The
decision and sampling eﬃciencies much improve as we choose narrower ranges. As
%BD and %AD increase and %TD decreases for such a choice of priors, it is obvious
that DE and SE will improve. The trend in improvements is similar in Table 6.9,
which summaries the results for the design without the PK constraint. Though not
presented, we have found the similar distributions for the optimum dose selection
and dose allocation to those presented. On the whole, the results show that the
eﬃciency of the proposed adaptive design can be improved by the choice of more
appropriate priors for the dose-response parameters.
6.5.2 Priors for PK Parameters
Since our PK model is non-linear in the parameters, the Fisher information matrix
depends on them. Therefore, in the search for the D-optimal time points, we need
to assume some prior values for the parameters: see Section 3.5.2. We start with
some best guess about the parameters. However, once the estimates are available
from the trial, we use them to ﬁnd the optimal time points. Also, the maximum
likelihood estimation procedure for the PK parameters requires some initial values.
To see whether the assumed prior values have an impact on the design, we conduct
some simulation studies.
Six sets of prior values are investigated in the simulation studies. Each set consists
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of the mean PK parameters which are some multiple of the standard deviation away
from the true values. The main idea is to make them as far away as possible to see
the impact on the design when we have complete ignorance about the parameters.
The ﬁrst set assumes that the mean PK parameters β are 3 standard deviations
below the true ones. The variance components and error variance are assumed to
Table 6.10: PK parameter values for the sensitivity analysis.
Set V ke ka σ
2
1 σ
2
2 σ
2
3 σ
2
1 0.80 0.02 0.20 0.040 0.000025 0.0025 0.0000125
2 1.20 0.03 0.30 0.053 0.000033 0.0033 0.0000166
3 1.60 0.04 0.40 0.080 0.000050 0.0050 0.0000250
4 2.40 0.06 0.60 0.080 0.000050 0.0050 0.0000250
5 2.80 0.07 0.70 0.053 0.000033 0.0033 0.0000166
6 3.20 0.08 0.80 0.040 0.000025 0.0025 0.0000125
be one quarter of the true values. The second set contains the mean parameters
which are 2 standard deviations below the true values, whereas the variance compo-
nents and error variance are one third of the true values. In a similar way, we have
the third set of prior values. In the fourth set, the PK parameters are one standard
deviation above the true values, with the variance components and error variance
one half of the true values. Similarly, we construct the ﬁfth and sixth sets of priors.
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Figure 6.26: Design points obtained at various sets of prior values following the
administration of the lowest dose to a cohort.
Table 6.10 gives the six sets of values that we obtain. The D-optimal time points
obtained for the various prior values are shown in Figure 6.26. Some of the points
corresponding to diﬀerent sets are almost identical and therefore we see three points
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instead of four. It seems that the time points change with the diﬀerent priors.
Therefore, emphasis should be given to the priors. We do this by replacing the prior
values with the current knowledge in advance of a trial.
Table 6.11: Sensitivity of the design to the assumed priors for the PK parameters
in Scenario 1.
Set %BD %TD %AD DE SE
1 65.5 2.1 39.8 0.932 0.779
2 65.5 2.4 39.5 0.928 0.776
3 67.1 0.8 39.9 0.951 0.781
4 66.1 1.1 39.5 0.941 0.775
5 65.1 1.1 38.5 0.952 0.786
6 62.9 2.0 37.5 0.925 0.774
Table 6.11 summarises the simulation results obtained under diﬀerent sets of priors.
It is evident from the ﬁgures that the design is less sensitive to the assumed prior
values for the PK parameters. The small variability that is seen in the numerical
results is mainly due to randomness. Set 6 is the one that has been used in the
original simulation study for Example 2. Although the priors have an impact on
optimal design, they do not have an impact on the adaptive design. This might
be due to the fact that the learning through gathering information in the ﬁrst few
cohorts is substantial and it stabilises the estimates.
6.5.3 Target Maximum Concentration
The implementation of the design presented in Example 2 requires a target value for
the maximum concentration. We set that target at the true optimal dose. That is,
we obtain the target Cmax using (3.35) for the true values of the OD and the mean
PK parameters β. However, the target may be misspeciﬁed, and, therefore, this
section is devoted to assessing the impact of such misspeciﬁcation on the design.
Other than taking it at the true OD, we will set this target at the doses which are
one and two levels away. Moreover, we check it for Scenario 1 only. Checks for the
other scenarios are possible using the same idea.
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The true optimal dose in Scenario 1 is -0.6. The other doses that we are interested
in are -1.8, -1.2, 0.0 and 0.6. As discussed earlier, we set the target Cmax at these
doses in separate runs of the trials.
Table 6.12: Sensitivity of the design to the assumed target for Cmax in Scenario 1.
Dose %BD % of 3-BD %TD %AD DE SE
-1.8 0.8 10.5 2.0 3.0 0.672 0.627
-1.2 0.8 85.4 2.0 3.8 0.885 0.722
-0.6 62.9 91.2 2.0 37.5 0.925 0.774
0.0 59.4 91.6 0.6 34.8 0.935 0.790
0.6 55.3 85.9 4.0 33.4 0.889 0.756
No PK 54.0 85.1 5.6 32.6 0.875 0.743
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Figure 6.27: Optimum dose selection and dose allocation when the target Cmax is
taken at the doses below the true optimum dose.
Table 6.12 contains a summary of the simulation results obtained from 1,000 trials.
Figures 6.27-6.28 present the distributions of the recommended doses and allocated
doses to the cohorts under diﬀerent choices of target values. When targets are taken
at the doses below the true optimum dose, all performance indicators give poor val-
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Figure 6.28: Optimum dose selection and dose allocation when the target Cmax is
taken at the true optimum dose and the doses above it.
ues. In such cases, the design identiﬁes the optimum dose very poorly. Although
the decision eﬃciency for -1.8 is poor, the measure provides a satisfactory value for
-1.2. This is because of the fact that the probabilities of a successful outcome at
doses -1.2 and -0.6 are quite close.
The scenario has three doses -1.2, -0.6 and 0.0 for which the probabilities of success
are 0.73, 0.77 and 0.71, respectively. Therefore, we create a column % of 3-BD
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in Table 6.12 showing how frequently these were recommended for further studies.
As the target moves to the doses above the true OD, correct identiﬁcation of the
optimum dose is less likely. Also, fewer patients are allocated to the true OD. % of
3-BD gives a better picture of the recommended doses. Although we have a very
small ﬁgure for %BD corresponding to -1.2, % of 3-BD gives a very high ﬁgure. This
means that many of the trials recommended doses -1.2 and -0.6. There is a similar
behaviour for dose allocation. As a result, we have fairly large values for DE and SE.
The DE corresponding to dose 0.0 is higher than that at dose -0.6, since the above
three doses are selected more often than for the original design. Similarly, for dose
0.0, SE is slightly higher and that is evident from the relevant distribution of dose
allocation in Figure 6.28. It is important to note that the performance indicators are
more sensitive when the design considers the target Cmax at a dose below the true
OD. However, it is less sensitive when the dose is above the true OD. All of these
results demonstrate the need for care in setting the target value for the maximum
concentration, although there is some margin for misspeciﬁcation.
6.6 Example 3
This example tries to explore the behaviour of a design which uses the combined
criterion in Section 5.3.3 for dose optimisation. As mentioned earlier, the criterion
is intended to serve two purposes: allocation of the most eﬃcacious doses to the
cohorts and improvement in the estimation of the dose-response parameters. We
conduct simulation studies, details of which are given in the following section, to
investigate whether the intended objectives are met.
6.6.1 Simulation Settings
Here, we use the continuation ratio dose-response model introduced in Section 4.2.
The dose-response scenarios in Figure 4.1 are investigated. The same scenarios have
been used as in Example 1 and more details of them are available in Section 6.3.1.
We assume that the acceptable level for the probability of toxicity is γ = 0.2.
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The design follows the general algorithm described in Section 5.2. Each trial assigns
the lowest available dose of 0.5 mg/kg body weight to the ﬁrst cohort of patients.
Escalation or de-escalation of doses to the ﬁrst four cohorts is based on the up-and-
down design presented in Section 5.2. Since the Fisher information matrix in (4.9)
is singular, to have a non-zero value for the determinant of M(ξk, ϑˆk) in Section
5.3.2 immediately after the up-and-down stage, we need to ensure that at least two
of the doses allocated to the ﬁrst four cohorts are diﬀerent.
The design does not use any PK constraint and therefore only requires dose-response
outcomes to be simulated. These are drawn from a trinomial distribution with the
true probabilities corresponding to a dose obtained for the respective scenario. Once
the trial passes the up-and-down stage, the model-based procedure starts. This re-
quires estimation of the dose-response parameters and assignment of the best dose
to the next cohort. The Bayesian estimates of the dose-response parameters are
obtained at each steps after the up-and-down stage, using the same set of priors as
in Example 1.
The penalised combined criterion in (5.9) is utilised to assign doses at each step of
a trial. As the dose-optimisation criterion to be used already penalises observations
for low eﬃcacy or high toxicity or both, not additional constraint is imposed. The
rules presented in Section 5.6 are used to stop a trial. Here, the optimum dose is
deﬁned as the dose that has been repeated r times. However, for the trials that
utilise the maximum number of cohorts m, the optimum dose is deﬁned as the one
for which the estimated probability of success is maximum, subject to the constraint
that the estimated probability of toxicity at that dose is no more than γ. Utilisation
of the maximum number of cohorts means that the trial came through a reasonable
number of steps. Consequently, we can expect the estimates of the parameters to be
reliable, as the determinant of the FIM is in the optimisation criterion. Therefore,
we can use these estimates to predict the dose-response curves more accurately to
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obtain the dose which is best in terms of the probabilities of success and toxicity.
We set r = 6 and m = 20 in our simulations.
The penalty function to be used in the simulation study was introduced in (5.7).
It has the control parameters CS and CT . To motivate on the values for these
parameters, we conduct an investigation described below.
Optimum Values for CS and CT
Figure 4.1 shows the dose-response scenarios that we are going to consider in this
example. In Scenario 1, the true optimal dose lies at the beginning. Since the
probability of success is low and the probability of toxicity is high at the higher doses,
the penalty resulting from high CS and CT values will restrict the dose selection
from the end of the dose region: see Figure 6.29. In Scenario 2, success is low at the
beginning and toxicity is high at the higher doses. Therefore, penalising doses from
both ends will keep the dose selection in the middle, where the true optimal dose
lies. The success curve in Scenario 3 is of a ﬂat type. Even at the early doses, suc-
cess is quite high, and toxicity at the higher doses is not as high as in the previous
two scenarios. As a result, the penalty for taking observations from both ends is
smaller than that for the previous scenario. However, it still keeps the dose selection
in the middle of the dose region. The true optimal dose in Scenario 4 lies at the
end of the dose region. The probabilities of success and toxicity remain very low for
more than half of the available doses. Also, we do not have any dose for which the
probability of toxicity is very high. Penalising observations for low success and high
toxicity gives very high penalty values for most of the early doses in this scenario
and thereby will keep the dose selection from the upper end of the dose region. To
summarise, for all of our scenarios, we plan to penalise for taking a dose which is
either low oﬃcious or highly toxic or both.
Having decided on the non-zero values for the control parameters, we assume that
they take the same value, that is, CS = CT = C. Since a non-zero value of C will
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Figure 6.29: Penalty function for the four scenarios assuming CS = CT = 1.
keep patients away from low eﬃcacious or highly toxic doses, we need to ﬁnd its
optimum value. We have tried various values of C. Figures 6.30-6.32 depict some
features of the resulting designs to guide the choice for C.
In each case, the results are based on 200 simulations of the respective scenario. In
Figure 6.30, we have the percentages indicating how often toxic doses are allocated
to the patients. It also shows the percentages of toxic doses selected as the OD.
The percentages for correct identiﬁcation of the OD are displayed too. It reveals
that, as the value of C increases, fewer patients are treated with toxic doses. In
all of the scenarios, there is a fall in the percentage of toxic doses as the OD when
the value of C increases from 0 to 1. It increases and then decreases for the other
values of C. However, it levels oﬀ for Scenario 3 at C = 1. As C increases, the
percentage for correct identiﬁcation of the OD usually increases initially. It then
levels oﬀ in Scenario 3 and gradually decreases in Scenario 1. The corresponding
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Figure 6.30: Percentage of cohorts treated at the toxic doses during the trials,
percentage of toxic doses recommended as the optimum dose and percentage of
trials with the correct OD selection. Diﬀerent values for the control parameters CS
and CT have been used assuming CS = CT = C.
change in Scenario 2 is very slight. Since Scenario 4 is one where we do not have
any dose for which the toxicity level is higher than the acceptable level, although we
cannot draw the ﬁrst two curves related to toxic doses, we can show the percentage
for correct identiﬁcation of the OD. All of these results suggest that C = 1 could be
a reasonable choice.
Figures 6.31-6.32 present the bias and mean square error for diﬀerent scenarios. As
C increases, one would expect the penalised D-optimum design to be further away
from the D-optimum design. Consequently, the bias and mean square error would
also increase. This was found to be true on some occasions, but not always. Small
number of simulations could be a possible reason. Therefore, together with the
previous results, we decide to use C = 1 in this example.
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Figure 6.31: Biases of the parameter estimates for diﬀerent choices of control pa-
rameters CS and CT assuming CS = CT = C.
6.6.2 Numerical Results
With the control parameter values set to 1, we run the penalised combined criterion
for each of the scenarios. One thousand simulated trials are generated in each case
for various values of the weight a. It is important to note that, when a = 0, the
dose selection is based on the probability of success only with no PK constraint. On
the other hand, the criterion reduces to the penalised D for a = 1: see (5.9). Tables
6.13-6.16 illustrate the simulation results.
Table 6.13: Combined criterion for Scenario 1.
a %BD %TD %AD DE SE
0.0 53.5 31.8 31.9 0.681 0.516
0.2 64.0 27.8 35.2 0.722 0.515
0.4 74.0 21.9 37.8 0.780 0.478
0.6 86.0 12.6 42.0 0.873 0.502
0.8 94.3 4.7 43.8 0.952 0.513
1.0 81.1 12.3 32.0 0.877 0.377
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Figure 6.32: Mean square errors of the parameter estimates for diﬀerent choices of
control parameters CS and CT assuming CS = CT = C.
Table 6.13 shows the results for Scenario 1. The penalised D-criterion gives better
results than maximisation of the probability of success. It is seen for all measures
apart from SE. This is expected, as the criterion based on the maximisation of the
probability of success only is deﬁned so that more patients are treated during the
trial with eﬃcacious doses more often. The penalised D-optimum criterion does not
take care of this. The design performs the best overall when a = 0.8. Here, the
design can identify the true optimum dose 0.5 most accurately. Only a few trials
gave toxic doses for further study in the next phase. About 44% of the cohorts
are treated at the OD throughout the trials. On the whole, the combined criterion
enhances the performance for Scenario 1.
The results for Scenario 2 for diﬀerent values of a are compared in Table 6.14. The
best result in terms of all the performance indicators is attained at the weight 0.
However, there is little variation in the performance for the values of a between 0
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and 0.6. The only noticeable diﬀerence is observed for a = 1. For this choice of
weight, the design identiﬁes the OD less accurately compared with the other weights.
Fewer cohorts are treated with the best dose as the weight increases and there is
also a sharp drop when the weight is 1. The eﬃciency measures DE and SE are
both considerably smaller in this case.
We obtain similar results for the weights ranging between 0 and 0.8 in Scenario 3. As
in the previous scenario, we observe a decreasing trend in the dose allocation, with
a sharp drop at weight 1. All of the performance values indicate that the penalised
D is performing poorly compared to the other cases. However, it might be worth
combining the criteria in this case, with a in [0.2,0.8].
Table 6.14: Combined criterion for Scenario 2.
a %BD %TD %AD DE SE
0.0 68.0 7.0 36.2 0.913 0.638
0.2 66.0 7.8 35.6 0.903 0.629
0.4 66.0 7.8 35.3 0.901 0.622
0.6 64.2 7.4 34.0 0.905 0.616
0.8 57.6 8.3 30.4 0.888 0.590
1.0 49.7 8.1 16.2 0.843 0.493
Table 6.15: Combined criterion for Scenario 3.
a %BD %TD %AD DE SE
0.0 84.5 2.2 49.5 0.968 0.842
0.2 86.9 1.7 48.9 0.973 0.838
0.4 84.6 2.2 47.6 0.969 0.824
0.6 85.4 2.6 45.8 0.964 0.801
0.8 85.6 1.1 42.0 0.971 0.771
1.0 62.1 3.8 22.6 0.899 0.652
The optimum value of a in Scenario 4 is 0.4, since both DE and SE attain their
largest values. However, looking at the ﬁgures for the best dose recommendation
and allocation, it can be claimed that the design is performing similarly for the
weights between 0.4 and 0.8. That is, higher values of a gives the design the best
performance. But, as in Scenarios 2 and 3, the penalised D-optimum design is not
performing well in this scenario.
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When a = 0, for the ﬁrst three scenarios, the performance values are consistent with
the ones obtained for the case 'No PK' in Tables 6.1-6.2. Although the combined
criterion does not consider the toxicity constraint in Section 5.4 during dose alloca-
tion, the ﬁgures are very similar. However, for a = 0 in Scenario 4, the results are
better than those that we obtained earlier. Since the optimum dose is the last dose
in the dose region, the toxicity constraint often restricts us from choosing it for the
cohorts. This can be regarded as one possible reason for having better results than
before.
Table 6.16: Combined criterion for Scenario 4.
a %BD %TD %AD DE SE
0.0 69.5 0 27.0 0.899 0.485
0.2 69.5 0 27.3 0.888 0.484
0.4 73.4 0 28.2 0.914 0.488
0.6 72.0 0 28.2 0.893 0.481
0.8 75.0 0 29.6 0.901 0.481
1.0 47.3 0 26.4 0.784 0.460
It is worth mentioning that SE is large when the weight is 0 and small when the
weight is 1 for Scenarios 1-3. This is because maximisation of probability of suc-
cess allocates most of the cohorts to the most eﬃcacious doses compared to the
D-criterion. Even though we penalise the D-criterion for low eﬃcacious or high
toxic doses, the improvement in SE is not that noticeable. In Scenario 4, the SE
values are close to each other, apart from the one corresponding to a = 1. This is a
scenario where we do not have any dose for which the probability of toxicity exceeds
the acceptable level, but it has many doses for which the probability of success is
very low. Therefore, the diﬀerences among the SEs are not very substantial for this
scenario.
We have looked at three approaches for dose ﬁnding in our examples. In one ap-
proach, the intention is to allocate doses to the patients that are best in terms of
current knowledge. This kind of approach is known as the "best intention" approach
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in the literature. The other approach targets the most eﬀective gathering of infor-
mation and is based on the theory of optimal design. The third approach tries to
make a trade-oﬀ between the two. Best intention designs are ethically attractive, as
they take care of the patients, but, unlike the one based on optimal design, it has
limitations in terms of convergence. Since here we have small numbers of cohorts,
the convergence property of the D-optimum design is not that important. However,
combining the two approaches, on the whole, may improve the performance of the
adaptive design.
6.7 Discussion of the Results
This chapter has made detailed simulation studies to learn about the adaptive de-
signs. Two classes of designs are presented: one considers eﬃcacy and toxicity end
points and the other, along with these outcomes, also considers pharmacokinetic
information. Three examples are introduced in this context and the major results
are discussed below.
The design presented in Section 6.3 is conceptually similar to that of Zhang et al.
(2006), but their design does not incorporate pharmacokinetic information. They
ﬁnd a dose that maximises the diﬀerence between the estimated success probability
and λ times the estimated toxicity probability, given that the estimated toxicity
probability is smaller than a pre-speciﬁed level, where 0 ≤ λ ≤ 1. The value of λ
can be varied to include toxicity in the criterion and no general recommendation is
made about its value. But, in many real scenarios, such a diﬀerence with a non-zero
λ may lead to doses which are not optimum. Scenario 3 in Example 1 is such a case,
where the diﬀerence at some sub-optimal doses is the same as that at the optimal
dose. Therefore, we decide to use λ = 0. The decision also helps to avoid double
dependence on the probability of toxicity.
In this example, along with dose-response outcomes, we have considered an im-
portant PK measure, AUC, and its inter-patient variability in the dose escalation.
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The main purpose of this study was to investigate the role of PK measures in dose
ﬁnding, and, by means of detailed comparisons, we showed that utilising the PK
information can be very beneﬁcial.
The simulation results from four diﬀerent dose-response scenarios indicate that the
incorporation of such measures can improve the accuracy of dose-ﬁnding studies. It
is also shown that the method is capable of limiting overdosing by a considerable
amount depending on the location of the OD. The proposed PK-guided approach
can therefore be used as a reliable dose-ﬁnding procedure in situations where more
careful escalation is essential to avoid toxicity. However, we have found the design
to be sensitive to the target AUC, but less sensitive to the dose-skipping constraint.
Section 6.4 presents the second example with a diﬀerent set of PK and dose-response
models. The dose-optimisation criterion and the toxicity constraint used are the
same as in Example 1. However, this time the PK constraint is on the maximum
concentration. The reason for using the maximum concentration is that often clini-
cians are more interested in it than the AUC because of the simplicity in comparing
it with a threshold to decide on the nature of the dose-response outcome. The inter-
patient variability in Cmax is also taken into consideration in the dose escalation.
Results from the simulation study of four plausible dose-response scenarios show a
gain in the eﬃciency of dose ﬁnding due to considering additional PK information.
We can identify the optimum dose accurately and can allocate most relevant doses
to the cohorts in a trial by using the proposed design. It also restricts us from
recommending a toxic dose as the optimum dose for further study in the next phase.
We achieve similar gains in both examples when PK information is used. It is im-
portant to mention that, in both cases, we obtained a small bias and mean square
error for the PK parameter estimates. This happens as the D-criterion has been
employed to obtain the time points to collect blood samples to measure the concen-
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tration of the drug. The bias and mean square error of the dose-response parameter
estimates obtained using the two approaches are very similar. Therefore, consider-
ation of the additional pharmacokinetic information is not improving the quality of
the dose-response parameter estimates, but rather it is helping us to ﬁnd the best
dose.
To assess whether the observed diﬀerences between the PK-guided design and the
other design are appreciable, we present conﬁdence intervals for the various measures
in Tables A.1 and A.2. Non-overlapping intervals are found in most cases, which
conﬁrms our claim regarding the PK-guided design. Because of time constraints,
the number of simulations was restricted to 1,000 in both examples. We expect that
a larger number of simulations would not change the estimated values very much,
and, therefore, we would obtain similar results for optimum dose selection and dose
allocation. However, as the standard error of the proportions would decrease with
the increased number of simulations, shorter conﬁdence intervals for the measures
would be obtained. That is, the signiﬁcance of our results would then be even more
pronounced.
Sensitivity analyses of the designs to the diﬀerent parameters are presented in Sec-
tion 6.5. Since the computations are very time consuming, we restrict ourselves to
Scenario 1 in Example 2. However, investigation for the other examples and scenar-
ios will be straightforward.
Section 6.5.1 shows the results for the assumed priors of the dose-response param-
eters. It is seen that, as the priors become narrower, the eﬃciency of the method
increases. That is, the method can identify the optimum dose more accurately and
does not recommend toxic doses as the optimum dose very often. Also, more pa-
tients are allocated to the best doses throughout the trials. This means that the
more one knows about the scenario, the better the chance of a successful trial. A
summary of the results is also presented for the design which does not consider the
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constraint on Cmax in Table 6.9. It is observed that both methods produce similar
results as the priors become more dense. Therefore, the additional constraint on
the PK parameter is useful in the presence of a vague prior. If a reliable prior is
available, the method itself is able to produce reliable results, even if we do not
consider pharmacokinetic information.
The priors for the PK parameters are mainly used to initiate the ﬁnding of D-
optimal time points and the maximum likelihood estimates of the parameters. Once
estimates from the trial data are available, they are used. The sensitivity of the
design to the assumed priors for the PK parameters is shown in Section 6.5.2 for
six sets of values. The results are very similar to each other. Therefore, we can
conclude that the design is not especially sensitive to the priors. The whole idea
was to see what happens in the presence of vague priors. If the initial values for the
parameters are far away from the true ones, these may lead the PK sampling times
to be diﬀerent initially, but that will not have a great impact on the optimum dose
ﬁnding for the next phase.
Section 6.5.3 contains the simulation results to check the sensitivity of the design to
the assumed value of Cmax. The design is much more sensitive when the target is
taken at a dose below the true optimum dose. The degree of sensitivity is less when
the target is at a dose above the true optimum dose. Also, the results are still better
when we do not have any PK constraint. On the whole, the design is sensitive to the
target value of the maximum concentration. Therefore, to implement the proposed
PK-guided design, one needs to carefully select the target value, since the future of
the trial depends highly on it.
We have explained in Section 1.1.1 how the response following a dose depends on
the concentration of the drug. Although concentration is a function of the dose,
for a ﬁxed value of the latter, due to population variability, we can obtain diﬀerent
values of the former for diﬀerent patients. The proposed PK constraints in (5.11)
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and (5.12) take into account the concentration along with the inter-patient vari-
ability. Since a population D-optimum design is used to collect blood samples, we
achieve precise estimates of the parameters. The constraints are deﬁned in terms
of the population mean parameters and their standard errors, as shown in Section
3.8. Although the constraints are working like a brake on dose escalation, they are
adapted during the trial and work in a ﬂexible way by modifying the strength of
restriction. Other constraints such as the toxicity limit (5.10) or the dose-skipping
constraint work diﬀerently. They are not ﬂexible and are purely for safety reasons.
For instance, the constraint of not skipping more than one dose level at a time is
used in both PK-guided and the other designs: see Section 5.3. The impact was re-
ported in Section 6.3.2. The results in Tables 6.4 and 6.5 tell us that, other than the
diﬀerence in dose allocation, the dose-skipping constraint does not have a noticeable
eﬀect on optimum dose selection. So, the gain that we claim in the presented designs
is largely due to the PK constraint. The PK constraint and the constraint on dose
skipping work diﬀerently. The dose-skipping constraint aims to minimise jumps over
multiple doses. Although it slows down the escalation procedure to make it safer,
this may still lead to unacceptably toxic doses being applied. The PK constraints are
intended to limit such occurrences, as well as to choose the best dose more accurately.
Although PK-guided designs are found to be sensitive to target values, we have no-
ticed that they still outperform the other designs in the cases where the target is at
the dose above the true OD: see Tables 6.3 and 6.12. As the PK-guided designs are
sensitive, we recommend using them in situations where such targets can be reason-
ably well assessed. With such targets, people would expect improved performance
of the design, and we have shown it numerically in our work.
PK information is commonly collected in early clinical trials and it is often analysed
for the purpose of dose selection. Here, we propose a systematic method with a
two-fold aim: ﬁrst, to obtain the best dose level for further study in the next phase
with the minimum chance of toxic responses during the trial, and, second, to obtain
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the most eﬃcient estimates of the population PK parameters. The second goal is
achieved by using the population D-optimum design for the sampling times. A PK-
guided trial will make sense only if the PK information is accurate and we assure
this by the choice of design.
The results obtained in Section 6.6 indicate that the proposed combined criterion is
a promising one in dose-ﬁnding studies. It has been found that, for Scenarios 1 and
4, the combined criterion produces the best results for large values of the weight.
Dose-optimisation criteria like maximisation of the probability of success and the
penalised D-criterion are not that attractive for these scenarios. For Scenarios 2
and 3, there is not much diﬀerence between the results for the combined criterion
and those for the criterion that maximises the probability of success. However, as
we expect to obtain better estimates of the dose-response function, it would be good
to use the combined criterion in these scenarios too. We have also found the com-
bined criterion to always outperform the penalised D-criterion. Except in Scenario
1, maximisation of the probability of success is found to produce better results than
the penalised D-criterion.
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Chapter 7
Conclusions and Future Work
The development of a new drug product is a lengthy and costly process. Since a
lengthy development time is not very well accepted, continuous eﬀorts have been
made by researchers to shorten it. As a consequence, adaptive dose-ﬁnding designs
are available in the literature to minimise the drug development time and costs. The
main essence of an adaptive design is that the dose level to be used for the next
patient depends on the outcomes obtained from the previous patients who have al-
ready received diﬀerent doses from the dose region.
Although many adaptive designs are available, we believe that there is still scope for
further improvements. The whole purpose of our research has been to develop a ﬂex-
ible model-based design to ﬁnd the optimum dose more often without exposing many
patients to either subtherapeutic or toxic doses. Furthermore, if recommended, by
applying the population D-optimum design for blood sampling, the method allows
us to eﬃciently estimate the population PK parameters, and, also to use the ﬁtted
PK models to enhance the dose-ﬁnding studies.
7.1 Conclusions
The expressions derived in Chapter 3 for measuring the inter-patient variability in
the area under the concentration curve and the maximum concentration are gen-
eral. The methodology can be adapted for any underlying pharmacokinetic model.
People researching in this area often use a non-parametric approach to ﬁnd these
quantities. But that requires collecting too many blood samples to measure the
concentration of the drug. Even if the AUC and Cmax are obtained from such data,
there is no straightforward method to assess the inter-patient variability. In that
way, the proposed method is very ﬂexible. The use of the D-optimum design will
ensure the eﬃciency in parameter estimation with fewer blood samples. This will
lead eﬃcient estimation of the area under the concentration curve and the maximum
concentration, and also their inter-patient variabilities.
Chapter 4 has the continuation ratio and Cox models, which we use to model the
probabilities of the dose-response outcomes. It has been shown that the associated
Fisher information matrix in each case is singular. Although other work mentions
the singularity, there are no explicit results for the information matrices. The an-
alytical forms will reduce the time for any optimisation problem involving these
matrices. Also, knowing the rank of the FIM tells us how many diﬀerent dose levels
are necessary to ensure non-singularity of the matrix.
The essence of the methodology presented in Chapter 5 is that, following the assign-
ment of the current best dose to a cohort of patients, the dose-response outcomes
are observed. The algorithm runs following an up-and-down design for the initial
four cohorts. The up-and-down stage need not be exactly for four cohorts. Since
the ranks for the continuation ratio and Cox models are 2 and 3, respectively, to
implement the combined criterion, we have to run the up-and-down design so that
at least 2 or 3 diﬀerent doses are assigned to the cohorts. Therefore, we have set
it as four to keep it general. Once the trial is past the up-and-down stage, the
dose is selected for each cohort based on a chosen dose-optimisation criterion and
constraints evaluated at the current estimates of the model parameters. If we plan
to incorporate pharmacokinetic information, we also need to measure the concen-
tration of a drug in the blood at the sequentially obtained locally D-optimal time
points after each assignment of dose. The algorithm, dose-optimisation criterion
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and constraints presented in this chapter are general. The criterion that maximises
the estimated probability of success is ethical, since the current knowledge about
success is employed in dose escalation. The penalised D-criterion gathers informa-
tion so that the variability in the parameter estimates is minimised. The combined
criterion provides a bridge between these two. All of the presented methodology can
be applied to any dose-response and pharmacokinetic models.
To study the design properties under diﬀerent dose-optimisation criteria and con-
straints, we have introduced three diﬀerent examples in this thesis. The ﬁrst exam-
ple is a one-compartment PK mixed-eﬀects model with bolus input and ﬁrst-order
elimination and a continuation ratio dose-response model. In this case, the dose-
optimisation criterion is the maximisation of the estimated probability of success
with constraints on toxicity and the area under the concentration curve. The sec-
ond example assumes the Cox model for binary eﬃcacy and toxicity responses.
This is accompanied by a one-compartment PK mixed-eﬀects model with ﬁrst-order
absorption. The dose-optimisation criterion employed is the maximisation of the
estimated probability of success with constraints on toxicity and the maximum con-
centration. The last example utilises the penalised combined criterion for ﬁnding
doses for each successive cohort in a trial. This example is based on the continuation
ratio model for trinomial dose-response outcomes. Unlike the other examples, here
we apply the criterion without any additional constraint, since it utilises a penalty
function to address the issue of low eﬃcacy or high toxicity.
We have developed code to conduct all of the computations in R. The code is written
so that it can be applied to other dose-response models. But, of course, that will
require us to deﬁne any such model in R. It is important to note that the part of
the code that deals with the D-optimal time points is based on the package PFIM
3.2. Since the package can work with other PK models from the literature, it will
not be diﬃcult to extend the methodology to those models.
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Simulation studies for various plausible dose-response scenarios in the diﬀerent ex-
amples show that the designs are able to identify the optimum dose accurately. They
limit toxic doses as the optimum dose by a considerable amount and assign the most
relevant doses to the cohorts during a trial. We have also seen that the eﬃciency of
a dose-ﬁnding design can be increased if it is possible to assume a target value for
the AUC or Cmax. Finally, we can conclude that the presented designs are eﬃcient
and ethical, and can be used as reliable dose-ﬁnding procedures.
Implementation of the PK-guided approach requires a reliable value for the target
AUC and Cmax. Since we did not have one for our examples, for the simulations,
we set the target value as the one obtained for the true PK parameters and the
true OD. In real trials for new drugs, it may be elicited from the experiences of
the clinicians. Previous studies of similar drugs or extrapolation from pre-clinical
studies of the same drug could be some possible options as well. If no information
on the target values is available, we cannot implement the methods. In that case,
the combined criterion will be the best option.
Although we have listed existing designs in Chapter 2 for combined phase I/II trials,
none of them utilise pharmacokinetic information. Our motivation was to see if any
improvement is possible due to the use of this kind of data. Also, we wanted to
combine the objectives of best intention and optimum designs into a single frame-
work. The purpose is to ensure that patients are allocated at the most eﬃcacious
doses and also we obtain precise estimates of the parameters.
7.2 Future Work
The current research eﬀort is dedicated to developing a ﬂexible dose-ﬁnding design
for early phase clinical trials. In the future, we want to focus on the following issues,
which are not covered in the thesis.
The penalised combined criterion has been used for the continuation ratio dose-
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response model. Although we believe that it will perform in a similar way, it would
be interesting to apply it to the Cox model. This will require us to develop code for
computing the penalised D-optimum design. Since we have the analytical form for
the information matrix, this will be straightforward.
We want to develop an R package to have functions to run the presented methods
in the thesis. These functions will enable us to ﬁnd a dose for the next cohort of
patients and to generate simulated trials under a speciﬁed dose-response relation-
ship. That is, given data from a trial, the package will guide us to administer doses
to the successive cohorts. Also, it will have the feature to summarise the behaviour
of dose selection for a speciﬁc scenario through simulations.
In many practical situations, the probability of response may not be limited to dose
only, but may also depend on the covariates of the individual. If such a dependence
is overlooked in the modelling, we may end up with unreliable estimates of the
model parameters. For accurate prediction of the dose-response relationship in such
a situation, it will be worthwhile to consider the covariates. Therefore, another
possible direction would be the extension of the presented methodology to include
covariates.
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Appendix A
Flow Chart for the Design and
Supplementary Material
A.1 Solutions to the Diﬀerential Equations: One-
Compartment PK Model with First-Order Ab-
sorption
From Section 3.2.1, we have
dX1(t)
dt
= kaX2(t)− keX1(t)
and
dX2(t)
dt
= −kaX2(t).
For notational simplicity, we write
X ′1 = kaX2 − keX1
and
X ′2 = −kaX2,
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which in matrix form can be expressed as X ′ = AX, where X ′ = (X ′1, X
′
2)
T ,
X = (X1, X2)
T and
A =
 −ke ka
0 −ka
 .
We obtain the eigenvalues λ = −ka and λ = −ke from the characteristic equation
|A − λI2| = 0. It can be shown that the corresponding eigenvectors are (ka/(ka −
ke),−1)T and (ka/(ka − ke), 0)T . Therefore, the general solution to the diﬀerential
equations is
 X1(t)
X2(t)
 = c1
 kaka − ke
−1
 e−kat + c2
 kaka − ke
0
 e−ket.
That is, X1(t) = c1ka/(ka − ke)e−kat + c2ka/(ka − ke)e−ket and X2(t) = −c1e−kat.
Using the initial conditions, we have c1 = −x and c2 = x. Thus, we ﬁnd that
X1(t) =
xka
ka − ke (e
−ket − e−kat)
and X2(t) = xe
−kat.
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A.2 Structure of the Proposed Design
The ﬂow chart below shows the diﬀerent steps of the general algorithm presented in
Section 5.2.
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A.3 Eﬃciency versus Design Points: Example 1
The graphs below are for deciding the number of blood samples to be considered
per patient in Section 6.3.1.
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Figure A.1: Rationale for setting the number of design points in the one-
compartment PK model with bolus input and ﬁrst-order elimination. The locally
D-optimum design points are obtained using the initial prior values Ψ0 assuming
that the lowest dose is given to a cohort of 3 patients.
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A.4 Dose-Response Scenarios at the Prior Ends
The graphs below are the scenarios that can be obtained at the prior ends.
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Figure A.2: Dose-response curves at the lower and upper ends of the priors used in
the simulation study. These are for the continuation ratio model in Example 1.
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A.5 Boxplots of PK Parameter Estimates Obtained
in Example 1
The boxplots below are for the PK parameter estimates in Example 1 in Section
6.3.
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Figure A.3: Boxplots of the PK parameter estimates obtained from the simulations.
The horizontal dashed lines indicate the true parameter values.
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A.6 Boxplots of Dose-Response Parameter Estimates
Obtained in Example 1
The boxplots below are for the dose-response parameter estimates in Example 1 in
Section 6.3.
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Figure A.4: Boxplots of the dose-response parameter estimates obtained from the
simulations for Scenarios 2 and 3. The horizontal dashed lines indicate the true
parameter values. For each parameter, the left boxplot corresponds to the design
which takes into account the AUC and the right boxplot to the one which ignores
it.
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Figure A.5: Boxplots of the dose-response parameter estimates obtained from the
simulations for Scenario 4. The horizontal dashed lines indicate the true parameter
values. For each parameter, the left boxplot corresponds to the design which takes
into account the AUC and the right boxplot to the one which ignores it.
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A.7 Eﬃciency versus Design Points: Example 2
The graphs below are for deciding the number of blood samples to be considered
per patient in Section 6.4.1.
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Figure A.6: Rationale for setting the number of design points in the one-
compartment PK model with ﬁrst-order absorption. The locally D-optimum design
points are obtained using the initial prior values Ψ0 assuming that the lowest dose
is given to a cohort of 3 patients.
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A.8 Boxplots of PK Parameter Estimates Obtained
in Example 2
The boxplots below are for the PK parameter estimates in Example 2 in Section
6.4.
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Figure A.7: Boxplots of the PK parameter estimates obtained from the simulations
for Scenarios 2 and 3. The horizontal dashed lines indicate the true parameter
values.
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Figure A.8: Boxplots of the PK parameter estimates obtained from the simulations
for Scenario 4. The horizontal dashed lines indicate the true parameter values.
A.9 Boxplots of Dose-Response Parameter Estimates
Obtained in Example 2
The boxplots below are for the dose-response parameter estimates in Example 2 in
Section 6.4.
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Figure A.9: Boxplots of the dose-response parameter estimates obtained from the
simulations for Scenario 2. The horizontal dashed lines indicate the true parameter
values.
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Figure A.10: Boxplots of the dose-response parameter estimates obtained from the
simulations for Scenarios 3 and 4. The horizontal dashed lines indicate the true
parameter values. For each parameter, the left boxplot corresponds to the design
which takes into account the Cmax and the right boxplot to the one which ignores
it.
A.10 Conﬁdence Intervals for Dose Selections
The tables below present conﬁdence intervals for each of the performance measures
in Examples 1 and 2. They correspond to Tables 6.1 and 6.6.
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Appendix B
R Code
B.1 R Program
Below is the R code for simulating designs under various dose-optimisation criteria
and constraints introduced in Chapter 5.
####################################################
################ Calling PFIM ######################
####################################################
source("E:\\PKmodels\\elimination\\optimisation\\PFIM3.2.r")
#main programme
source("E:\\PKmodels\\elimination\\optimisation\\model.r")
#first-order elimination model (model 1)
source("E:\\PKmodels\\absorption\\optimisation\\PFIM3.2.r")
#main programme
#source("E:\\PKmodels\\absorption\\optimisation\\model.r")
#first-order absorption model (model 2)
#if working directory changes, directory
#in PFIM3.2.r needs to be changed
####################################
###### Libraries to be used ########
####################################
library(mvtnorm)
library(nlme)
library(deSolve)
library(lattice)
library(cubature)
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library(compiler)
###################################################
####### Functions to be used in the program #######
###################################################
source("E:\\Programme functions\\functions.R")
###################################################
############## Design parameters #################
###################################################
lower.dose<-0.5
upper.dose<-10
increment<-0.5
dose.scale<-"not log"
#first eg.
#lower.dose<--3
#upper.dose<-3
#increment<-0.6
#dose.scale<-"log"
#second eg.
true.dose<-seq(lower.dose,upper.dose,increment)
#sequence of doses
cohort.size<-3
trial.cohort<-20 #number of cohorts in a trial
stop.freq<-6
#a trial stops early when the same dose is repeated r times (r=6)
dose.skip<-2
#to ensure a dose not more than 2 level higher
up.down<-4
#no. of cohorts in the up-and-down procedure
########################################################
############## Methods and criteria ################
########################################################
scenario<-1
nsim<-1000
#number of simulations to run
######## Include PK? ###########
method<-"PK"
#method<-"not PK"
########### Dose-response model ###########
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doseresponse.model<-"CR"
#doseresponse.model<-"Cox"
########### PK model ###########
PK.model<-1
#bolus input and first-order elimination
#PK.model<-2
#first-order absorption
######## Dose-optimisation criteria ##########
criterion<-"maximisation of prob. of success"
#criterion<-"combined"
######### PK constraint #############
# PK.constraint<-"none"
PK.constraint<-"auc"
#PK.constraint<-"cmax"
###### Acceptable level for probability of toxicity #######
target.toxicity<-0.20
#target.toxicity<-0.33
#### Control parameters and weight for the combined criterion ####
#CS<-1
#CT<-1
#a<-0.6
#weight in the combined criterion
#a=1 means penalised D-criterion and a=0 means
#max. of prob. of success
######## Thresholds in up-and-down design ########
pL<-target.toxicity/3
pM<-(2*target.toxicity)/3
pU<-target.toxicity
## Tolerance limit and max. function evaluation ##
tol.limit<-1e-3
#tolerance limit for the integration
maxEval.limit<-5000
#maximum number of function evaluations needed
##### True PK parameters for simulation #####
if(method=="PK") {
if(PK.model==1) {
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lower.sampling<-0 #sampling region for PK
upper.sampling<-30
#sampling time for PK (in hours)
fixed<-c(0.5,0.06) #fixed PK parameters: (v,cl)
var.comp<-c(0.004,0.00005) #variance-components of the parameters
error.variance<-0.000225 #error variance
}
if(PK.model==2) {
lower.sampling<-0
upper.sampling<-50
#sampling time for PK (in hours)
#theta=(v,ke,ka)
fixed<-c(2.0,0.05,0.50)
var.comp<-c(0.1600, 0.0001, 0.0100) # CV is exactly 20%
error.variance<-0.00005 #since my obs. are also tiny (STD is 0.007)
}
}
#####################################################
### True dose-response parameters for simulation ###
#####################################################
############# CR model ##############
if(scenario==1 & doseresponse.model=="CR") {
theta1.true<-1.44
theta2.true<-0.26
theta3.true<--1.70
theta4.true<-0.25
lower.lim<-c(-3.4,0,-3.4,0)
upper.lim<-c(2.88,0.52,2.88,0.50)
}
if(scenario==2 & doseresponse.model=="CR") {
theta1.true<--3.5
theta2.true<-1.0
theta3.true<--6
theta4.true<-0.72
lower.lim<-c(-12,0,-12,0)
upper.lim<-c(0,2,0,1.44)
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}if(scenario==3 & doseresponse.model=="CR") {
theta1.true<--0.80
theta2.true<-0.50
theta3.true<--3.80
theta4.true<-0.30
lower.lim<-c(-7.6,0,-7.6,0)
upper.lim<-c(0,1,0,0.60)
}
if(scenario==4 & doseresponse.model=="CR") {
theta1.true<--6.50
theta2.true<-0.75
theta3.true<--8.00
theta4.true<-0.65
lower.lim<-c(-12,0,-12,0)
upper.lim<-c(0,1.5,0,1.30)
}
################# Cox model ##################
if(scenario==1 & doseresponse.model=="Cox") {
theta1.true<-0
theta2.true<-1
theta3.true<-4
theta4.true<-2
theta5.true<-3
theta6.true<-3
lower.lim<-c(-3,-2,1,-1,0,0)
upper.lim<-c(3,4,7,5,6,6)
#margin: 3
}
if(scenario==2 & doseresponse.model=="Cox") {
theta1.true<--0.5
theta2.true<-1.0
theta3.true<-0.5
theta4.true<-1.0
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theta5.true<-0.0
theta6.true<-2.0
lower.lim<-c(-3.5,-2,-2.5,-2,-3,-1)
upper.lim<-c(2.5,4,3.5,4,3,5)
#margin: 3
}
if(scenario==3 & doseresponse.model=="Cox") {
theta1.true<--1.0
theta2.true<-2.0
theta3.true<-1.0
theta4.true<-2.0
theta5.true<-1.0
theta6.true<-4.0
lower.lim<-c(-4,-1,-2,-1,-2,1)
upper.lim<-c(2,5,4,5,4,7)
#margin: 3
}
if(scenario==4 & doseresponse.model=="Cox") {
theta1.true<--2.0
theta2.true<-0.5
theta3.true<-0.0
theta4.true<-0.5
theta5.true<-4.0
theta6.true<-4.0
lower.lim<-c(-5,-2.5,-3,-2.5,1,1)
upper.lim<-c(1,3.5,3,3.5,7,7)
#margin: 3
}
##### Initial values for a trial to start with #####
starting.dose.level<-1
if(method=="PK") {
if(PK.model==1) {
ini.pkpara<-c(0.1,0.005) #PK parameters
ini.varcomp<-c(0.0007,0.0000006) #variance-components
ini.error.std<-0.002 #error std.
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ini.time<-c(1,5,20) #time points. sampling region [0,30]
}
if(PK.model==2) {
#PK parameters : (v,ke,ka)
ini.pkpara<-c(3.20, 0.08, 0.80) #fixed+3*sqrt(var.comp)
ini.varcomp<-c(4.0e-02, 2.5e-05, 2.5e-03) #var.comp/4
ini.error.std<-0.003535534 #error std. #sqrt(error.variance/4)
ini.time<-c(1,15,30,40) #time points. sampling region [0,50]
}
}
##### True probabilities of dose-response #####
##### outcomes under a specific scenario #####
if(doseresponse.model=="CR") {
true.neu<-psi0(theta1.true,theta2.true,theta3.true,theta4.true,
true.dose)
true.effi<-psi1(theta1.true,theta2.true,theta3.true,theta4.true,
true.dose)
true.toxic<-psi2(theta3.true,theta4.true,true.dose)
}
if(doseresponse.model=="Cox") {
true.psi00<-psi00(theta1.true,theta2.true,theta3.true,theta4.true,
theta5.true,theta6.true, true.dose)
true.psi01<-psi01(theta1.true,theta2.true,theta3.true,theta4.true,
theta5.true,theta6.true,true.dose)
true.effi<-psi10(theta1.true,theta2.true,theta3.true,theta4.true,
theta5.true,theta6.true,true.dose)
#true prob. of success
true.psi11<-psi11(theta1.true,theta2.true,theta3.true,theta4.true,
theta5.true,theta6.true,true.dose)
#true.effi<-psi1.(theta1.true,theta2.true,theta3.true,theta4.true,
theta5.true,theta6.true,true.dose)
#marginal prob. of efficacy. no need
true.toxic<-psi.1(theta1.true,theta2.true,theta3.true,theta4.true,
theta5.true,theta6.true,true.dose)
#marginal prob. of toxicity
}
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##### Identifying the true optimal dose #####
index.safe<-which(true.toxic<=target.toxicity)
#index of safe doses
candi.true.effi<-true.effi[index.safe]
true.efficacy.od<-max(candi.true.effi)
#prob.of success at the true OD
true.od.level<-which(true.effi==true.efficacy.od &
true.toxic<=target.toxicity)
true.od<-true.dose[true.od.level]
#true OD
true.toxicity.od<-true.toxic[true.od.level]
#prob. of toxicity at the true OD
##### Identifying the target AUCs #####
if(PK.constraint=="auc") {
if(PK.model==1) {
auc.true<-auc1(fixed[1],fixed[2],upper.sampling,true.dose)
#first-order elimination
}
if(PK.model==2) {
auc.true<-auc2(fixed[1],fixed[2],fixed[3],upper.sampling,true.dose)
#first-order absorption
}
auc.lim<-auc.true[true.od.level]
#value for target AUC
}
######## Identifying the target Cmax ########
if(PK.constraint=="cmax") {
if(PK.model==2) {
tmax.true<-(log(fixed[3])-log(fixed[2]))/(fixed[3]-fixed[2])
cmax.true<-cmax2(fixed[1],fixed[2],fixed[3],tmax.true,true.dose)
#first-order absorption
}
cmax.lim<-cmax.true[true.od.level]
#value for target Cmax
}
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##########################################################
########## Declaring variables to store the ##########
########## estimates over the simulations ##########
##########################################################
pk1.hat=c()
pk2.hat=c()
pk3.hat=c()
varcomp1.hat=c()
varcomp2.hat=c()
varcomp3.hat=c()
stddev.error.hat=c()
#to store PK parameter estimates
od=c()
#to store optimal doses
theta1.hat=c()
theta2.hat=c()
theta3.hat=c()
theta4.hat=c()
theta5.hat=c()
theta6.hat=c()
#to store dose-response parameter estimates
count.stops<-0
#counts trial with early stopping (achieving r)
count.stops.updown<-0 #counts trial stopped at up-and-down stage
updown.dose=c() #dose at which a trial stops in up-and-down stage
updown.cohort=c() #cohorts used in up-and-down stage
od.complete=c() #from the complete analysis
stopped.at=c() #no. of cohorts used in a trial when it stops early
stopped.dose=c() #optimum dose selected in such a trial
########################################################
############## Start of the Program #############
########################################################
for(l in 1:nsim) {
########### Values to start with ###########
h<-starting.dose.level #starting dose level
d<-1 #to create an index for the subjects
if(method=="PK") {
pk.esti<-ini.pkpara
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var.comp.esti<-ini.varcomp
error.esti<-ini.error.std
# initial values for PK parameters
}
next.dose<-true.dose[h] #dose for a trial to start with
previ.level<-h #to be used in the skip calculation
stage<-1 #stage of a trial
######### End of values to start with ###########
if(doseresponse.model=="CR") {
alloc.first<-true.dose[h]
tri.res<-rmultinom(1,size=cohort.size,prob=c(true.neu[h],
true.effi[h],true.toxic[h]))
#generating dose-response outcomes for the starting dose
r0.1<-tri.res[1,1] #neutral response
r1.1<-tri.res[2,1] #efficacious response
r2.1<-tri.res[3,1] #toxic response
alloc.dose=c(alloc.first) #allocated doses to cohorts in a trial
r0=c(r0.1) #neutral outcomes over cohorts in a trial
r1=c(r1.1) #efficacious outcomes over cohorts in a trial
r2=c(r2.1) #toxic outcomes over cohorts in a trial
}
if(doseresponse.model=="Cox") {
alloc.first<-true.dose[h]
dose.res<-rmultinom(1,size=cohort.size,prob=c(true.psi00[h],
true.psi01[h],true.effi[h],true.psi11[h]))
#dose-response outcomes for the starting dose
r0.1<-dose.res[1,1] #(0,0)
r1.1<-dose.res[2,1] #(0,1)
r2.1<-dose.res[3,1] #(1,0)
r3.1<-dose.res[4,1] #(1,1)
alloc.dose=c(alloc.first) #allocated doses to cohorts in a trial
r0=c(r0.1) #(0,0) outcomes over cohorts in a trial
r1=c(r1.1) #(0,1) outcomes over cohorts in a trial
r2=c(r2.1) #(1,0) outcomes over cohorts in a trial
r3=c(r3.1) #(1,1) outcomes over cohorts in a trial
}
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stop.iter<-0
for(i in 1:trial.cohort) {
#############################################################
############# Generation of PK responses ##############
#############################################################
if(method=="PK") {
con.cohort=c()
#concentrations obtained from a cohort
#after receiving a specific dose
if(PK.model==1) {
source("E:\\PKmodels\\elimination\\optimisation\\stdin.r")
#input file
res<-tryCatch(PFIM(),error=function(e)NULL)
if(!is.null(res)) {
time<-round(c(res$prot.opti[[1]][[1]][[1]][1],res$prot.opti[[1]]
[[1]][[2]][1],res$prot.opti[[1]][[1]][[3]][1]),digits=2)
#extracting the optimal time points
} else {
stop.iter<-stop.iter+1
}
}
#end of (PK.model==1)
if(PK.model==2) {
source("E:\\PKmodels\\absorption\\optimisation\\stdin.r")
res<-tryCatch(PFIM(),error=function(e)NULL)
if(!is.null(res)) {
time<-round(c(res$prot.opti[[1]][[1]][[1]][1],res$prot.opti[[1]]
[[1]][[2]][1],res$prot.opti[[1]][[1]][[3]][1],res$prot.opti[[1]]
[[1]][[4]][1]),digits=2)
} else {
stop.iter<-stop.iter+1
}
}
#end of (PK.model==2)
k<-1
for(a in 1:cohort.size) {
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mean.b<-rep(0,length(beta))
varcov.b<-diag(var.comp,nrow=length(mean.b),ncol=length(mean.b))
b<-rmvnorm(1,mean.b,varcov.b) #random effects for an individual
theta<-fixed+b #PK parameters for an individual
x<-true.dose[h]
if(dose.scale=="log") {
x<-exp(x)
}
Theta1<-theta[1,1]
Theta2<-theta[1,2]
f=c()
for(g in 1:length(time)) {
if(PK.model==1) {
f[g]<-f1(x,Theta1,Theta2,time[g])
} else {
Theta3<-theta[1,3]
f[g]<-f2(x,Theta1,Theta2,Theta3,time[g])
}
}
mean.error<-rep(0,length(time))
varcov.error<-diag(error.variance,nrow=length(mean.error),
ncol=length(mean.error))
epsi<-rmvnorm(1,mean.error,varcov.error)
y<-f+epsi #concentration for an individual
s<-1
for(u in k:(k+length(time)-1)) {
con.cohort[u]<-y[1,s]
s<-s+1
}
k<-k+length(time)
}
#end of the loop with index 'a'
subject<-c(rep(d,length(time)),rep(d+1,length(time)),
rep(d+2,length(time)))
dose<-rep(x,cohort.size*length(time))
t<-rep(time,cohort.size)
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data.cohort=data.frame(subject=subject,dose=dose,t=t,
conc=con.cohort)
if(d==1) {
data.d<-data.cohort
} else {
data.d<-rbind(data.d,data.cohort)
}
d<-d+cohort.size
}
#end of (method=="PK")
##################################################
## Dose selection based on up-and-down design ##
##################################################
if(stage<up.down) {
if((stage==(up.down-1))&(all(alloc.dose[1]==alloc.dose))) {
h<-h+1
} else {
if(doseresponse.model=="CR") {
prop.toxic<-(sum(r2)/(cohort.size*stage))
}
if(doseresponse.model=="Cox") {
prop.toxic<-(sum(r1+r3)/(cohort.size*stage))
}
if(prop.toxic<=pL) {
if(h==length(true.dose)) {
h<-h } else {
h<-h+1 }
}
else if((prop.toxic>pL)&(prop.toxic<pM)) {
h<-h
}
else if((prop.toxic>=pM)&(prop.toxic<pU)) {
if(h==1) {
h<-h } else {
h<-h-1
}
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} else {
count.stops.updown<-count.stops.updown+1
updown.dose<-c(updown.dose,true.dose[h])
updown.cohort<-c(updown.cohort,stage)
break #breaks the trial to the end
}
}
} else {
## start of stage>up.down: model-based approach ##
if(method=="PK") {
#applies when PK information is considered
#######################################################
############# Fitting the PK model ###############
#######################################################
if(PK.model==1) {
grouped.data<-groupedData(formula=conc~t|subject,data=data.d)
model.d<-tryCatch(nlme(conc~f1(dose,Theta1,Theta2,t),
fixed=Theta1+Theta2~1,data=grouped.data,
random=Theta1+Theta2~1,start=list(fixed=pk.esti))
,error=function(e)NULL)
if(!is.null(model.d)) {
summ<-summary(model.d)
pk.esti<-c(summ$coefficients$fixed[[1]],
summ$coefficients$fixed[[2]])
var.comp.esti<-c(as.numeric(VarCorr(summ)[1,1]),
as.numeric(VarCorr(summ)[2,1]))
error.esti<-summ$sigma } else {
stop.iter<-stop.iter+1
}
}
#end of (PK.model==1)
if(PK.model==2) {
grouped.data<-groupedData(formula=conc~t|subject,data=data.d)
model.d<-tryCatch(nlme(conc~f2(dose,Theta1,Theta2,Theta3,t),
fixed=Theta1+Theta2+Theta3~1,data=grouped.data,
random=Theta1+Theta2+Theta3~1,start=list(fixed=pk.esti))
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,error=function(e)NULL)
if(!is.null(model.d)) {
summ<-summary(model.d)
pk.esti<-c(summ$coefficients$fixed[[1]]
,summ$coefficients$fixed[[2]],summ$coefficients$fixed[[3]])
var.comp.esti<-c(as.numeric(VarCorr(summ)[1,1]),
as.numeric(VarCorr(summ)[2,1]),as.numeric(VarCorr(summ)[3,1]))
error.esti<-summ$sigma } else {
stop.iter<-stop.iter+1
}
}
#end of (PK.model==2)
}
#end of(method=="PK")
###############################################################
############## Fitting the dose-response model ##############
###############################################################
if(doseresponse.model=="CR") {
denomit.integ<-adaptIntegrate(lf1.cond,lowerLimit=lower.lim,
upperLimit=upper.lim,tol=tol.limit,maxEval=maxEval.limit)
#integrates the likelihood function
theta1.integ<-adaptIntegrate(theta1.f1,lowerLimit=lower.lim,
upperLimit=upper.lim,tol=tol.limit,maxEval=maxEval.limit)
theta2.integ<-adaptIntegrate(theta2.f1,lowerLimit=lower.lim,
upperLimit=upper.lim,tol=tol.limit,maxEval=maxEval.limit)
theta3.integ<-adaptIntegrate(theta3.f1,lowerLimit=lower.lim,
upperLimit=upper.lim,tol=tol.limit,maxEval=maxEval.limit)
theta4.integ<-adaptIntegrate(theta4.f1,lowerLimit=lower.lim,
upperLimit=upper.lim,tol=tol.limit,maxEval=maxEval.limit)
theta1<-(theta1.integ$integral/denomit.integ$integral)
theta2<-(theta2.integ$integral/denomit.integ$integral)
theta3<-(theta3.integ$integral/denomit.integ$integral)
theta4<-(theta4.integ$integral/denomit.integ$integral)
#posterior estimates
}
if(doseresponse.model=="Cox") {
denomit.integ<-adaptIntegrate(lf2.c,lowerLimit=lower.lim,
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upperLimit=upper.lim,tol=tol.limit,maxEval=maxEval.limit)
#integrates the likelihood function
theta1.integ<-adaptIntegrate(theta1.f2,lowerLimit=lower.lim,
upperLimit=upper.lim,tol=tol.limit,maxEval=maxEval.limit)
theta2.integ<-adaptIntegrate(theta2.f2,lowerLimit=lower.lim,
upperLimit=upper.lim,tol=tol.limit,maxEval=maxEval.limit)
theta3.integ<-adaptIntegrate(theta3.f2,lowerLimit=lower.lim,
upperLimit=upper.lim,tol=tol.limit,maxEval=maxEval.limit)
theta4.integ<-adaptIntegrate(theta4.f2,lowerLimit=lower.lim,
upperLimit=upper.lim,tol=tol.limit,maxEval=maxEval.limit)
theta5.integ<-adaptIntegrate(theta5.f2,lowerLimit=lower.lim,
upperLimit=upper.lim,tol=tol.limit,maxEval=maxEval.limit)
theta6.integ<-adaptIntegrate(theta6.f2,lowerLimit=lower.lim,
upperLimit=upper.lim,tol=tol.limit,maxEval=maxEval.limit)
theta1<-(theta1.integ$integral/denomit.integ$integral)
theta2<-(theta2.integ$integral/denomit.integ$integral)
theta3<-(theta3.integ$integral/denomit.integ$integral)
theta4<-(theta4.integ$integral/denomit.integ$integral)
theta5<-(theta5.integ$integral/denomit.integ$integral)
theta6<-(theta6.integ$integral/denomit.integ$integral)
#posterior estimates
}
############################################################
########### Dose selection for the next cohort ###########
############################################################
if(doseresponse.model=="CR") {
psi1.hat<-psi1(theta1,theta2,theta3,theta4,true.dose)
#estimates of prob. of success at different doses
psi2.hat<-psi2(theta3,theta4,true.dose)
#estimates of prob. of toxicity at different doses
}
if(doseresponse.model=="Cox") {
psi1.hat<-psi10(theta1,theta2,theta3,theta4,theta5,theta6,true.dose)
#estimates of prob. of success at different doses
psi2.hat<-psi.1(theta1,theta2,theta3,theta4,theta5,theta6,true.dose)
#estimates of prob. of toxicity at different doses
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}######################################################
#### Criterion: maximisation of prob. of success #####
######################################################
if (criterion=="maximisation of prob. of success" ) {
if(method=="not PK") {
index<-which(psi2.hat<=target.toxicity)
#identifying indexes of the doses for which the condition is met
} else {
#when (method=="PK")
if(PK.model==1) {
if(PK.constraint=="auc") {
auc.hat<-auc1(pk.esti[1],pk.esti[2],upper.sampling,true.dose)
#AUC estimates at various doses
c.v.f1.esti<-c.v.f1(pk.esti[1],pk.esti[2],upper.sampling,next.dose)
c.cl.f1.esti<-c.cl.f1(pk.esti[1],pk.esti[2],upper.sampling,next.dose)
c.var.esti<-(((c.v.f1.esti^2)*var.comp.esti[1])+((c.cl.f1.esti^2)*
var.comp.esti[2]))
#variance of AUC
}
}
if(PK.model==2) {
if(PK.constraint=="auc") {
auc.hat<-auc2(pk.esti[1],pk.esti[2],pk.esti[3],upper.sampling,
true.dose)
c.v.f2.esti<-c.v.f2(pk.esti[1],pk.esti[2],pk.esti[3],
upper.sampling,next.dose)
c.ke.f2.esti<-c.ke.f2(pk.esti[1],pk.esti[2],pk.esti[3],
upper.sampling,next.dose)
c.ka.f2.esti<-c.ka.f2(pk.esti[1],pk.esti[2],pk.esti[3],
upper.sampling,next.dose)
c.var.esti<-(((c.v.f2.esti^2)*var.comp.esti[1])+((c.ke.f2.esti^2)*
var.comp.esti[2])+((c.ka.f2.esti^2)*var.comp.esti[3]))
#variance of AUC
} else {
#when (PK.constraint=="cmax")
tmax.hat<-(log(pk.esti[3])-log(pk.esti[2]))/(pk.esti[3]-pk.esti[2])
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cmax.hat<-cmax2(pk.esti[1],pk.esti[2],pk.esti[3],tmax.hat,true.dose)
cmax.v.f2.esti<-cmax.v.f2(pk.esti[1],pk.esti[2],pk.esti[3],
tmax.hat,next.dose)
cmax.ke.f2.esti<-cmax.ke.f2(pk.esti[1],pk.esti[2],pk.esti[3],
tmax.hat,next.dose)
cmax.ka.f2.esti<-cmax.ka.f2(pk.esti[1],pk.esti[2],pk.esti[3],
tmax.hat,next.dose)
cmax.var.esti<-(((cmax.v.f2.esti^2)*var.comp.esti[1])+
((cmax.ke.f2.esti^2)*var.comp.esti[2])+
((cmax.ka.f2.esti^2)*var.comp.esti[3]))
#variance of Cmax
}
}
if(PK.constraint=="auc") {
c.std.esti<-sqrt(c.var.esti)
rel.c<-(auc.hat-auc.lim)/c.std.esti
} else {
cmax.std.esti<-sqrt(cmax.var.esti)
rel.c<-(cmax.hat-cmax.lim)/cmax.std.esti
}
delta<-(1/psi1.hat[previ.level])
index<-which(psi2.hat<=target.toxicity & rel.c<=delta)
#indexes of the doses for which both conditions are met
}
#end of (method=="PK")
if(length(index)==0) {
h<-1
} else {
candi.psi1.hat<-psi1.hat[index]
#extracting efficacy estimates for these doses
h<-which(psi1.hat==max(candi.psi1.hat))
#the dose level with maximum efficacy estimate
}
} else {
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#end of first dose-optimsation criterion
##########################################################
############# Criterion: combined criterion ############
##########################################################
m.mat<-matrix(c(0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0),
nrow=4,ncol=4,byrow="TRUE")
#initial 'M' matrix
for(i in 1:length(alloc.dose)){
x<-alloc.dose[i]
I11.x<-I11(theta1,theta2,theta3,theta4,x)
I12.x<-I12(theta1,theta2,theta3,theta4,x)
I22.x<-I22(theta1,theta2,theta3,theta4,x)
I33.x<-I33(theta3,theta4,x)
I34.x<-I34(theta3,theta4,x)
I44.x<-I44(theta3,theta4,x)
I<-matrix(c(I11.x,I12.x,I13,I14,I12.x,I22.x,I23,I24,I31,I32,I33.x,
I34.x,I41,I42,I34.x,I44.x),nrow=4,ncol=4,byrow=TRUE)
#FIM for an individual
m.mat<-m.mat+(cohort.size*I)
#contructs the matrix 'M'
}
penalty.upto<-penalty(theta1,theta2,theta3,theta4,alloc.dose)
#penalty at the adminstered doses
penalty.sum<-sum(penalty.upto)
#sum of penalties at the administered doses
#formation of the objective function
combined.cri<-function(x) {
I11.x<-I11(theta1,theta2,theta3,theta4,x)
I12.x<-I12(theta1,theta2,theta3,theta4,x)
I22.x<-I22(theta1,theta2,theta3,theta4,x)
I33.x<-I33(theta3,theta4,x)
I34.x<-I34(theta3,theta4,x)
I44.x<-I44(theta3,theta4,x)
I<-matrix(c(I11.x,I12.x,I13,I14,I12.x,I22.x,I23,I24,I31,I32,I33.x,
I34.x,I41,I42,I34.x,I44.x),nrow=4,ncol=4,byrow=TRUE)
#FIM for an individual
penalty.x<-penalty(theta1,theta2,theta3,theta4,x)
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det(((stage/(stage+1))*m.mat+(1/(stage+1))*cohort.size*I)/
((stage/(stage+1))*penalty.sum+(1/(stage+1))*penalty.x))
# penalised D-criterion is here
}
combined.cri.values=c()
x.dose<-lower.dose
for (i in 1:length(true.dose)) {
combined.cri.values[i]<-combined.cri(x.dose)
x.dose<-x.dose+increment
}
scaled.d<-combined.cri.values/max(combined.cri.values)
scaled.psi1<-psi1.hat/max(psi1.hat)
#standardising the values
cri.values<-a*scaled.d+(1-a)*scaled.psi1
#combining two criterion
if(stage<trial.cohort) {
index<-which(cri.values==max(cri.values))
if(length(index)==0) {
h<-1
} else {
h<-index
}
} else {
#when ("stage==trial.chort"), the last estimates
#are used to find the OD
index<-which(psi2.hat<=target.toxicity)
#identifying indexes of the doses for which the condition is met
if(length(index)==0){
h<-1
} else {
candi.psi1.hat<-psi1.hat[index]
#extracting the estimates of the prob. of success at these doses
h<-which(psi1.hat==max(candi.psi1.hat))
#dose level with the maximum prob. of success
}
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}}
#end of the combined criterion
#########################################################
########### Restriction on dose escalation ############
#########################################################
if(stage<=trial.cohort) {
#with <=, the restriction is on the last stage also
if((h-previ.level)>dose.skip){
h<-previ.level+dose.skip
#to avoid restriction on the last stage
} else {
h<-h
}
}
}
####### end of stage>up.down #########
next.dose<-true.dose[h]
#selected dose for the next cohort
previ.level<-h
#current dose level is going to be the previous
#dose level in the next stage
stage<-stage+1
#counts stage for a trial
if(doseresponse.model=="CR") {
tri.res<-rmultinom(1,size=cohort.size,prob=c(true.neu[h],
true.effi[h],true.toxic[h]))
#dose-response outcomes for a cohort which received the new dose
r0<-c(r0,tri.res[1,1])
r1<-c(r1,tri.res[2,1])
r2<-c(r2,tri.res[3,1])
alloc.dose<-c(alloc.dose,true.dose[h])
}
if(doseresponse.model=="Cox") {
dose.res<-rmultinom(1,size=cohort.size,prob=c(true.psi00[h],
true.psi01[h],true.effi[h],true.psi11[h]))
#dose-response outcomes for a cohort which receives the new dose
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r0<-c(r0,dose.res[1,1])
r1<-c(r1,dose.res[2,1])
r2<-c(r2,dose.res[3,1])
r3<-c(r3,dose.res[4,1])
alloc.dose<-c(alloc.dose,true.dose[h])
}
max.freq<-max(table(alloc.dose))
#determines the maximum frequency that a dose occurred with
if(max.freq==stop.freq & stage<=(trial.cohort-1)) {
count.stops<-count.stops+1
stopped.at<-c(stopped.at,length(alloc.dose))
stopped.dose<-c(stopped.dose,true.dose[h])
break
#breaks the trial and moves to store the estimates
}
}
#end of the loop with index 'i'
##############################################################
####### Storing the estimates only when the trial is #######
####### above the up-and-down phase #######
##############################################################
if(stage>up.down) {
if(method=="PK") {
pk1.hat<-c(pk1.hat,pk.esti[1])
pk2.hat<-c(pk2.hat,pk.esti[2])
pk3.hat<-c(pk3.hat,pk.esti[3])
varcomp1.hat<-c(varcomp1.hat,var.comp.esti[1])
varcomp2.hat<-c(varcomp2.hat,var.comp.esti[2])
varcomp3.hat<-c(varcomp3.hat,var.comp.esti[3])
stddev.error.hat<-c(stddev.error.hat,error.esti)
}
#end of (method=="PK")
if(stage==trial.cohort+1) { #recommended dose for the next phase
od.complete<-c(od.complete,true.dose[h])
#OD from complete analysis
alloc.sim<-capture.output(alloc.dose[-length(alloc.dose)])
#removing the recommended dose for the next
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#phase from the list of allocated doses
cat(alloc.sim,file="E:/Office/alloc
dose/alloc.txt",sep="\n",append=TRUE)
#saving the doses allocated to cohorts to an external file
} else {
alloc.sim<-capture.output(alloc.dose)
cat(alloc.sim,file="E:/Office/alloc
dose/alloc.txt",sep="\n",append=TRUE)
}
od<-c(od,true.dose[h])
#records all the ODs: early and complete
theta1.hat<-c(theta1.hat,theta1)
theta2.hat<-c(theta2.hat,theta2)
theta3.hat<-c(theta3.hat,theta3)
theta4.hat<-c(theta4.hat,theta4)
#theta5.hat<-c(theta5.hat,theta5)
#theta6.hat<-c(theta6.hat,theta6)
}
#end of stage>up.down
}
#end of the loop with index 'l'
################## End of the program ###################
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B.2 Functions in R
Below are the functions used in the program.
####################################################
######## One-compartment PK model with bolus #######
######## input and first-order elimination #######
####################################################
################ Model ###################
f1<-function(x,v,cl,t) {
(x/v)*exp(-(cl/v)*t)
}
#'x' represents dose
############ AUC and its variance ###############
auc1<-function(v,cl,t1,x) {
(x/cl)*(1-exp(-(cl/v)*t1))
}
#t1 is the upper sampling time
c.v.f1<-function(v,cl,t1,x) {
((x*t1)/(v^2))*(-exp(-(cl/v)*t1))
}
#derivative w.r.t. v
c.cl.f1<-function(v,cl,t1,x) {
(x/cl)*(exp(-(cl/v)*t1))*((1/cl)+(t1/v))-(x/cl^2)
}
#derivative w.r.t. cl
###################################################
######### One-compartment PK model with #########
######### first-order absorption #########
###################################################
################# Model #####################
f2<-function(x,v,ke,ka,t) {
((x*ka)*(exp(-ke*t)- exp(-ka*t)))/(v*(ka-ke))
}
#'x' represents dose
############ AUC and its variance ################
auc2<-function(v,ke,ka,t1,x) {
((x*ka)/(v*(ka-ke)))*((1-exp(-ke*t1))/ke-(1-exp(-ka*t1))/ka)
}
#t1 is the upper sampling time
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c.v.f2<-function(v,ke,ka,t1,x) {
z1<-1-exp(-ke*t1)
z2<-1-exp(-ka*t1)
(-(x*ka)/((v^2)*(ka-ke)))*(z1/ke-z2/ka)
}
c.ke.f2<-function(v,ke,ka,t1,x) {
z1<-1-exp(-ke*t1)
z2<-1-exp(-ka*t1)
((x*ka)/(v*((ka-ke)^2)))*(z1/ke-z2/ka)+
((x*ka)/(v*(ka-ke)))*(-z1/ke^2+(t1*exp(-ke*t1))/ke)
}
c.ka.f2<-function(v,ke,ka,t1,x) {
z1<-1-exp(-ke*t1)
z2<-1-exp(-ka*t1)
(-(x*ke)/(v*((ka-ke)^2)))*(z1/ke-z2/ka)+
((x*ka)/(v*(ka-ke)))*(z1/ka^2-(t1*exp(-ka*t1))/ka)
}
############## Cmax and its variance ###############
cmax2<-function(v,ke,ka,tmax,x) {
((x*ka)/(v*(ka-ke)))*(exp(-ke*tmax)-exp(-ka*tmax))
}
cmax.v.f2<-function(v,ke,ka,tmax,x) {
-((x*ka)/(v^2*(ka-ke)))*(exp(-ke*tmax)-exp(-ka*tmax))
}
cmax.ke.f2<-function(v,ke,ka,tmax,x) {
((x*ka)/(v*(ka-ke)^2))*(exp(-ke*tmax)*(2-ka*tmax)-
exp(-ka*tmax)*(1+(ka*(1-ke*tmax))/ke))
}
cmax.ka.f2<-function(v,ke,ka,tmax,x) {
(x/(v*(ka-ke)^2))*(ke*exp(-ke*tmax)*(-1+ka*(ka*tmax-1))+
exp(-ka*tmax)*(ke-ka*(ke*tmax-1)))
}
##########################################################
######## Functions representing the probabilities #######
######## of trinomial dose-response outcomes #######
##########################################################
psi0<-function(theta1,theta2,theta3,theta4,x) {
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z1<-exp(theta1+theta2*x)
z2<-exp(theta3+theta4*x)
1/((1+z1)*(1+z2))
}
psi1<-function(theta1,theta2,theta3,theta4,x) {
z1<-exp(theta1+theta2*x)
z2<-exp(theta3+theta4*x)
z1/((1+z1)*(1+z2))
}
psi2<-function(theta3,theta4,x) {
z2<-exp(theta3+theta4*x)
z2/(1+z2)
}
#########################################################
######### Likelihood function for the CR model #########
#########################################################
lf1<-function(w) {
v<-1
w1<-w[1]
w2<-w[2]
w3<-w[3]
w4<-w[4]
for (i in 1:length(alloc.dose)) {
dose.i<-alloc.dose[i]
r0.i<-r0[i]
r1.i<-r1[i]
r2.i<-r2[i]
z1<-exp(w1+w2*dose.i)
z2<-exp(w3+w4*dose.i)
psi0<-1/((1+z1)*(1+z2))
psi1<-z1*psi0
v<-v*(psi0^r0.i)*(psi1^r1.i)*((1-psi0-psi1)^r2.i)
}
return(v)
}
lf1.c<-cmpfun(lf1) #compiling the likelihood function
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lf1.cond<-function(w) { #likelihood function with
lf1.c(w)*(w[1]>=w[3]) #the condition that theta1>theta3
}
theta1.f1<-function(w) {
(w[1])*lf1.c(w)*(w[1]>=w[3]) #function in the numerator when we find
} #the posterior estimate for theta1
theta2.f1<-function(w) { #function in the numerator when we find
(w[2])*lf1.c(w)*(w[1]>=w[3]) #the posterior estimate for theta2
}
theta3.f1<-function(w) { #function in the numerator when we
(w[3])*lf1.c(w)*(w[1]>=w[3]) #find the posterior estimate for theta3
}
theta4.f1<-function(w) { #function in the numerator when we
(w[4])*lf1.c(w)*(w[1]>=w[3]) #find the posterior estimate for theta4
}
#in the likelihood function and thereafter,
#w[1], w[2], w[3] and w[4] represent theta1, theta2,
#theta3 and theta4, respectively
###########################################################
########### Penalty function for the CR model #########
###########################################################
penalty<-function(theta1,theta2,theta3,theta4,x) {
((psi1(theta1,theta2,theta3,theta4,x))^(-CS))*
((1-psi2(theta3,theta4,x))^(-CT))
}
###########################################################
################# FIM for the CR model ##################
###########################################################
I11<-function(theta1,theta2,theta3,theta4,x) {
(psi1(theta1,theta2,theta3,theta4,x)*(1-psi2(theta3,theta4,x)))/
(psi0(theta1,theta2,theta3,theta4,x)*((1+exp(theta1+theta2*x))^2))
}
I12<-function(theta1,theta2,theta3,theta4,x) {
(x*I11(theta1,theta2,theta3,theta4,x))
}
I13<-0
I14<-0
#I21<-I12
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I22<-function(theta1,theta2,theta3,theta4,x) {
((x^2)*I11(theta1,theta2,theta3,theta4,x))
}
I23<-0
I24<-0
I31<-0
I32<-0
I33<-function(theta3,theta4,x) {
(psi2(theta3,theta4,x))*(1-psi2(theta3,theta4,x))
}
I34<-function(theta3,theta4,x) {
(x*I33(theta3,theta4,x))
}
I41<-0
I42<-0
#I43<-I34
I44<-function(theta3,theta4,x) {
((x^2)*I33(theta3,theta4,x))
}
####################################################################
###### Defining the associated functions for the Cox Model #######
####################################################################
psi00<-function(theta1,theta2,theta3,theta4,theta5,theta6,x) {
z1<-exp(theta1+theta2*x)
z2<-exp(theta3+theta4*x)
z3<-exp(theta5+theta6*x)
1/(1+z1+z2+z3)
}
psi01<-function(theta1,theta2,theta3,theta4,theta5,theta6,x) {
z1<-exp(theta1+theta2*x)
z2<-exp(theta3+theta4*x)
z3<-exp(theta5+theta6*x)
z1/(1+z1+z2+z3)
}
psi10<-function(theta1,theta2,theta3,theta4,theta5,theta6,x) {
z1<-exp(theta1+theta2*x)
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z2<-exp(theta3+theta4*x)
z3<-exp(theta5+theta6*x)
z2/(1+z1+z2+z3)
}
psi11<-function(theta1,theta2,theta3,theta4,theta5,theta6,x) {
z1<-exp(theta1+theta2*x)
z2<-exp(theta3+theta4*x)
z3<-exp(theta5+theta6*x)
z3/(1+z1+z2+z3)
}
psi1.<-function(theta1,theta2,theta3,theta4,theta5,theta6,x) {
#marginal prob. of efficacy
psi10(theta1,theta2,theta3,theta4,theta5,theta6,x)+
psi11(theta1,theta2,theta3,theta4,theta5,theta6,x)
}
psi.1<-function(theta1,theta2,theta3,theta4,theta5,theta6,x) {
#marginal prob. of toxicity
psi01(theta1,theta2,theta3,theta4,theta5,theta6,x)+
psi11(theta1,theta2,theta3,theta4,theta5,theta6,x)
}
#####################################################################
############# Likelihood function for the Cox model ###############
#####################################################################
lf2<-function(w) {
v<-1
w1<-w[1]
w2<-w[2]
w3<-w[3]
w4<-w[4]
w5<-w[5]
w6<-w[6]
for (i in 1:length(alloc.dose)) {
dose.i<-alloc.dose[i]
r0.i<-r0[i]
r1.i<-r1[i]
r2.i<-r2[i]
r3.i<-r3[i]
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z1<-exp(w1+w2*dose.i)
z2<-exp(w3+w4*dose.i)
z3<-exp(w5+w6*dose.i)
psi00<-1/(1+z1+z2+z3)
psi01<-z1*psi00
psi10<-z2*psi00
v<-v*(psi00^r0.i)*(psi01^r1.i)*(psi10^r2.i)*
((1-psi00-psi01-psi10)^r3.i)
}
return(v)
}
lf2.c<-cmpfun(lf2)
# compiling the likelihood function
theta1.f2<-function(w) {
(w[1])*lf2.c(w)
}
theta2.f2<-function(w) {
(w[2])*lf2.c(w)
}
theta3.f2<-function(w) {
(w[3])*lf2.c(w)
}
theta4.f2<-function(w) {
(w[4])*lf2.c(w)
}
theta5.f2<-function(w) {
(w[5])*lf2.c(w)
}
theta6.f2<-function(w) {
(w[6])*lf2.c(w)
}
#in the likelihood function and thereafter, w[1], w[2],
#w[3] and w[4] etc. represent theta1, theta2, etc.
########################## End ##############################
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